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Washington University in St. Louis, 2015
Dr. David Piwnica-Worms, Chair
Dr. Erik Herzog, Co-Chair
Cardiovascular disease (CVD) is the leading cause of morbidity, mortality, and health care
costs in the developed world and is often undiagnosed until clinical presentation with a
major adverse cardiovascular event (MACE). Plasma myeloperoxidase (MPO) content is an
emerging biomarker for risk, progression, and prognosis at different stages of CVD. Enzyme-
linked immunosorbent assays (ELISAs) are currently used to measure clinical plasma MPO
concentration, but ELISAs are costly and time-intensive. Luminol is a chemiluminescent
compound with specificity for MPO activity in vivo, but is not sensitive enough for use
as a bioluminescence reporter of plasma MPO oxidation. The luminol derivative L-012 is
more sensitive to oxidation, but little is known about its sensitivity or specificity to reactive
oxygen species (ROS) produced by MPO and its interactions with the myriad components of
whole plasma. Therefore L-012 was first characterized as an MPO-dependent bioluminescence
reporter in whole blood and plasma. The data indicated that L-012 is not a reporter of all
MPO-dependent reactions, but specifically reports halogenation with chloride or bromide.
Additionally, plasma components inhibited MPO both specifically and non-specifically and
prevented precision measurement of plasma MPO activity with L-012 bioluminescence. To
overcome this, a method was developed to isolate MPO on a solid substrate, remove small
molecule antioxidants, and eliminate specific inhibition by plasma proteins. With this method,
xii
MPO activity from human samples could be assayed using bovine plasma supplemented with
purified human MPO as calibration standards. The assay can be performed in under an hour,
comprises only two steps, and uses no costly immunologic reagents. The assay was validated
with a pilot study using 72 plasma samples from cardiology patients undergoing elective
catheterization. Individuals in this cohort assayed by the bioluminescence method were
concordant with a parallel ELISA within 2 ± 11 µg/L MPO and overall the measurements
from the two assays were not significantly different. To further validate the assay, an outside
laboratory also measured MPO from 67 of the same plasma samples with an approved, clinical
MPO ELISA. The newly developed MPO assay agreed with the outside ELISA on par with
the parallel ELISA. In conclusion, a clinical assay for plasma MPO activity was developed
with comparable sensitivity and specificity to current ELISAs which can be performed at a
fraction of the time and cost.
xiii
There is a single light of science,
and to brighten it anywhere
is to brighten it everywhere.
Isaac Asimov
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Chapter 1
Introduction
1.1 Cardiovascular disease
1.1.1 Prevalence and risk factors
Cardiovascular disease (CVD) is the leading cause of morbidity, mortality, and health care
costs in the United States and the rest of the developed world.1 The CVD mortality rate
estimated for the United States in 2005 was 2,400 deaths per day.2 More than one of every
three Americans has at least one form of CVD, and the lifetime risk after 40 in a previously
disease-free individual is >50% for women and >65% for men.3 The correlation between
economic development and CVD prevalence has led some to call it a “disease of affluence”,
although lower socioeconomic populations in developed nations are most afflicted.4 CVD
burden is rising in developing economies as well, attributable to sedentary lifestyle, decreased
infectious disease mortality, urban environmental exposures, and shifts in dietary norms.5–7
While developed nations are projected to experience decreasing losses in disability-adjusted
life years due to CVD through 2020, developing nations will see 55% greater loss in the
same period.8 By 2020, CVD is expected to be the leading cause of death globally, with the
heaviest burden shifting to developing nations.9
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CVD risk can be predicted by both acquired and inheritable traits. Associations with
behaviors and their effects have led to CVD being considered a lifestyle disease. Tobacco use
and physical inactivity are drivers of acquired CVD progression, as are dietary factors such as
high sodium, high trans-unsaturated fatty acid, and low poly-unsaturated fatty acid intake.10
Risk is also heritable: diagnosis of premature CVD in parents or grandparents increases
the odds of CVD development by a factor of ~2 or more after adjusting for lifestyle risk
factors.11–14 Number of siblings and the extent of their disease also predicts risk of future
CVD development.15–17 Propensity for many secondary lifestyle risk factors, such as elevated
body mass index, abdominal fat, low-density lipoprotein (LDL), total cholesterol, and low
high-density lipoprotein (HDL) can also be considered heritable risk factors.18–20 Although
molecular biology techniques have helped advance research, specific CVD genetic markers
have yet to outperform traditional risk factors.21
The greatest danger of progressive CVD is a major adverse cardiovascular event (MACE).
The definition of MACEs varies slightly between studies, but generally includes myocardial
infarction (MI), stroke, and acute coronary syndrome (ACS). Most MACEs are caused by
thromboemboli obstructing blood flow in vulnerable arteries: coronary obstruction causes
ACS and eventually MI, cerebral obstruction results in stroke. These arterial systems are
poorly supported by anastomoses, experience high systolic blood pressure, and supply vital
and energetically demanding organs. Nearly every MACE can be attributed to atherosclerosis
as the initiator of thrombosis.
1.1.2 Historical perspective of atherosclerosis
Atherosclerosis is pathological inflammation in the arterial wall, creating asymmetric loci of
thickened intima called atheromas or plaques. Early-stage atherosclerosis in central arteries
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appears in childhood and is nearly universal.22–24 These fatty streaks can progress through
life and become vulnerable plaques, which tend to have thinner fibrous caps, eroded shoulder
regions, calcifications, and necrotic cores. Consensus on the mechanisms and impact of
atherosclerosis have changed radically throughout medical history.
Atherosclerosis has occurred in humans for at least 5,000 years.25 Although it was
described by anatomists as early as the 16th century, it was not given its own nomenclature
until 1829.26,27 Through the remainder of the 19th century, atherosclerosis was included in
the then-mainstream “senescence hypothesis” that diseases of aging were part of normal
physiology. Early investigations suggested that inflammation was involved, but pathologists
debated if this was a cause or consequence.28 In 1913, a military researcher in St. Petersburg
began to publish on induced atherosclerosis in rabbits fed high-cholesterol diets. The work
would remain largely ignored by the medical community until 1950; from then it took more
than a decade for the cholesterol hypothesis to be accepted.29–31 Research shifted back
to inflammation in a similar manner, but has only been fully accepted as the driver of
atherosclerosis in the last 20 years.32–37 Researchers are now probing the cellular mechanisms
of plaque progression by considering the interactions of hemodynamic stress, lipid metabolism,
and the immune system.
1.1.3 Innate immunity and atherosclerosis
Monocyte-lineage cells are known to be central components of atherosclerosis progression.38
Monocytes differentiate from a common myeloid progenitor cell (CMPC) shared with
granulocytes and platelets. As CMPCs mature into monocytes, they can be categorized based
on their expression of Ly-6C as “resident” Ly-6Clow or “inflammatory” Ly-6Chigh monocytes,
the latter of which is implicated in atherogenesis.39 These Ly-6Chigh monocytes also express
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myeloperoxidase, which contributes to oxidative damage.40 (see page 10) Depleting monocytes
in a murine atherosclerosis model markedly reduces lesion initiation and development, but
established plaque inflammation and rupture is not affected.41 This suggests that monocytes
play a key role in establishing new plaques in this model, but progression is driven by other
cells. Some of the candidate cells reside in the vascular wall and are derived from monocytic
precursors.
Ly-6Chigh monocytes can further differentiate into two classes of antigen-presenting cells
(APCs) abundant in plaques. Macrophages are long-lived APCs that secrete cytokines and
process lipids in atheromas.42,43 Scavenger receptors on their surface recognize LDL and
oxidized LDL (oxLDL) for uptake. LDL and oxLDL accumulate to cytotoxic concentrations,
differentiating the macrophages into foam cells that form the necrotic cores in vulnerable
plaques. Dendritic cells (DCs) are a diverse class of APCs, some of which are also derived from
Ly-6Chigh monocytes.44,45 Monocyte-derived DCs are thought to promote plaque progression
similarly to macrophages, while evidence suggests DCs derived directly from CMPCs may
inhibit atherogenesis.46–49 The heterogeneity between and within the two classes of APCs
suggests that the cells are better described along a continuum of effector molecule expression
that would more closely define their roles in atherosclerosis.50,51
Another group of innate immune cells derived from CMPCs comprises granulocyte lineages
that differ in function from macrophages and DCs. Neutrophils and their immature, banded
forms compose ~95% of circulating granulocytes in healthy adults; the remaining granulocytes
are almost entirely eosinophils with a small fraction (<1%) basophils.52 Neutrophils are
phagocytes, much like monocytes and macrophages, and primarily function as first-line
antimicrobial cells. Unlike the chronic inflammatory APCs, unperturbed neutrophils are
cleared from circulation in ~5 days and die within hours once activated by inflammatory
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mediators or foreign antigens.53–55 Neutrophils are armed with granules packed with an
array of hydrolases and oxidoreductases to kill invading microbes, which can be done by
fusing granules to phagosomes or by expelling the enzymes into the extracellular space
along with genomic DNA in aptly-named neutrophil extracellular traps (NETs).56,57 More
recent findings implicate neutrophils in animal and human atherosclerosis through diverse
mechanisms, including endothelial disruption, leukocyte recruitment, plaque destabilization,
cytokine production, and metabolite modification.58–60 Myeloperoxidase is also concentrated
in primary granules and has numerous atherogenic effects on disease models. (see page 10)
Together, this evidence suggests that neutrophils may have a role comparable to that of
macrophages in the transition from stable to vulnerable plaques and the subsequent MACEs
that result from plaque rupture. Differentiating stable and vulnerable lesions is an active
area of CVD research.
1.1.4 Assessing plaque vulnerability
The term “vulnerable plaque” was first introduced in 1989 to specify lesions that were prone
to endothelial ruptures and subsequent thrombus formation.61 This was a departure from
the belief that ACS resulted from coronary artery occlusion by large atheromas; vulnerable
plaques are not necessarily large enough to perturb blood flow prior to rupture.62 In one study,
new MACEs in patients previously treated with percutaneous coronary intervention (PCI)
often had culprit lesions that were mild or unnoticed at the time of the first intervention.63
This study also showed that predicting future MACEs from lesions uninvolved in an initial
MACE was difficult without invasive assessments of plaque morphology.
Plaques can be classified based on lipid content, fibrous cap structure, calcifications,
and cellular infiltrates. Ruptured plaques are responsible for most MACEs and are richly
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infiltrated with inflammatory cells. (see page 4) The luminal thrombus generally extends from
the point of endothelial rupture into the plaque core containing necrotic debris, foam cells,
extracellular lipids, fibroblasts, and calcifications. In contrast, eroded plaques are typified
by a lack of endothelium over a larger section of the artery and a small or absent lipid core.
The exposed intima is primarily smooth muscle cells with inflammatory infiltrates ranging
from absent to moderate.64–66 Thrombi are thought to form more slowly on erosions than on
ruptured plaques, but are more likely to embolize. Calcified nodules are the rarest of the
three thrombotic plaques and are defined by calcifications that erupt through the endothelium
and induce thrombosis in the arterial lumen. These are more common in the right coronary
artery and are thought to be the result of repeated plaque exacerbation and healing in vessels
subject to torsional stress.67,68
Plaque vulnerability is difficult to measure via traditional angiography, but other
techniques have been developed with improved resolution, tissue penetration, and molecular
imaging capabilities. Computed tomographic angiography and magnetic resonance imaging
(MRI) can detect lesions invisible to traditional angiography with better resolution and
contrast.69 Molecular MRI probes have also been developed to target processes behind
plaque vulnerability and thrombosis such as platelet activation, neovascularization, leukocyte
adhesion, and foam cell apoptosis.70 Positron emission tomography and single photon emission
tomography have comparably poor spatial resolution, but can be extremely sensitive for
molecular imaging.71,72 These techniques vary in advantages and disadvantages, but are all
limited to macroscopic resolution. The underlying structures that impart vulnerability can
be microscopic and require intravascular techniques to visualize. High-resolution imaging
of individual plaques, their underlying tissue organization, and some molecular processes
is possible with intravascular ultrasound, optical coherence tomography, and intravascular
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fluorescence imaging.73–75 This allows physicians to assess a patient’s atherosclerosis on a
plaque-by-plaque basis, but with associated risks and costs that prohibit widespread use.
1.1.5 Vulnerable patient biomarkers
Secondary prevention is treatment of subclinical conditions before substantial morbidity. As
CVD often first presents with MACEs, prioritizing pre-clinical disease based on statistical
indicators of plaque vulnerability is a favorable strategy. This approach focuses on better
screening techniques to identify “vulnerable patients” rather than invasive imaging for
vulnerable plaques.76,77 Vulnerable patients are defined by systemic characteristics with tests
that are accessible, minimally invasive, cost effective, and outperform current assessments
such as Framingham Risk Score.78 Poor sensitivity from current screening methods has led
researchers to consider direct measures of inflammation, myocardial damage, and microvascular
dysfunction.79 Measuring plasma biomarkers for these pathologies requires only a blood draw
and clinical laboratory equipment. Of note, the gold standards for MI diagnosis are plasma
markers—the cardiac troponins—with which the assay receiver operating characteristic curve
integral can be >0.90 with modern high-sensitivity kits.80 Many other biomarkers for aspects
of CVD are in use or are being investigated for clinical utility.81–84 (Table 1.1) Parameters
approximated by these biomarkers include systemic and vascular inflammation, predisposition
for blood coagulation, myocardial ischemia, and hemodynamic strain. Most are circulating
proteins that are assayed with immunologic purification techniques such as the enzyme-
linked immunosorbent assay (ELISA). A typical sandwich ELISA uses animal antibodies
conjugated to enzymes such as horseradish peroxidase (HRP) to produce quantifiable changes
in a chemical reporter. ELISA costs are high as they use many biological reagents and are
labor-intensive to perform. A promising biomarker, myeloperoxidase (MPO), is capable of
8
Chapter 1: Introduction Cardiovascular disease
Table 1.1: Current and potential plasma biomarkers for CVD risk stratification and diagnosis.81–84 Most
are proteins measured with clinical immunoassays such as ELISA.
Indication Analyte
cardiac injury aspartate aminotransferase
carbonic anhydrase III
creatine kinase-MB (activity)
creatine kinase-MB (mass)
glycogen phosphorylase BB
heart fatty acid binding protein
hydroxybutyrate dehydrogenase
lactate dehydrogenase
myoglobin
myosin light chains
troponin I
troponin T
congestive heart failure B-type natriuretic peptide
N-terminal pro-B-type natriuretic peptide
inflammation C-reactive protein
interleukin 6
lipoprotein-associated phospholipase A2
myeloperoxidase
soluble fragment CD40 ligand
ischemia free fatty acids unbound to albumin
ischemia-modified albumin
plaque instability choline
pregnancy-associated plasma protein A
thrombogenic potential D-dimer
fibrin
the same reaction achieved with HRP in clinical ELISA kits; this presents a new possibility
in secondary CVD prevention.
9
Chapter 1: Introduction Myeloperoxidase
1.2 Myeloperoxidase
1.2.1 Structure and function
Myeloperoxidase (MPO) was first isolated from purulent fluids taken from tuberculosis
patients.85 Initially named “verdoperoxidase” for the green color it gave to pus, MPO received
its modern name once it was discovered to originate from myeloid-lineage cells. Human
MPO is encoded by an 11 kb gene on chromosome 17q23.1 near the other anti-microbial
human peroxidases with which it shares a genetic common ancestor: lactoperoxidase and
eosinophil peroxidase.86,87 MPO is transcribed as preproMPO and contains a signal peptide
sequence targeting it to the endoplasmic reticulum (ER), where it is heavily glycosylated
with mannose-rich oligosaccharides and receives a heme cofactor.88 The 89 kDa proMPO then
arrives to the cis-Golgi, from which it may have two different fates. Most loses the pro-peptide
in the trans-Golgi and is sent to primary granules for endoproteolysis and dimerization into
tetrameric, 150 kDa mature MPO.89 (Figure 1.1) Some proMPO instead receives further
glycosylation with complex oligosaccharides in the cis-Golgi while retaining the pro-peptide
for constitutive secretion as a 89 or 84 kDa monomer.90–92 Although mature MPO is a
tetramer, each symmetric dimer functions independently. Additionally, the active site is not
structurally modified during Golgi processing, suggesting that the secreted monomeric form
may be similarly active as the mature form.93–95 Isoforms of mature MPO with modified
subunits and enzymatic properties have been isolated from neutrophils, but little is known
about the biological importance of these variants.96–101
MPO is a member of the reactive oxygen species (ROS) cascade important in human
innate immunity. (Figure 1.2) Defects in the phagocytic NADPH oxidase (Phox) complex that
initiates the ROS cascade manifest as chronic granulomatous disease (CGD), characterized
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Figure 1.1: Crystal structure of mature MPO. preproMPO is translated from a single gene product
cleaved to proMPO in the ER. As it progresses through the Golgi network, proMPO is bound to a heme
cofactor, glycosylated, and cleaved into a heavy and light chain (red and blue, respectively) linked by disulfide
bonds. Tetrameric MPO is formed in the primary granules by removal of the pro-peptide and formation of
covalent disulfide bonds between two heavy chains. The reaction centers (Fe3+ of the heme shown in orange)
of each dimer function independently. A small portion of proMPO is processed as a single, intact peptide and
constitutively secreted as an active monomer. Structural data from Fiedler.102
by frequent and severe microbial infections.103 The Phox complex generates superoxide (O2–·)
in the phagosomal space, which is quickly dismutated into hydrogen peroxide (H2O2). MPO
catalyzes the reaction between H2O2 and Cl– to produce hypochlorous acid (HOCl), the active
ingredient in household bleach.104 Neutrophils initiate this reaction by fusing their primary, or
azurophilic, granules to phagosomes where H2O2 is being produced. Although these granules
contain other antimicrobial enzymes, MPO is the most abundant and constitutes up to 5%
of the mature neutrophil dry weight.57,105 MPO genetic deficiency does not manifest as CGD,
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Figure 1.2: MPO and the phagocytic ROS cascade MPO normally functions as part of the neutrophil
ROS cascade. Phosphorylation events cause the assembly of the Phox complex, which transfers electrons
from cytosolic NADPH to molecular oxygen in the phagosome, creating superoxide (O2–·) radicals. O2–· is
dismutated to H2O2 in acidic environments such as the phagosome or in the presence of superoxide dismutase.
H2O2 can directly oxidize biomolecules or serve as a substrate for MPO to produce HOCl. Unlike H2O2,
HOCl cannot be neutralized by defensive catalases excreted by phagocytosed microbes
although there is some evidence suggesting that neutrophils with dysfunctional MPO have
increased phagocytosis and Phox activation.106–109 Clinical presentation of MPO deficiency
is most common in diabetics with compromised immune systems, but has been known to
manifest in patients with disseminated Candida infections.110,111 Genetic screening in the
United States, Germany, and Italy suggests that only 0.05–0.15% of the population has
MPO mutations manifesting as defects in protein sequence or processing, and in only a small
fraction of these individuals will a mutation become symptomatic.112–114
MPO reaction kinetics are complex owing to the flexible redox chemistry of the heme
cofactor. Native MPO contains Fe3+ with no coordinated oxygen, but heme oxidation state
and ligand binding result in five intermediate states. (Figure 1.3) H2O2 generated by the
Phox complex or oxidative metabolism oxidizes native MPO twice to form MPO compound I.
Physiologic Cl– can donate two electrons to reduce compound I back to native MPO, forming
HOCl as a byproduct. This two-electron redox cycling is known as the halogenation cycle
and can utilize electron donors Br–, I–, or the pseudohalide SCN– in addition to Cl–.115
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Figure 1.3: MPO redox chemistry. The current model of MPO enzymatic activity includes six redox
and ligand-binding states for each catalytic heme center. H2O2 (red) generated by the Phox complex or
oxidative metabolism serves as a dual electron acceptor to oxidize MPO to compound I. Two electrons are
transferred from abundant halide ions to compound I to form hypohalous acids, primarily HOCl in vivo,
which are responsible for MPO-mediated microbial killing. This halogenation cycle of two-electron transfers is
rapid, but MPO can be shifted into slower peroxidation cycles by single electron transfers from donor species
AH2. Buildup of radical peroxidation intermediates AH· along with excess H2O2 favors the shift of MPO
into peroxidation activity, kinetically sequestering MPO from halogenation. In this manner, H2O2 serves
as both a reactant and inhibitor of MPO-mediated halogenation. Scheme adapted from Malle, Furtmüller,
Sattler & Obinger.115
However, compound I can also oxidize organic molecules in a single-electron reaction to
form MPO compound II. In the presence of excess H2O2, compound II can enter a slow,
catalase-like cycle with compound III and ferrous MPO, shifting enzyme mass away from
the halogenation cycle. In this way, H2O2 is both a substrate for- and an inhibitor of MPO
halogenation.116 Accumulating radicals produced by peroxidation can also react with native
MPO to form the ferrous intermediate, further shifting activity away from halogenation.
This feedback inhibition loop manifests as an initial kinetic burst of H2O2 consumption
followed by steady-state kinetics.117 This shift can be influenced by pH, with optimum
halogenation kinetics found in acidic environments similar to the lysosome.118 Substrate
(pseudo)halides also influence redox cycle preference with Cl–, Br–, I–, and SCN– increasingly
favoring halogenation over peroxidation.118–120
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1.2.2 Pathology
MPO and its product ROS are not able to distinguish biomolecules originating from the
host from those made by invading microbes. Oxidation of host biomolecules has a number
of negative consequences that have been observed experimentally in vitro and naturally in
vivo. Genetic polymorphisms causing increased MPO production have been associated with
early-onset multiple sclerosis, but some animal and human studies paradoxically suggest
that the hypomorphic or downregulated MPO may promote other mechanisms of disease
development. Genetic associations with Alzheimer’s disease have also been conflicting, but
MPO has been shown to associate with amyloid plaques along with apolipoprotein E.121
MPO can target alter nucleic acids either by peroxidation or halogenation, so it is not
surprising that researchers have found links between MPO and neoplasms. Cells producing
MPO may be subject to oxidative damage if inhibition mechanisms become dysfunctional.
Certain point-mutations in the MPO promoter region are associated with acute promyelocytic
leukemia, and circulating primary tumor cells with these mutations have increased MPO
mRNA levels.122 Expression and genotype studies have also associated MPO with solid tissue
tumors such as cancer of the colon, breast, and pancreas.123–125
CVD is the chronic disease most associated with pathologic MPO activity. In addition
to neutrophils (see page 5), macrophages in atheromas also express MPO.126 Human MPO
expressed in macrophages transplanted into a murine atherosclerosis model resulted in
increased lesion size, suggesting that the enzyme has some causative role.127 Part of the
explanation focuses on molecules oxidation products which have been shown to increase lesion
progression. MPO can directly activate some matrix metalloproteinases (MMPs), which
contribute to plaque progression and fibrous cap erosion.128 This effect can be compounded
indirectly by oxidative inactivation of MMP inhibitors.129 LDL can be converted to into
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atherogenic oxLDL by ROS produced by MPO.130,131 oxLDL is recognized by scavenger
receptors on the surface of macrophages and accelerates differentiation into foam cells.132–134
HDL is similarly oxidized and rendered dysfunctional by MPO; this inhibits reverse cholesterol
transport by which HDL normally protects against atherogenesis.135,136 MPO disrupts nitric
oxide signaling and reduces vasomotor activity in response to coronary ischemia.137–139 The
reactive nitrogen species created by MPO are capable of modifying amino acids, perhaps
by transient nitrite intermediates at sites of nitric oxide production, providing another
MPO-mediated route to dysfunctional proteins.140 Lastly, MPO can induce endothelial cell
apoptosis and exposure of underlying thrombogenic tissue.141 Although researchers have not
reached consensus on the extent of the causative role MPO plays in CVD progression, its
correlation is well-established. This has led to research demonstrating that circulating MPO
content can predict various clinical outcomes in patients with CVD.
1.2.3 Biomarker utility
Increasing awareness of the role inflammation plays in the initiation, progression, and outcomes
of CVD led researchers to focus on inflammation biomarkers to improve preventative and
supportive care. Although plasma MPO concentration was first investigated for its biomarker
utility in the context of other inflammatory diseases, it was not until the early 21st century that
MPO was found beneficial in predicting CVD outcomes. The first report of coronary artery
disease (CAD) diagnostic value came in 2001 when the upper quartile of both plasma MPO
and intracellular neutrophil MPO predicted CAD status with an odds ratio = 11.9 and 20.4,
respectively.142 Subsequent studies found similar results in a variety of clinical scenarios. MPO
predicted both short- and long-term risk of MACEs in patients presenting with ACS.143–145
Differentiating ACS from angina pectoris was improved with plasma MPO measurement, as
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was differentiation between stable and unstable angina.145–147 Evidence is also growing to
support the diagnostic utility of plasma MPO prior to MACE presentation. When measured
in patients with diagnosed peripheral artery disease, MPO outperformed C-reactive protein
(CRP) in predicting the occurrence of the first MACE, improving stratification already
performed using ankle brachial index (ABI).148 Other studies found similar correlations
between serum MPO and ABI, even after adjusting for serum CRP and other CVD risk
factors.149,150 Congestive heart failure, which is often a co-morbidity of atherosclerosis, is also
associated with plasma MPO.151,152 At least one report has shown that MPO can rise early in
people with other risk factors for CVD; obese children age 6–12 had plasma MPO correlated
with insulin, CRP, and MMPs.153 A large study in Germany also showed that MPO in
>2,000 randomly selected adults correlates with leisure-time physical activity more than the
traditional biomarker oxLDL, suggesting that MPO might even serve as a population-level
indicator of public health.154 On the opposite end of the CVD spectrum, MPO has also shown
utility in assessing post-MI patients.155–158 Measurement of the timecourse of rising MPO
and the subsequent fall have also demonstrated clinical utility, but this technique may prove
difficult given the cost and time requirements of current MPO ELISAs.159,160
The role MPO could serve as a biomarker is still uncertain as other studies have failed
to demonstrate increased diagnostic and prognostic value over other indicators. One study
found that MPO is only clinically useful when used in conjunction with other biomarkers such
as cardiac troponin I, and even then it was outperformed by plasma N-terminal pro-B-type
natriuretic peptide in conjunction with troponin I.161 Another study in 49 younger adults
with acute MI showed no difference in MPO versus controls.162 A larger study of 303 patients
presenting with ACS and 120 healthy controls found that although MPO was higher in the
ACS group, it was not useful in predicting MI or a composite of all-cause mortality with MI,
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a finding echoed in an independent study performed soon after.163,164 A similarly-powered
study in patients with stable CAD found that while MPO predicted mortality during a 5-year
study period, it was correlated with other MI risk factors such as age, left-ventricular ejection
volume, and poor renal function.165
Although these findings appear to be in direct contradiction with the positive studies,
the question of MPO biomarker utility is nuanced. Caveats otherwise ubiquitous in clinical
diagnostic studies, such as differences in statistical power, outcome definition, follow-up
period, study population, and analysis methods, are applicable to MPO trials. Protocols
for measuring MPO are poorly standardized although important confounding factors have
been identified. Intravenous heparin and low molecular weight heparins are commonly
administered as anticoagulants that function by increasing antithrombin activity.166,167
Although heparins have been shown to reduce neutrophil activation and MPO release, it
also mobilizes extracellular MPO previously bound to the endothelium resulting in increased
measurable plasma concentration.137,168–170 Heparin can also affect measured MPO when used
as a phlebotomy anticoagulant as demonstrated by studies finding discordant assay results
between serum and each of the vacuum tube additives heparin, ethylenediaminetetraacetic
acid (EDTA), and citrate.171,172 In a recent meta-analysis, these differences in methodology
were considered adequate to justify separating studies into protocol-based subgroups for better
estimates on MPO utility in the CVD treatment pipeline.173 A less-controversial declaration is
that more research is warranted to determine the clinical advantages of measuring circulating
MPO at various stages of CVD progression. Despite ample numbers of patients along the
CVD spectrum (see page 2), current ELISAs and similar methods to measure MPO make
such studies a costly proposition. One solution to this problem is to specifically measure
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MPO in plasma via an inexpensive and widely-adaptable reporter used commonly outside of
medicine: luminescent oxidation of luminol and related compounds.
1.2.4 Oxidative bioluminescence
Chemiluminescence is analogous to fluorescence, in which molecular energy of an unstable
reaction intermediate is converted into electromagnetic radiation. Unlike with fluorophores
excited by incident photons, the energy released in chemiluminescence is derived from
potential energy in the bonds of the luminophore. The organic compound 5-amino-2,3-
dihydrophthalazine-1,4-dione, better known by the common name luminol,1 is one of the
simplest and most well-studied of the substituted diacylhydrazide class of luminophores.
(Figure 1.4A) These compounds release a photon with peak intensity at ~450 nm when
the diacylhydrazide moiety is hydrolyzed, releasing molecular nitrogen in the process.175
(Figure 1.4B) The earliest detailed description of luminol synthesis appeared as part of a
graduate thesis defended in 1902.176 The synthesis was simplified soon after and luminol was
studied for the vivid, blue light produced by what was described as “the most striking instance
of chemiluminescence.”177 Its most well-known role today is in the domain of forensics, where
its luminescence in the presence of alkaline H2O2 and a metallic catalyst allows crime scene
investigators to rapidly identify and photograph trace residues of dried blood.178
Bioluminescence is defined as chemiluminescence resulting from biological processes; the
phenomenon has arisen through convergent evolution in bacteria, dinoflagellates, fungi, and
various animal phyla.179,180 Peroxidases, notably HRP, were found to be bioluminescent in
the presence of luminol, a property used today to quantify bound immunoglobulin-HRP
1Literature searches on the early uses of luminol show many false leads due to the drug phenobarbital, which
was discovered and marketed under the name “Luminal” by German pharmaceutical company Bayer AG
shortly after luminol was described.174 Clinical case reports from the first half of the 20th century erroneously
mention “luminol” as a sedative or anxiolytic.
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Figure 1.4: Luminol and related luminophores. (A) The structure of chemiluminescent cyclic
diacylhydrazides luminol, isoluminol, and L-012. Luminol is a well-studied molecule used in biologic, forensic,
and environmental sciences. Isoluminol is similar but comparatively difficult to synthesize; it is used when a
probe with decreased cell membrane permeability is required. L-012 is many orders-of-magnitude brighter
than either luminol isomer, but is poorly characterized in current literature. (B) The oxidation reaction of
luminol and related luminophores which produces chemiluminescence. Deprotonation of the hydrazide drives
the reaction in the presence of moderate oxidizing agents. Hypochlorous acid produced by MPO or HRP
rapidly oxidizes the luminophore, which is the basis for its use in immunoassays and leukocyte activation
studies.
conjugates in protein blots and ELISAs.181 The ROS produced by HRP are the same as those
from the Phox-MPO cascade. As expected, activated leukocytes were soon discovered to be
bioluminescent when treated with luminol.182 Although luminol exhibits chemiluminescence
in the presence of a myriad organic and inorganic catalysts, its bioluminescence in neutrophils
was soon demonstrated to require the ROS cascade: not only could CGD be detected by
the absence of neutrophil bioluminescence, but heterozygous carriers produced ~50% less
signal than that from controls.183 Luminol can also be used as a bioluminescence probe in
vivo. Previous work from the D. Piwnica-Worms group has demonstrated luminol specificity
for MPO activity both in vivo and in blood ex vivo.184 Given the ease of synthesis, low
cost, and biological specificity for MPO, luminol or similar bioluminescence has the desirable
characteristics for a platform upon which a new clinical assay can be developed.
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Although luminol has a long history as a luminophore, it is not the most sensitive
to oxidation. Other substituted luminophores have been synthesized on the 2,3-
dihydrophthalazine-1,4-dione backbone with varying quantum yield.185 Isoluminol is another
diacylhydrazide differing from luminol only in the aromatic-ring position of the primary amine.
Although similar in chemiluminescence properties, the two probes differ in their partition
coefficients. As meta-substituted isoluminol is more hydrophilic than ortho-substituted
luminol, it has been used as a probe for extracellular ROS.186,187 A more recently discovered
analogue, 8-amino-5-chloro-7-phenyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione (L-012), is
far brighter than either luminol isomer when used with cells and cell-free immuno-assays in
vitro.188,189 (Figure 1.4A) Although the advantage over luminol in terms of detectable photons
is clear from early literature reports, publications regarding the specific ROS reported by
L-012 are contradictory.190–192 Unlike with luminol, imaging studies with L-012 in vivo have
not robustly demonstrated the extent of MPO specificity.193,194
The experimental protocols, data, and discussions that follow discuss the investigation of
L-012 for the intended purpose of measuring plasma MPO activity in the context of CVD
risk stratification, diagnosis, and intervention assessment. To accomplish this, L-012 was first
characterized as a bioluminescence probe for MPO activity in vitro and in living tissues with
emphasis on extracellular MPO in blood plasma. Conditions for optimum bioluminescence
sensitivity and specificity in plasma model systems as well as freshly collected human
plasma were determined. Various strategies were then considered to overcome the problems
encountered when attempting a direct plasma MPO assay. This resulted in a novel solid-
substrate adsorption technique, referred to as the MPO activity on a polymer surface (MAPS)
assay, that provided sufficient MPO isolation to produce linear bioluminescence signal for
inverse regression against known standards. Lastly, a pilot study with clinical cardiology
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patients presenting for elective central catheterization was completed to compare the results
of the novel MAPS assay to commercially obtained clinical MPO ELISA kits.
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L-012 bioluminescence of MPO in blood
2.1 Introduction
Inflammation plays a key role in a growing list of diseases processes. Its roles in cardiovascular
disease (CVD) and the underlying pathology of atherosclerosis have become increasingly
central to the understanding of the disease.1–6 Biomolecules in blood plasma indicative of
systemic inflammation are the subject of a growing body of research aimed at improving the
diagnostic accuracy and detection sensitivity of atherosclerosis progression in pre- and post-
symptomatic CVD.7–10 One of the molecules drawing increased interest is the heme-containing
antimicrobial enzyme myeloperoxidase (MPO), which is primarily produced in neutrophils
and monocytes. MPO is part of the non-specific reactive oxygen species (ROS) cascade
initiated by a respiratory burst of O2 consumption in neutrophils upon activation by foreign
antigen recognition.11 Although the MPO product hypochlorous acid (HOCl) is important to
the microbicidal activity of neutrophils, it can also convert low-density lipoprotein (LDL)
into the increasingly pro-inflammatory form oxidized LDL (oxLDL), which is a key driver in
differentiating macrophages into the resident foam cells in the cores of necrotic atheromatous
plaques.12–15 Neutrophils in the shoulder regions of vulnerable plaques and the re-expression of
MPO by macrophages during foam cell differentiation led to studies finding that plasma MPO
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is predictive of CVD risk, progression, and prognosis.16–27 Clinical assays for plasma MPO
concentration are enzyme-linked immunosorbent assays (ELISAs) or similar immunochemical
methods which are costly, time-intensive, and do not utilize the enzyme activity intrinsic
to MPO as a means of readout. The small compound luminol serves as a bioluminescence
probe for MPO activity in vivo and in vitro by emitting a photon upon reaction with HOCl
produced by MPO in the presence of hydrogen peroxide (H2O2).28 A related compound,
L-012, is also oxidized by ROS but produces luminescence orders-of-magnitude greater than
that of luminol and has potential to serve as an indicator for plasma MPO activity.29,30
Although L-012 has been used to image ROS produced by leukocytes in vivo, the specifics of
L-012 bioluminescence have yet to be well-studied.31,32
This chapter focuses first on characterizing the chemiluminescence of L-012 in order to
investigate questions left unanswered by published studies on the compound. Next, the
interaction of L-012 and MPO as a bioluminescence reporter system is investigated for
optimization of sensitivity and specificity for ROS produced by MPO activity. Last, attempts
to assay MPO in plasma and difficulties caused by plasma components are investigated.
2.2 Methods
2.2.1 Reagents and materials
Lyophilized L-012 was provided by Wako Chemicals USA (Richmond, Virginia; product
number 120-04891) was resuspended to 16.1 mM in ultrapure water and stored in 200 µL
aliquots at −20 ℃. Lyophilized human MPO from EMD Millipore/Calbiochem (Darmstadt,
Germany; product number 475911) was resuspended in pH = 6.0 buffer containing 100 mM
NaCl and 50 mM acetate, as recommended by the supplier, with final concentration 100 mg/L.
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Single-use 10 µL aliquots were stored at −20 ℃. All other reagents were supplied by Sigma
Aldrich (St. Louis, Missouri). Phorbol-12-myristate-13-acetate (PMA) was dissolved in
dimethyl sulfoxide (DMSO) and stored at −20 ℃. Glucose oxidase (GOx) from Aspergillus
niger was resuspended and stored in the same manner as MPO. Modified Earle’s balanced
salt solution (MEBSS) was prepared from concentrated stocks to final concentrations 144 mM
NaCl, 5.4 mM KCl, 800 µM MgSO4, 800 µM NaH2PO4, 5.6 mM glucose, 4.0 mM HEPES,
and 1.2 mM CaCl2 added last to prevent precipitation. Once mixed, working MEBSS was
adjusted with NaOH and HCl to pH = 7.4 and sterilized by filtration. All microtiter plate
experiments were performed using 96-well, black-walled, flat-bottom, tissue culture-treated
polystyrene microtiter plates (Corning Inc.; Corning, New York; product number 3603).
2.2.2 Bioluminescence imaging
Bioluminescence images were obtained with the ONYX/M imaging system with a
XR/MEGA-10Z camera (Stanford Photonics; Palo Alto, California), the IVIS100, or the
IVIS50 imaging systems (Caliper Life Sciences/PerkinElmer; Waltham, Massachusetts) as
noted in the detailed methods descriptions. All whole-blood imaging sequences were obtained
with sample plates warmed by a 37 ℃ stage heater. All IVIS images were obtained as 1
min integrations with F-number = 1, 8×8 pixel binning, and field of view (FOV) = 10 cm
unless otherwise noted. IVIS images were exported as raw counts using Living Image 2.60.1
(Xenogen/PerkinElmer). Images in the ONYX/M were obtained with 10 s integrations to
prevent camera saturation and combined into 1 min images with the Fiji distribution of
ImageJ image analysis software.33 ONYX data were either gathered as raw luminescence or
counts depending on hardware capability, as noted in detailed experiment methods.
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2.2.3 Data analysis and statistics
Images were quantified with the Fiji distribution of ImageJ image analysis software.33 Data
from the ONYX/M were processed to correct for optical vignetting as detailed in the Appendix
Section §7.4.2 on page 229. Regions of interest (ROIs) were created in microtiter plate arrays
using the Quadrangular ROI array program, the source code of which can be found on
page 226. Quantifications were normalized to image ROI pixel area to account for inter-
experiment differences in ROI layout. All statistical analyses were performed in IBM SPSS
Statistics 21 (Armonk, New York) unless otherwise noted. The novel weighted least squares
(WLS) regression method is explained in detail in Appendix Section §7.2 and the code for
implementing the method can be found on page 212. Nonlinear regression confidence bands
were calculated with the delta method.34
2.2.4 Human plasma samples
Human blood was obtained from the cephalic vein of healthy volunteers into lithium heparin
vacuum tubes for whole blood experiments and K2EDTA tubes for plasma isolation. Plasma
was isolated by two-stage centrifugation at 4 ℃: 1,000 × g in the collection tubes for 15 min
followed by 14,000 × g in microcentrifuge tubes for 10 min. Plasma was stored at −20 ℃
and thawed at 4 ℃ before use. The Institutional Review Board at Washington University in
St. Louis approved these study protocols.
2.2.5 MPO bioluminescence in blood ex vivo
All solutions were prepared in MEBSS without added serum. Blood was drawn immediately
before use. Mouse and rat blood was obtained after anesthetizing the animals with 2% v/v
isoflurane in oxygen. Mouse blood was collected by lancet puncture to the facial vein and
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allowed to flow into a 400 µL lithium heparinized tube. Rat blood was collected from the
lateral tail vein via a 300 µL syringe and a 29.5 gauge needle. Once drawn, the blood was
carefully transferred to a 400 µL lithium heparinized tube. Data in Figure 2.1A were obtained
by mixing 50 µL blood with 50 µL PMA or DMSO pre-mixed with luminol, final concentration
100 µM, and imaging in the ONYX/M. Data in Figure 2.2 and Figure 2.3 were obtained by
combining 100 µL mixed blood and bioluminescent probe with 100 µL PMA or DMSO in
a microtiter plate; final concentrations for each experiment were 0.5% v/v blood, 100 µM
luminol or L-012, and 5 µM PMA or equivalent 0.5% v/v DMSO and imaged in the IVIS100.
Data in Figure 2.4 were obtained by combining 25 µL PMA or DMSO, 25 µL 4-aminobenzoic
hydrazide (4-ABH) dilution, and 50 µL diluted rat blood before imaging in the IVIS100 with
16×16 binning and a 15 cm FOV.
2.2.6 MPO halogenation kinetics
Halide bioluminescence data shown in Figure 2.5A were obtained by making a halide-free
phosphate buffer (5.19 mM NaH2PO4 and 4.81 mM Na2HPO4, pH = 7.0) and supplementing
with sodium halide salts. Bioluminescence was initiated by arraying a microtiter plate with
50 µL H2O2 (200 µM final concentration) and adding 150 µL of a halide solution containing
L-012 (final concentration 100 µM) ±MPO in the same phosphate buffer. Individual halide
titrations shown in Figure 2.5B were performed in an acidic citrate buffer system (3.09 mM
citric acid and 21.9 mM trisodium citrate, calculated pH (CpH) = 6.0). 45 µL buffered H2O2
with a final concentration 100 µM was added to 35 µL (pseudo)halide solution in each well.
The reaction was initiated by adding 150 µL L-012 (final concentration 35 µM) ±MPO.
Cross-titrations of Cl– and Br– shown in Figure 2.6 were performed by serially diluting NaCl
and NaBr separately in water before arraying 50 µL of each halide solution in quadruplicate
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into microtiter plate wells. Each of the 100 µL mixed halide solutions in the wells received
50 µL solutions prepared to give final concentrations of 8.84 mM NaH2PO4, 1.22 mM
Na2HPO4, 100 µM L-012, and either 500 ng/L MPO diluted into Dulbecco’s phosphate
buffered saline (DPBS) or buffer control. The reaction was initiated by the addition of H2O2
with a final concentration of 200 µM before immediate photon counting in the ONYX/M.
2.2.7 MPO bioluminescence with glucose oxidase H2O2
generation
Cross titrations in Figure 2.7 were performed in DPBS-buffered solutions mixed in a 96-well
microtiter plate and imaged in the ONYX/M with photon-counting enabled. Glucose and
GOx cross-titration reactions in Figure 2.7A were initiated by sequentially mixing 50 µL L-012
(15 µM final concentration), 50 µL GOx, and 100 µL glucose. MPO and GOx cross-titration
reactions shown in Figure 2.7B were initiated by sequentially mixing 50 µL MPO, 50 µL
GOx, and 100 µL pre-mixed L-012 and glucose (final concentrations 30 µM and 20 mM,
respectively).
2.2.8 Bioluminescence spanning linear pH titrations
In order to increase precision in measuring the effects of pH on MPO-dependent and
-independent oxidation of luminol and L-012, buffers with overlapping pK a coverage were
tested with an electronic pH meter. Buffer planning and simulated titrations were completed
in CurTiPot v3.6.1.35 The buffer system used in Figure 2.8 was chosen for its wide, near-linear
buffering range. The final solution contained 2.4 mM of each: Na2EDTA dihydrate, Tris HCl,
lysine, and trisodium citrate, the pK as of which are shown in Figure 2.8A. Buffer capacity
was measured at room temperature with stepwise addition of ~5 M NaOH or ~12 M HCl,
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shown compared to the CurTiPot predictions in Figure 2.8B. Stock buffer solution titrations
to pH = 4.0, 5.0, 6.0, 7.0, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, and 11.0 were made with the same HCl
and NaOH, filter sterilized, and stored at 4 ℃ for future use. Basal rate chemiluminescence
shown in Figure 2.8C was measured by serially diluting H2O2 at into each of the buffer
solutions, arraying two 96-well microtiter plates (in groups of 11 as they were imaged) with
5 µL of either luminol or L-012 in water. Each reaction was initiated by adding 95 µL each
pH×H2O2 solution to a plate row containing one of the two probes every 45 s. The signal
was strongly dependent on reaction duration, so each 30 s image was taken 45 seconds apart
in the IVIS100 (8×8 binning, 15 cm FOV) so each row had an image taken at the same
reaction timepoint.
A simplified, mostly inorganic buffer system was chosen for pH experiments involving
MPO in order to minimize the chance of pharmacological effects from the buffer components.
The buffer was prepared with 120 mM NaCl and 10 mM of each NaH2PO4, B(OH)3, and
sodium acetate. The pH was adjusted with ~5 M NaOH as shown compared to the CurtTiPot
prediction in Figure 2.9A. Large stock volumes of buffered pH = 6.0, 6.5, 7.0, 7.4, 8.0,
and 9.0 were filter-sterilized and stored at 4 ℃ until use. MPO solutions were prepared
in corresponding buffers accounting for dilution to give 50 µg/L final MPO concentration.
Solutions of final concentrations 0, 10, 100, and 1,000 µM H2O2 in water were prepared
accounting for dilution into the reaction volume, as were solutions of 10 µM either luminol or
L-012 in water. Reactions were prepared by sequentially aspirating 85 µL of a specific pH
buffer, 5 µL air, 5 µL of the luminol or L-012 solution, 5 µL air, 5 µL H2O2 solution, and
a final 5 µL of air into tips of a multichannel pipette. Reactions were initiated by rapidly
expelling the entire tip volume into microtiter plate wells, the large bolus of buffer serving
as a turbulent mixing step. Imaging began precisely 3 s after addition with the normal
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maximum instrument gain = 1.750 for luminol plates and gain = 1.400 for L-012 solutions to
prevent camera saturation or damage. Ratios from the 10 µM H2O2 series taken at the 2 min
timepoint are shown in Figure 2.9B and were calculated using log-linked gamma regression.
Solubility curves for L-012 in acidic buffer were measured by serially diluting L-012 into
water before adding to CpH = 5.75 buffer containing 4.50 mM citric acid, 20.5 mM trisodium
citrate, and 250 mM NaBr in 1 mL polystyrene cuvettes. Absorbance at 550 nm was measured
every 5 s for 2 min and the slope from unweighted linear regression was calculated with 95%
confidence intervals.
2.2.9 Plasma filtrate titration
Plasma inhibition titrations shown in Figure 2.11 were obtained by first preparing centrifugal
ultrafiltration concentrators (Corning Life Sciences Spin-X tubes with 5 kDa and 100 kDa
filtration membranes, product numbers 431482 and 431486) by filtering 6 mL ultrapure
water for 20 min at 4 ℃, 4,000 × g to remove contaminants from the manufacturing process.
Plasma was collected from the cephalic vein of a healthy volunteer into a K2EDTA vacuum
tube as described on page 42. Plasma was diluted to 0.5% v/v in CpH = 6 citrate buffer
containing 3.1 mM citric acid, 22 mM trisodium citrate, and 10 mM NaBr, which was then
loaded into the filtration tubes and spun for 1 h at 4 ℃, 4,000 × g. Control plasma was
diluted into the same buffer and stored at 4 ℃ for the centrifugation duration to serve as
a control. Filtrates or dilute whole plasma were further diluted into the same buffer along
with reagents adjusted for final reaction volumes to give 500 ng/L MPO and 50 µM L-012.
Reactions were initiated by arraying microtiter plates with 10 µL H2O2 (final concentration
50 µM) and adding 75 µL diluted plasma filtrates supplemented with MPO and L-012 before
immediately imaging raw luminescence in the ONYX/M. Bioluminescence was intensity was
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integrated for 1 min and fit to the equation
B = Ball maxIC
H
50
[filtrate]H + ICH50
(2.1)
to quantify the extent of plasma inhibition. The term Ball max refers to the common asymptotic
maximum shared by all plasma filtrates, while the terms H and IC50 were calculated for
each filtrate. Confidence bands were calculated using the delta method.34
2.2.10 Antioxidant titration
Titration curves to quantify bioluminescence inhibition by ascorbic and uric acids shown
in Figure 2.12 were obtained with similar experimental protocols. A final in-well MPO
concentration of 80 ng/L was chosen based on 20 µg/L MPO, typical of a healthy donor,
at a sample dilution of 0.4% v/v based on previous plasma bioluminescence assays. Both
series of experiments were performed in CpH = 6.0 citrate buffer containing 20 mM NaBr,
3.05 mM citric acid, and 22.0 mM trisodium citrate. The ascorbic acid titration shown
in Figure 2.12A was obtained by co-diluting ascorbic acid with constant concentrations of
MPO (80 ng/L final concentration) and L-012 (30 µM final concentration). The oxidizer
solution contained buffered H2O2 at a final concentration 100 µM. The uric acid titration in
Figure 2.12B also included 200 ppm v/v polysorbate 20 (Tween20) in the dilution buffer to
reduce inter-replicate variance. 30 µM final L-012 was added to the oxidizer solution along
with H2O2 immediately before imaging. In both experiment series, 75 µL of each antioxidant
solution was arrayed into a microtiter plate in quadruplicate and imaging raw luminescence
was initiated in the ONYX/M immediately after the addition of 75 µL oxidizer solution.
Inhibition data were quantified from 1 min exposures taken at the 1 min timepoint. Effects
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of ascorbic acid were quantified using equation
B = Bmin +
(Bmax −Bmin) IC50H
IC50
H + [ascorbic acid]H
(2.2)
where Bmin and Bmax are the asymptotic minimum and maximum, H is the Hill coefficient,
and IC50 is the concentration of ascorbic acid with half-maximal inhibition. Uric acid
inhibition was regressed with the same equation, but the F -ratio test determined the term
Bmin to be insignificantly different from 0, thus the simplified equation
B = BmaxIC50
H
IC50
H + [uric acid]H
(2.3)
required fewer degrees of freedom and thus more precision in the remaining terms H and
IC50. Confidence bands were calculated using the delta method.34
2.3 Results
2.3.1 L-012 ROS sensitivity compared to luminol in whole blood
ex vivo
Previously published data demonstrate that luminol is specific for MPO activity in vivo and
in blood ex vivo, but the luminol analogue L-012 is not as well-studied and reports on the
ROS detected by L-012 differ across the literature.28–30,36–38 Although luminol was sensitive
enough to detect ROS production in blood diluted below 0.1% v/v, L-012 had sufficient
sensitivity to detect single-cell bioluminescence. (Figure 2.1)
To directly compare the sensitivity of luminol and L-012, fresh blood collected from adult
male Sprague-Dawley rats and C57BL/6 mice were diluted into MEBSS with each probe.
Rats have more circulating neutrophils than mice, and of the common inbred mouse strains,
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Figure 2.1: Bioluminescence of human blood ex vivo. (A) Serial dilutions of whole human blood
from a healthy volunteer into MEBSS and imaged with 100 µM luminol after treatment with 5 µM PMA or
0.5% v/v DMSO control. Raw data from individual replicates are shown (n = 4). (B) Images of individual
blood cells treated with 1 µM PMA and 50 µM L-012 in an MEBSS imaging solution. The skin of a healthy
volunteer was pricked with a 29.5 gauge needle, which was then gently agitated into imaging solution. These
images were obtained by integrating luminescence for 1 min at the 10 min timepoint.
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C57BL/6 mice have relatively limited acute inflammation activity;39–42 as expected from this,
rat blood produced more bioluminescence signal with either probe when treated with PMA.
Blood from either animal had similar times to peak bioluminescence of 15–20 min, but rat
blood required more time for signal to decay back to the DMSO-treated control baseline.
L-012 was ~20–40-fold brighter than luminol in blood from both animals. (Figure 2.2A)
Sensitivity (signal ratio of PMA-induced bioluminescence to DMSO-treated control) was also
greater with L-012 by a factor of ~2. (Figure 2.2B)
2.3.2 L-012 specificity for whole-blood MPO activity
To directly compare the specificity of luminol and L-012 for MPO activity, bioluminescence
with each probe using fresh blood from Mpo–/– and Mpo+/+ C57BL/6 mice was compared.
Bioluminescence from the Mpo+/+ mice was as previously observed. (Figure 2.3A) Luminol
bioluminescence did not differentiate Mpo–/– blood treated with PMA from that treated
with DMSO. Mpo–/– blood imaged with L-012 after PMA treatment showed increased
bioluminescence compared to DMSO control but rapidly reached a sharp threshold to a signal
plateau that was maintained for the duration of the time series. (Figure 2.3B)
Specificity of L-012 for MPO activity was also verified pharmacologically with the MPO
inhibitor 4-ABH. L-012 bioluminescence in whole blood from Sprague-Dawley rats treated
with PMA showed similar initial rates of increase in the first 5 min of imaging. Peak
bioluminescence output was inversely proportional to 4-ABH concentration and was reached
earlier with more inhibitor present. (Figure 2.4A) Regression using bioluminescence from
each peak timepoint shows that 4-ABH inhibits L-012 bioluminescence with an IC 50 = 63 µM
(95% confidence interval 48–78 µM), consistent with literature reports of MPO inhibition.28,43
(Figure 2.4B)
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Figure 2.2: L-012 bioluminescence in rat and mouse blood ex vivo. (A) 0.5% v/v blood from either
C57BL/6 mice or Sprague Dawley rats in MEBSS imaged with 100 µM luminol or L-012 after treatment
with 5 µM PMA or 0.5% v/v DMSO control. (B) Signal from PMA-treated blood normalized to DMSO
control by log-linked gamma regression. Colored bands are 95% confidence intervals about the mean ratio
(n = 4). Dashed line denotes a ratio = 1.
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Figure 2.3: ROS specificity of L-012 in Mpo–/– blood ex vivo. (A) 0.5% v/v blood from Mpo+/+ or
Mpo–/– C57BL/6 mice imaged with 100 µM luminol or L-012 after treatment with 5 µM PMA or 0.5% v/v
DMSO control. Raw data (n = 4) are shown. (B) Bioluminescence from PMA-treated blood normalized to
signal from DMSO-treated controls. Ratios were determined by log-linked gamma regression and are shown
as mean ± 95% confidence intervals. Dashed line denotes a ratio = 1.
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Figure 2.4: L-012 bioluminescence inhibition by 4-ABH ex vivo. Diluted Sprague Dawley rat
blood imaged with 100 µM L-012 after treatment with 5 µM PMA or 0.5% v/v DMSO control. (A) Time
series showing that 4-ABH decreases total luminescence as well as the duration of active ROS generation.
(B) Luminescence data from each peak time-point fit a standard inhibition model with IC 50 = 63 µM (95%
confidence interval 48–78 µM). This is similar to inhibition observed with luminol bioluminescence.28,43 Data
are plotted as mean ± standard deviation (n = 4). Regression line and 95% confidence bands are shown as a
dashed line and gray shading, respectively.
2.3.3 Halide substrates for MPO bioluminescence
Literature reports of MPO activity in the presence of various (pseudo)halide electron donors
suggest that physiologic Cl– is the least effective in reducing MPO compound-I back to native
MPO: Br–, I–, and SCN– have incrementally higher affinity.44–47 From this, it was expected
that bioluminescence intensity would have the same relationship to halogenation substrate.
Preliminary data confirmed that MPO-dependent bioluminescence in the presence of Br– was
many orders-of-magnitude brighter than that using only Cl–, but I– failed to differentiate MPO
from buffer. (Figure 2.5A) Titration of each of the four substrates provided stronger evidence
that L-012 bioluminescence is not indicative of all MPO activity but rather of chlorination and,
more so, bromination to respectively generate HOCl and HOBr. Bioluminescence substrate
efficiency was quantified by approximating the complex kinetics of MPO (see Figure 1.3 on
page 13) with the Michaelis-Menten equation, showing a Km = 17 mM (95% confidence
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Figure 2.5: MPO halogenation substrate kinetics. (A) Bioluminescence time series of MPO
halogenation in the presence of 200 µM H2O2, 100 µM L-012, and sodium halide salts in pH = 7.0 phosphate
buffer. Insets in the NaCl and NaI plots are the same data vertically scaled according to the axis label
to show detail. 150 mM NaCl allowed some MPO resolution, but this was quenched at 500 mM. Despite
literature reports of I– as the most reactive halide for MPO halogenation,46,48 NaI did not differentiate MPO
from buffer. Of the three true halides, Br– bioluminescence was orders-of-magnitude brighter. (B) Separate
titration curves of (pseudo)halides ±MPO with 100 µM H2O2 and 30 µM L-012 in a CpH = 6.0 citrate buffer.
Bioluminescence was measured for 1 min after mixing reagents in a microtiter plate. Both Cl– and Br– can be
fit as Michaelis-Menten substrates: Cl– giving a Km = 17 mM (95% confidence interval 10–23 mM) and Br–
giving Km = 2.3 mM (95% confidence interval 1.7–2.9 mM). Data are plotted as mean ± standard deviation
(n = 4). Regression with shaded 95% confidence bands are shown where applicable.
interval 10–23 mM) for Cl– and Km = 2.3 mM (95% confidence interval 1.7–2.9 mM) for Br–.
The ~10-fold difference in Km as well as bioluminescence signal magnitude are consistent
with the literature.46 However, MPO reactions involving I– and SCN– did not allow for
similar bioluminescence, even over a wide range of substrate concentrations. (Figure 2.5B)
Bromination is inhibited by excess Cl–, as expected if Cl– is a competing MPO substrate with
slower kinetics. In the absence of Br–, chlorination bioluminescence is saturable with excess
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Figure 2.6: Chloride and bromide as competing MPO substrates. Cross-titration of Cl– and Br–
in the presence of 100 µM L-012, 200 µM H2O2, and 500 ng/L MPO or buffer control. Raw bioluminescence
data (n = 4) from the 5 min timepoint are shown. (A) Bioluminescence increases with Cl– in the absence of
Br–. In the presence of Br–, Cl– acts as an inhibitor. (B) The same data as in (A) arranged to show the
effect of Br–. MPO bioluminescence is saturable with Br– at all concentrations of Cl–. Peak bioluminescence
occurs with Br– in the absence of Cl–.
Cl–, but it decreases signal when Br– is available. (Figure 2.6A) The same data show the
saturable kinetics of bromination with a lower asymptote with increasing Cl–. (Figure 2.6B)
2.3.4 Hydrogen peroxide effects on MPO kinetics
H2O2 has the potential to function as both a substrate for MPO bioluminescence via
halogenation cycling and an inhibitor via shunting MPO mass into the slower peroxidation
cycles. (Figure 1.3) In order to investigate the effects of H2O2 concentration on MPO
bioluminescence with L-012, H2O2 was generated with GOx and substrate d-glucose. This
allows reaction duration to be used as an approximation for H2O2 concentration as an
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alternative to discrete concentrations varying between solutions. The assumption of linear
H2O2 generation by this system over time was tested with direct L-012 oxidation. Linear
increase in signal across a wide range of GOx concentrations in the presence of 20 mM
d-glucose were obtained for >1 h. (Figure 2.7A) Using this system, the inhibitory effect
of excess H2O2 on MPO bioluminescence was clearly observable. Direct L-012 oxidation
by H2O2 occurred in the absence of MPO as previously observed, but in the presence of
MPO bioluminescence fell after a duration made shorter by increasing concentrations of GOx.
(Figure 2.7B) This confirmed that excess H2O2 will inhibit MPO bioluminescence as suggested
by the literature, but this H2O2 effect on MPO activity is known to by pH-dependent.49,50
2.3.5 Optimizing pH for MPO detection with L-012
In order to investigate baseline oxidation of L-012 in a wide range of pHs, a linear buffer with
dispersed pK as was designed (Figure 2.8A) and tested against the predicted titration curve
from pH = 4 to pH = 11. (Figure 2.8B) As hypothesized, luminol was oxidized more readily
with increasing pH but was not significantly affected until pH > 7. L-012 was similarly more
sensitive to direct oxidation by H2O2 at higher pH, but began to be susceptible at pH > 5.
Unexpectedly, background chemiluminescence from both probes depended more on pH than
H2O2 concentration, suggesting that non-specific signal can be eliminated by optimizing
solution conditions. (Figure 2.8B)
A simplified buffer system with a near-linear titration from pH = 6 to pH = 11 was
designed to test the combined effects of pH on MPO activity and resulting luminol and L-012
oxidation. This system contained fewer components to reduce the risk unforeseen buffer
interactions, did not contain chelators that could potentially disrupt the heme cofactors of
MPO, and was free of amines that could react with MPO-produced HOCl. As with the
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Figure 2.7: Generating H2O2 with GOx. Using glucose and GOx instead of discrete H2O2 solutions
allowed for precise observation of MPO bioluminescence kinetics by using reaction duration as an approximation
of relative H2O2 concentration. (A) Bioluminescence time series of cross-titrated d-glucose and GOx with
15 µM L-012 in DPBS. The ONYX/M detected non-specific L-012 oxidation by H2O2 produced by the
glucose-GOx system. Signal intensity was proportional to substrate glucose concentration through multiple
orders of magnitude, but it inhibited bioluminescence at high concentrations. Moderate glucose concentrations
produced linear H2O2 for >1 h. (B) Bioluminescence time series of GOx titrated ±MPO in the presence
of 30 µM L-012 and 20 mM d-glucose. MPO-depended bioluminescence was detectable above direct L-012
oxidation by H2O2. Intensity and time of the transient signal peaks were influenced by GOx concentration. At
higher concentrations, H2O2 shifted from an MPO bioluminescence substrate to an inhibitor. This observation
agrees with reported electrochemical observations of MPO kinetics in the literature.49
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shown.
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previous buffer system, observed titration closely matched the simulations performed in
CurTiPot. (Figure 2.9A) Gamma regression to determine the signal ratio of 50 µg/L MPO
to buffer control showed that luminol was less susceptible than L-012 to the effects of pH on
MPO detection. Although L-012 was consistently brighter than luminol, its sensitivity is poor
above pH = 7 due to direct oxidation by H2O2. However, its sensitivity was ~100-fold greater
than that of luminol at pH = 6. (Figure 2.9B) Observations of L-012 precipitation in buffered
stock solution tubes raised concerns about solubility at low pH; aggregation on pipette-
or assay surfaces is a potential source of experimental error. L-012 began to precipitate
at concentrations > 60 µM in a pH = 5.75 buffer, suggesting a compromise between pH
requirements for MPO specificity and L-012 solubility should be used to assay MPO activity.
(Figure 2.9C)
Literature reports that MPO kinetics shift to favor halogenation over peroxidation in
acidic solutions, allowing for higher concentrations of substrate H2O2 without loss of MPO
activity.49,50 Pure human MPO imaged with L-012 in an acetate buffer with a CpH = 5.0
resulted in exponential decay of bioluminescence over time as expected if H2O2 was not
shifting MPO away from the halogenation reaction. (Figure 2.10A) Bioluminescence was
linear with MPO concentration up to 1 mM H2O2, and regression slopes increased with H2O2
as well. (Figure 2.10B)
The improvements seen with low-pH imaging solutions did not translate to MPO in
human plasma, however. MPO-independent bioluminescence were not a major confounding
variable with H2O2 concentrations below ~250 µM; reduced overall signal in acidic buffer
compounded the loss of signal associated with imaging MPO in the presence of plasma
proteins, making MPO measurement imprecise. (Figure 2.10C) Even after normalizing to
baseline signal, imaging with L-012 in mildly acidic buffer showed improved MPO resolution
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Figure 2.9: pH-dependent MPO resolution with luminol and L-012. (A) Titration curve of ~5 M
NaOH into 45 mL of a near-linear buffer system containing 10 mM PO43–, Ac–, and B(OH)3. Each pKa and
conjugate base relevant to the pH range is annotated along the pH axis. Dashed line shows simulated titration
values obtained with CurTiPot v3.6.1.35 (B) Ratio of bioluminescence intensity (50 µg/L MPO:buffer) in
the presence of 10 µM H2O2 and 10 µM luminol or L-012 integrated for 1 min after a 2 min incubation in
the ONYX/M. Ratios were calculated using log-linked gamma regression and are plotted as mean ± 95%
confidence interval. (C) Precipitation rates of L-012 in buffer made from 250 mM NaBr, 20.5 mM trisodium
citrate and 4.50 mM citric acid, CpH = 5.75. L-012 was mixed with buffer in a 1 mL plastic cuvette and
continuously monitored for changes in 550 nm absorbance in a spectrophotometer over 2 min. Changes in
absorbance were linear for this duration, due to pre-equilibrium precipitation of L-012 onto the cuvette wall.
Linear regression slope parameter (ΔAbs550 / min) ± 95% confidence interval are shown.
compared to strongly acidic buffer across an order-of-magnitude range of H2O2 concentrations.
(Figure 2.10D)
2.3.6 MPO inhibition by plasma
Titrating fresh plasma from a healthy donor directly into an acidic buffer containing
MPO, L-012, and H2O2 resulted in an IC 50 = 28 ppm v/v (95% confidence interval
21–35 ppm v/v) and a Hill coefficient H = 0.59 (95% confidence interval 0.51–0.67) when
regressed with equation (2.1). Ultrafiltration to selectively remove plasma components
resulted in more abrupt inhibition across the dilution range with H = 1.2 (95% confidence
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Figure 2.10: Acidic L-012 MPO resolution with varying H2O2. (A) Time series of MPO
bioluminescence with 40 µM L-012 diluted into buffer containing 1 mM EDTA, 150 mM NaBr, 16.7 mM
sodium acetate, and 8.33 mM acetic acid with a CpH = 5.0. Raw data (n = 4) from 1 min exposures in the
ONYX/M are shown. (B) MPO resolution from these data taken at the 5 min timepoint. Data are plotted
as mean ± standard deviation. WLS regression ± 95% confidence bands are shown as dashed lines and
shaded areas, respectively. (C) Time series of MPO bioluminescence with human plasma ± 100 µg/L MPO
diluted to 0.1% v/v in buffer containing 1 mM EDTA, 20 mM NaBr, 10 µM L-012, and varying H2O2. Each
of the pH solutions contains 25 mM of their respective buffering agent. Raw bioluminescence data (n = 4)
are shown. MPO is annotated with pre-dilution concentrations. (D) Signal ratio at the 5 min timepoint
of the time series shown in (C). Ratios are presented as mean ± 95% confidence interval as determined by
log-linked gamma regression. Dashed line indicates a ratio = 1.
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Figure 2.11: Whole plasma inhibition of MPO. (A) Titration curves of plasma filtrates in the presence
of 500 ng/L MPO, 50 µM L-012, and 10 mM NaBr buffered with 3.05 mM citric acid and 21.9 mM trisodium
citrate. Bioluminescence was measured for 1 min after adding H2O2 with a final concentration of 100 µM.
MPO inhibition by plasma was quantified by equation (2.1). Whole plasma inhibited MPO bioluminescence
with an IC 50 = 28 ppm v/v (95% confidence interval 21–35 ppm v/v) and H = 0.59 (95% confidence
interval 0.51–0.67). Filtration shifted the values of the IC 50 to 120 ppm v/v (95% confidence interval
110–140 ppm v/v) and the Hill coefficient H to 1.2 (95% confidence interval 1.1–1.3), resulting in sharper and
right-shifted inhibition curves. Data are shown as mean ± standard deviation (n = 4). Nonlinear regression
and 95% confidence bands are shown as dashed lines and shaded areas, respectively. (B) Regressed values
of IC50 for each plasma filtrate shown in part (A). Filtration cutoffs 5 and 100 kDa were not significantly
different by IC 50 or H (p = 0.21 and 0.30, respectively). Data are presented as the estimate ± 95% confidence
interval.
interval 1.1–1.3). Ultrafiltration also increased the IC 50 to 120 ppm v/v (95% confidence
interval 110–140 ppm v/v). (Figure 2.11A) There was no significant difference between 5 kDa
and 100 kDa ultrafiltration by either IC 50 (p = 0.21) or H (p = 0.30). (Figure 2.11B)
To determine the extent of small-molecule antioxidants to MPO bioluminescence inhibition
by plasma, two major physiological antioxidants were titrated with pure MPO in the presence
of H2O2 and L-012. An MPO concentration of 80 ng/L was chosen to represent a 0.4% v/v
dilution of 20 µg/L MPO plasma. Ascorbic acid was the more potent antioxidant with an
IC 50 = 36 nM (95% confidence interval 31–41 nM) as determined by equation (2.2). As
ascorbic acid concentration approached the dilution-adjusted physiologic reference range of
140–360 nM, MPO-dependent bioluminescence was almost entirely quenched.51 (Figure 2.12A)
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Figure 2.12: Antioxidant contribution to MPO inhibition. Physiological small-molecule antioxidants
(A) ascorbic acid and (B) uric acid titrated in the presence of 20 mM NaBr, 200 ppm v/v Tween20, 80 ng/L
MPO, and 30 µM L-012 in buffer containing 3.05 mM citric acid and 22.0 mM trisodium citrate. MPO
concentration was chosen to recapitulate plasma with a physiologic level of 20 µg/L MPO diluted to 0.4% v/v.
Ascorbic acid titration data were regressed using equation (2.2) and uric acid data with equation (2.3).
Physiologic reference ranges adjusted for the 0.4% v/v dilution are shown as black bars. Ascorbic acid
inhibited MPO bioluminescence with an IC 50 = 36 nM (95% confidence interval 31–41 nM) and signal
was quenched to baseline at the dilution-adjusted reference range 140–360 nM. Uric acid inhibited MPO
bioluminescence with an IC 50 = 150 nM (95% confidence interval 120–180 nM), within the dilution-adjusted
reference ranges for males (96–220 nM) and females (64–170 nM). Data are shown as mean ± standard
deviation (n = 4). Nonlinear regression results are shown as dashed lines ± 95% confidence bands in gray.
Physiologic reference ranges from McPherson & Pincus.51
Uric acid also potently inhibited MPO bioluminescence but with a higher IC 50 = 150 nM (95%
confidence interval 120–180 nM) by equation (2.3). This is similar to the dilution-adjusted
reference range for adults of either sex, (96–220 nM) and (64–170 nM) for males and females,
respectively.51 (Figure 2.12B)
To determine if antioxidant inhibition could be mitigated by consumption with H2O2, the
d-glucose/GOx system was used in the presence of varying dilutions of human plasma. Unlike
as previously seen in buffer (see Figure 2.7A), bioluminescence showed biphasic kinetics as
H2O2 accumulated. The timing and duration of the transition from low- to high-slope kinetics
depended on plasma dilution more so than on the presence of exogenous MPO. (Figure 2.13A)
Despite this, each plasma dilution shared the timepoint of maximum MPO resolution. Beyond
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~10 min, MPO-independent L-012 oxidation resulted in converging bioluminescence from
plasma ± MPO. (Figure 2.13B) At the 10 min timepoint, unsupplemented plasma dilution
showed a linear relationship with bioluminescence inhibition. In contrast, plasma with
exogenous MPO did not show a linear relationship between dilution and bioluminescence
signal. (Figure 2.13C)
2.4 Discussion
Inflammation is well-established as a central driver of the atherosclerosis responsible for
the majority of CVD morbidity and mortality.1–6 Detection and quantification of acute
inflammatory cells, primarily neutrophils, with the chemiluminescent compound luminol
has been demonstrated in the literature.52 Luminol bioluminescence is MPO-dependent in
vivo and in blood ex vivo; plasma MPO content is also a rising biomarker for CVD risk
and progression.16–28 The luminol derivative L-012 has more sensitivity to oxidation than
luminol, but little is known about its specificity for ROS and its behavior when used as a
bioluminescence reporter in vivo and in vitro.29,32,36 Here, L-012 is characterized for use as
a bioluminescent reporter of MPO activity in the context of application to a plasma MPO
assay.
Although luminol can detect neutrophil activation in human blood diluted to <0.1% v/v,
L-012 can be used to visualize single cells undergoing a respiratory burst. (Figure 2.1) The
increased oxidation sensitivity of L-012 is apparent when compared directly to luminol with
whole blood imaging, as in Figure 2.2: total luminescence is increased by a factor of ~40 and
sensitivity to leukocyte activation increased by a factor of ~2. Despite the clear improvement
in oxidation detection, surprisingly little has been published on L-012 chemistry and reports on
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Figure 2.13: Nonlinear plasma inhibition of MPO bioluminescence. (A) Time series of
plasma ± 150 µg/L MPO serially diluted in the presence of 1 mM EDTA, 50 µg/L GOx, 200 mM d-
glucose, 130 mM NaBr, and 30 µM L-012 buffered with 35 mM Na2HPO4 and 15 mM NaH2PO4 (CpH = 7.2).
Lines represent raw signal of individual wells (n = 4). (B) Signal ratio of plasma + MPO normalized
to untreated plasma at each dilution. Mean ± 95% confidence band as determined by log-linked gamma
regression are shown for each dilution across the time series. (C) Raw data from the image captured
10 min into the H2O2 production by GOx. Oxidation of L-012 is inhibited by untreated plasma with a
strong linear trend. Bioluminescence from plasma supplemented with MPO increases with total concentration
until 400–500 ppm v/v, above which the inhibition from plasma components overcomes the increasing MPO
activity.
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its sensitivity and specificity for different ROS are often contradictory.29,30,36–38 As previously
shown with luminol, L-012 has specificity for MPO activity in vivo, although there is some
MPO-independent background luminescence from PMA-activated blood from Mpo–/– mice.28
(Figure 2.3) The kinetics of Mpo–/– blood bioluminescence and the relatively weak PMA
response characteristic of C57BL/6 mice suggests that the nearly absolute specificity of
luminol for MPO activity in blood ex vivo may be a result of instrumentation and poor
quantum yield as opposed to intrinsic luminol chemistry. MPO-dependent bioluminescence
composes an overwhelming majority of overall detectable signal from more robust acute
inflammatory systems, as evidenced by the effect of the potent, specific MPO inhibitor 4-ABH
on PMA-activated rat blood. (Figure 2.4)
Although L-012 bioluminescence reports MPO activity from activated leukocytes in diluted
blood, the optimal reaction conditions, substrates, and product ROS for measuring MPO
activity are not known. Of the four (pseudo)halide substrates for MPO compound I, SCN–
and I– have the greatest rate constants and that of Br– is only slightly lower; the physiological
substrate Cl– is many orders of magnitude slower to react with MPO.46 This suggests that
NaBr is a more suitable MPO assay reagent than NaCl, which was verified experimentally. As
expected, Cl– and Br– were competitive substrates for MPO halogenation and the resulting
L-012 bioluminescence. (Figure 2.6) Contrary to the literature-based hypothesis, SCN–
and I– were poor bioluminescence reagents despite their well-documented reactivity with
MPO. (Figure 2.5) This suggested that L-012 should not be considered a general reporter of
MPO activity and, from this, a bioluminescent assay system for MPO detection may require
different optimal conditions from those published for MPO activity measured by other means.
This is well-illustrated when considering solution pH as an assay parameter.
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Luminol is known to be highly chemiluminescent in the presence of H2O2 in alkaline
solutions, but the effects of pH on L-012 sensitivity to H2O2 and other ROS has not been
published. Unlike luminol, L-012 will begin to oxidize even absence of H2O2 at pH > 5;
addition of H2O2 causes further MPO-independent chemiluminescence detrimental to assay
specificity. (Figure 2.8C) Although such an adequately acidic environment to prevent
background chemiluminescence also favors the MPO halogenation cycle responsible for its
bioluminescence, literature suggests that probe oxidation by hypohalous acids is also impeded
at low pH.46,50,53 Further complicating the issue is decreased solubility of L-012 in acidic
buffers; restrictions on probe concentration must also be considered when optimizing an
assay parameter as superficially straightforward as pH. (Figure 2.9C) Not only does reporter
precipitation add experimental variance to any enzyme activity assay, but L-012 additionally
forms a visible film at the air-liquid interface as it crashes out of solution. The local
concentration of L-012 is very high in this film, which is also exposed to molecular oxygen
from ambient air. Numerous experiments were prematurely terminated when L-012 was
used too near to its solubility limit in acidic buffers, causing stochastic “flashing” in random
microtiter plate wells which were bright enough to saturate the camera and wash out all
adjacent signal.
H2O2 is also more nuanced than substrates in classic enzyme assay systems; not only
can H2O2 directly oxidize L-012 and reduce assay specificity, but it can also inhibit the
halogenation reaction for which it is a substrate (see Figure 1.3 on page 13). As Figure 2.7B
illustrates, MPO-dependent bioluminescence is optimized in a narrow concentration of
H2O2, above which the MPO solutions are indistinguishable from their buffer controls.
As other reaction parameters are adjusted to maintain halogenation and reduce MPO-
independent L-012 oxidation, increasing H2O2 concentrations can be used while maintaining
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MPO resolution. (Figure 2.10A and Figure 2.10B) Although these experiments demonstrate
that reaction conditions can be manipulated to allow for robust linear MPO bioluminescence
with L-012, the discussion to this point has not considered a crucial component of a plasma
MPO activity assay.
As Figure 2.10 illustrates, optimization of MPO bioluminescence conditions in buffer is
insufficient for a plasma activity assay. Whole plasma is a complex mixture containing many
potent inhibitors of MPO activity and consequent bioluminescence. (Figure 2.11A) Although
macromolecular inhibitors such as ceruloplasmin have been identified in the literature, most
of the quenching activity of plasma is found in the <5 kDa fraction.54–58 (Figure 2.11B) This
agrees with the potent inhibition demonstrated by ascorbic acid; although it is one of many
small-molecule antioxidants in blood plasma, it alone is sufficient at physiologic concentration
to inhibit >95% of MPO-dependent bioluminescence in plasma. (Figure 2.12) Published
literature suggests that other compounds such as glutathione, cysteine, homocysteine, and
methionine are at least as potent in their MPO inhibition.59–61 These molecules not only
quench nearly all plasma bioluminescence, but represent a matrix of confounding parameters
that are highly variable between individuals and across time within individuals. Their effect
is further made problematic by the nonlinear relationship between plasma concentration and
inhibition; the extent of this nonlinearity is also a function of MPO activity as demonstrated by
Figure 2.13C. Dilution of the plasma below the threshold of inhibitory effects was unsuccessful
as MPO was also diluted to undetectable concentrations.
ELISAs measuring plasma MPO concentration bypass all of these difficulties through
immunospecific MPO isolation. Doing so comes at great cost, both in the monetary cost
of commercial ELISA kits and the time required to perform the many steps composing the
assays. Although some veterinary assays have been developed to utilize intrinsic MPO activity
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after immunologic purification, these approaches still use expensive biologic reagents that
limit accessibility to a test this project is intended to apply to CVD, which disproportionately
afflicts people with limited access to costly health care.62,63
In conclusion, the work presented in this chapter characterizes many previously
unpublished characteristics of the MPO–L-012 bioluminescence system that are important
factors in the design and development of a rapid assay for plasma MPO activity. Although
complex aspects of the system such as MPO kinetics and substrate/reporter interactions can
be exhaustively explored to find optimum conditions for MPO-dependent bioluminescence,
the parameter optima are not independent of plasma characteristics that vary widely between
samples. The remaining chapters will discuss the inception, optimization, and application of
a non-immunologic MPO assay that removes or mitigates confounding plasma components
before quantifying MPO activity with L-012 bioluminescence.
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Chapter 3
Myeloperoxidase sequestration on solid
substrates
3.1 Introduction
Over the last 20 years, inflammation has become a central component in the understanding of
cardiovascular disease (CVD) pathogenesis.1–4 As a consequence of this realization, biomarkers
of inflammation have joined those indicating congestive heart failure, elevated coagulation
cascade activity, and lipid oxidation as risk factors for major adverse cardiovascular events
(MACEs) such as myocardial infarction (MI) and stroke.5–8 One such indicator of inflammatory
leukocyte activation is myeloperoxidase (MPO), an enzyme found primarily in the azurophilic
granules of neutrophils. MPO concentration in either plasma or serum has been shown to be
a statistically relevant predictor of CVD risk, both for progression to symptomatic disease
and sequelae in patients presenting with a MACE.9–20 Clinical assays for plasma MPO use
immunological methods, primarily the sandwich enzyme-linked immunosorbent assay (ELISA),
to isolate MPO from other plasma components that prevent accurate measurement. Most
commercial assays rely on colorimetric oxidation of reporter dyes by horseradish peroxidase
(HRP) conjugated to secondary or tertiary antibodies instead of utilizing native MPO activity.
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MPO serves a physiological role in non-specific host defense by generating reactive
oxygen species (ROS), mostly in the form of hypochlorous acid (HOCl), at microbicidal
concentrations in phagosomes containing foreign microbes.21 MPO activity is non-specific;
ROS can damage host-biomolecules in the case of pathological inflammation such as that
found in atherosclerosis and other chronic disease processes.22 It comes as little surprise that
free MPO circulating through the body is inhibited, both by small-molecule antioxidants
and specific protein inhibitors such as ceruloplasmin.23–27 This was confirmed in the previous
chapter as whole plasma proved a potent inhibitor of MPO halogenation activity as read by
L-012. A bioluminescence assay thus requires a method to isolate MPO from the inhibitory
components in plasma. ELISAs accomplish this with anti-MPO immunoglobulins adsorbed
onto microtiter plates. A small body of literature investigates the concept of isolating MPO
in same manner as ELISA,1 but utilizing the intrinsic peroxidase activity to measure bound
protein in lieu of immunoconjugated HRP.28,29 The experiments described in this chapter
aimed at taking this simplified strategy further by completely eliminating immunoglobulins
from the assay. Solution conditions were optimized for selective retention of MPO from whole
plasma, disruption of MPO/inhibitor interactions, and L-012 bioluminescence sensitivity
and specificity for MPO activity. Additional experiments were conducted to find a suitable
bioluminescence standard curve against which human plasma samples with unknown MPO
can be calibrated. The resulting assay technique, referred to as the ‘MPO activity on a
polymer surface (MAPS) assay,’ is tested against commercially available ELISAs in Chapter 4.
1 in order to better diagnose and treat inflammatory diseases in horses
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3.2 Methods
3.2.1 Reagents and materials
Lyophilized L-012 was provided by Wako Chemicals USA (Richmond, Virginia; product
number 120-04891) was resuspended to 16.1 mM in ultrapure water and stored in 200 µL
aliquots at −20 ℃. Lyophilized human MPO from EMD Millipore/Calbiochem (Darmstadt,
Germany; product number 475911) was resuspended in pH = 6.0 buffer containing 100 mM
NaCl and 50 mM acetate, as recommended by the supplier, with final concentration 100 mg/L.
Single-use 10 µL aliquots were stored at −20 ℃. Lyophilized, citrated bovine plasma from
Sigma Aldrich (Saint Louis, Missouri; product number P4639) was resuspended to the original
10 mL with ultrapure water and gently agitated at room temperature until particulates had
dispersed. Reconstituted bovine plasma (RBP) was stored at −20 ℃. All other reagents were
supplied by Sigma Aldrich.
Saturated ammonium sulfate ((NH4)2SO4) was prepared by warming ultrapure water in a
37 ℃ water bath and incrementally adding solid (NH4)2SO4 until solvation was not complete
within 10 min. The solution was then allowed to cool overnight to room temperature, resulting
in visible crystals on the floor of the glass bottle. Using a weighted average of published
(NH4)2SO4 solubility at various temperatures, the saturated solution was declared as 4.05 M
(NH4)2SO4 in all subsequent calculations.30
The Bio-Dot vacuum filtration apparatus (Bio-Rad Laboratories; Hercules, California;
product number 170-6545) was graciously provided by Dr. Jason Weber. Nitrocellulose
membranes were supplied by GE Osmonics, Inc. (Schenectady, New York; product number
EP4HY00010). Polyvinylidene fluoride (PVDF) membranes were provided by EMD Millipore
(Billerica, Massachusetts; product number IPVH00010). Nitrocellulose and PVDF filter plates
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were supplied by Pall Corporation (Port Washington, New York; product numbers 5022
and 5026). Polystyrene adsorption experiments were performed using 96-well, black-walled,
flat-bottom, tissue culture-treated polystyrene microtiter plates (Corning Inc.; Corning, New
York; product number 3603).
3.2.2 Bioluminescence imaging
Bioluminescence images were obtained with the ONYX/M imaging system with a
XR/MEGA-10Z camera (Stanford Photonics; Palo Alto, California). Images were obtained
with 10 s integrations to prevent camera saturation and combined into 1 min images with the
Fiji distribution of ImageJ image analysis software.31 ONYX data were either gathered as raw
luminescence or counts depending on hardware capability, as noted in detailed experiment
methods.
3.2.3 Data analysis and statistics
Images were quantified with the Fiji distribution of ImageJ image analysis software.31 Data
from the ONYX/M were processed to correct for optical vignetting as detailed in the Appendix
Section §7.4.2 on page 229. Regions of interest (ROIs) were created in microtiter plate arrays
using the Quadrangular ROI array program, the source code of which can be found on
page 226. Quantifications were normalized to image ROI pixel area to account for inter-
experiment differences in ROI layout. All statistical analyses were performed in IBM SPSS
Statistics 21 (Armonk, New York) unless otherwise noted. The novel weighted least squares
(WLS) regression method is explained in detail in Appendix Section §7.2 and the code for
implementing the method can be found on page 212. Nonlinear regression confidence bands
were calculated with the delta method.32
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3.2.4 Human plasma samples
Human blood was obtained from the cephalic vein of healthy volunteers into K2EDTA tubes
for plasma isolation. Plasma was isolated by two-stage centrifugation at 4 ℃: 1,000 × g in
the collection tubes for 15 min followed by 14,000 × g in microcentrifuge tubes for 10 min.
Plasma was stored at −20 ℃ and thawed at 4 ℃ before use. The Institutional Review Board
at Washington University in St. Louis approved these study protocols.
3.2.5 Passive membrane binding
Images shown in Figure 3.1A was obtained by serially diluting MPO into pH = 6.0 DPBS
with 5 mM acetic acid (AcDPBS). Each dilution was applied in 0.5 µL droplets to a dry
nitrocellulose membrane. The membrane was immersed in AcDPBS on an orbital mixer for
13 min before immersion for imaging in a solution containing 500 µM L-012 and 10 mM
hydrogen peroxide (H2O2) and integrating raw luminescence for 1 min in the ONYX/M.
Image shown in Figure 3.1C and quantified in Figure 3.1D were obtained by first washing
the MPO residue from a consumed stock tube with heat-inactivated fetal bovine serum
(ΔFBS). A microtiter plate was arrayed in a diagonal pattern of the unknown MPO ΔFBS at
100, 10, or 0% v/v in AcDPBS. A prototype membrane loading cassette was assembled with
this plate as shown in Figure 3.1B by layering a nitrocellulose membrane, a sponge pad used
in western blot cassettes, and a discarded micropipette tip rack over the wells and securing
with elastic straps and aluminum spring clamps. The cassette was inverted, gently tapped on
a benchtop, and left standing for 10 min before the membrane was removed and washed in
AcDPBS for 10 min. The membrane was immersed in AcDPBS containing 10 mM H2O2 and
1 mM luminol and imaged for raw luminescence in the ONYX/M.
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Data from PVDF filter plates shown in Figure 3.2 were obtained by diluting MPO into
AcDPBS. A PVDF plate was pre-treated with methanol and rinsed three times with AcDPBS
before loading wells with 50 µL of the MPO dilutions. After a 5 min (luminol plates) or
30 min (L-012 plates) incubation, MPO was aspirated from the wells and three 250 µL
AcDPBS washes removed unbound MPO. The plate was then imaged in the ONYX/M with
80 µL AcDPBS-based imaging solution containing 10 mM H2O2 and either 1 mM luminol or
500 µM L-012.
Nitrocellulose plates were similarly imaged in the presence or absence of human plasma as
shown in Figure 3.3. MPO was diluted to 2.5 µg/L into Dulbecco’s phosphate buffered saline
(DPBS) or 50 µg/L into fresh citrated human plasma collected from a healthy volunteer,
which was then diluted to 5% v/v into DPBS. Nitrocellulose wells received 100 µL DPBS
±plasma and ±MPO for 30 min while shaking at 850 rpm. Each well was washed three times
with 300 µL DPBS and imaged with either 500 mM NaCl DPBS with 200 µM H2O2 and
100 µM L-012 (Figure 3.3A) or DPBS adjusted to pH = 6.0 with 200 µM H2O2 and 100 µM
L-012 (Figure 3.3B). Data shown are raw luminescence from the ONYX/M quantified at the
2 min timepoint of each imaging sequence.
3.2.6 Vacuum cassette MPO assay
Vacuum cassette data shown in Figure 3.4A and Figure 3.4B were obtained by serially diluting
MPO into DPBS at the concentrations shown. A nitrocellulose membrane in the Bio-Dot
apparatus was prepared by filtering 100 µL DPBS through each of the wells before similarly
filtering 100 µL of each MPO solution. Each well was washed with 400 µL DPBS and vacuum
pressure was maintained until each well was dry. The cassette was imaged with the membrane
in place by adding 200 µL DPBS with 10 µM L-012 and 100 µM H2O2. Raw luminescence
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for the time sequence and the 2 min timepoint are shown. Data from the 2 min timepoint
could not be fit to equation (3.1) due to high variance.
A similar protocol was used to image MPO diluted into filtered ΔFBS before loading
onto nitrocellulose as shown in Figure 3.4C and Figure 3.4D. Endogenous MPO remaining in
the ΔFBS after heating was removed via 50 kDa cutoff ultrafiltration (Corning, Inc; product
number 431485) at 4 ℃, 10,000 rpm for 80 min. Serial MPO dilutions made into whole,
filtered ΔFBS were diluted to 1% v/v in DPBS; 500 µL of each dilution was added to wells
over a nitrocellulose membrane in the vacuum cassette. After the ΔFBS solutions were
filtered through the membrane, each well was washed with 300 µL DPBS and vacuum pressure
was maintained until each well was dry. The cassette was imaged with the membrane in place
by adding 200 µL DPBS with 10 µM L-012 and 100 µM H2O2. Raw luminescence for the
time sequence and the 2 min timepoint are shown. Data from the 2 min timepoint were fit
to the equation
B = Bmax1 + eH([MPO]−D50) (3.1)
where MPO is quantified by the pre-dilution concentration in whole, filtered ΔFBS, H is
the Hill coefficient, D50 is the half-saturation concentration, and Bmax is the asymptotic
maximum bioluminescence signal.
3.2.7 MPO adsorption onto tissue culture-treated polystyrene
Adsorption of MPO from buffer and human plasma shown in Figure 3.5 was investigated by
diluting fresh human plasma collected in K2EDTA vacuum phlebotomy tubes to 0.5% v/v in
calculated pH (CpH) = 6.5 buffer containing 6.28 mM Na2HPO4, 18.7 mM NaH2PO4, and
130 mM NaCl. Serial dilutions of MPO accounting for the 0.5% v/v dilution were made into
this buffer ± diluted human plasma. Tissue culture treated microtiter plates were arrayed
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with 50 µL of each MPO dilution in quadruplicate then incubated for 30 min on a 1,000 rpm
orbital shaker. Each well was aspirated dry and washed three times with 150 µL dilution
buffer and a final time with 300 µL buffer before receiving 150 µL CpH = 6.0 imaging solution
containing 200 µM H2O2, 50 µM L-012, 2.28 mM Na2HPO4, 22.7 mM NaH2PO4, 500 mM
NaCl, and 20 mM NaBr. Plates were shaken for 1 min at 1,000 rpm before imaging photon
counts in the ONYX/M. Calibration curves from the 5 min timepoint were used for WLS
regression. MPO is annotated with pre-dilution concentrations in whole plasma; the same
adjustment was made in annotating MPO in pure buffer.
MPO adsorption kinetics onto polystyrene as shown in Figure 3.6 were measured by
serially diluting MPO into ΔFBS and further diluting this to 0.5% v/v in a CpH = 6.5
buffer containing 130 mM NaCl, 6.30 mM Na2HPO4, and 18.7 mM NaH2PO4. Each MPO
concentration was added in triplicate to a tissue culture-treated plate at 0, 35, 65, 90, 110,
125, 135, and 140 min timepoints of 1,000 rpm orbital shaking duration. Immediately after
the final addition, wells were aspirated dry and washed four times with 150 µL dilution buffer.
Each well then received 150 µL CpH = 6.0 imaging solution containing 200 µM H2O2, 50 µM
L-012, 500 mM NaCl, 20 mM NaBr, 2.28 mM Na2HPO4, and 22.7 mM NaH2PO4. The
plates were shaken for 2 min at 1,000 rpm and imaged for photon count quantification in the
ONYX/M. Counts from the 5 min timepoint were used in WLS regression with pre-dilution
MPO concentrations.
The effects of anticoagulation were investigated as shown in Figure 3.7 by obtaining fresh
plasma from the same healthy volunteer using K2EDTA and lithium heparin phlebotomy
tubes. MPO was serially diluted into 1% v/v plasma with each anticoagulant, accounting
for dilution into DPBS, and 50 µL of each MPO concentration was loaded in triplicate into
wells of a tissue culture-treated microtiter plate. After a 30 min incubation with 1,000 rpm
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orbital shaking, wells were aspirated dry and washed four times with 300 µL DPBS. Wells
were then treated with 150 µL CpH = 6.0 imaging solution containing 200 µM H2O2, 50 µM
L-012, 20 mM NaBr, 2.28 mM Na2HPO4, and 22.7 mM NaH2PO4, shaken briefly up to
1,000 rpm, and imaged with photon count quantification in the ONYX/M. Data from the
5 min timepoint were analyzed with WLS regression using pre-dilution MPO concentrations.
ΔFBS and human plasma were directly compared as MPO adsorption carriers by serially
diluting MPO into whole ΔFBS or human plasma from a healthy volunteer, then diluting
2 µL each of the sixteen solutions into 500 µL CpH = 6.5 buffer containing 130 mM NaCl,
6.29 mM Na2HPO4, and 18.7 mM NaH2PO4 in 900 µL polypropylene cluster tubes. After
mixing vigorously on a vortex shaker, 100 µL of each MPO concentration in carrier plasma
was arrayed onto a tissue culture-treated microtiter plate, which was then shaken at 1,000 rpm
for 30 min. Wells were then aspirated dry and washed twice with 150 µL dilution buffer
and once more with 300 µL before receiving 150 µL CpH = 6.0 imaging solution containing
100 µM H2O2, 50 µM L-012, 200 mM (NH4)2SO4, 20 mM NaBr, 3.09 mM citric acid, and
21.9 mM trisodium citrate. The plate was shaken briefly up to 1,000 rpm on an orbital
shaker and imaged in the ONYX/M to quantify raw luminescence as shown in Figure 3.8.
The 5 min timepoint of each carrier series was analyzed with WLS regression separately;
the human plasma series was also calibrated against the ΔFBS standards by WLS inverse
regression. Human plasma was compared to RBP as shown in Figure 3.9 with the same
protocol with the addition of 50 ppm v/v polysorbate 20 (Tween20) in the plasma dilution
buffer and 100 ppm v/v Tween20 in the imaging solution.
Microfiltration was used to fractionate RBP based on filter cutoffs to determine if
adsorption depended on micro- or macro-molecular interactions, demonstrated in Figure 3.10.
Centrifugal ultrafiltration concentrators (Corning Life Sciences Spin-X tubes with 5 kDa,
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30 kDa, and 100 kDa filtration membranes, product numbers 431482, 431484, and 431486)
were prepared by filtering 6 mL ultrapure water for 20 min at 4 ℃, 4,000 × g to remove
contaminants from the manufacturing process. RBP (30 µL, equal to the retention volume of
the feeder reservoirs) was diluted to 5% v/v into CpH = 6.5 buffer containing 130 mM NaCl,
6.28 mM Na2HPO4, and 18.7 mM NaH2PO4. Filter tubes were spun for 75 min at 4 ℃,
4,000 × g. The retained 30 µL of feeder solution was re-diluted with 6 mL of the dilution
buffer and mixed thoroughly to make the matching >cutoff solutions. From these, 0–300 µg/L
MPO solutions were made accounting for the 0.5% v/v RBP dilutions. Each sample was
loaded as quadruplicate 100 µL volumes into tissue culture-treated microtiter plate wells,
which were shaken at 1,000 rpm for a 30 min incubation. Wells were then aspirated dry
and washed twice with 150 µL dilution buffer and once with 300 µL before receiving 150 µL
CpH = 6.0 imaging solution containing 100 µM H2O2, 50 µM L-012, 200 mM (NH4)2SO4,
20 mM NaBr, 3.09 mM citric acid, and 21.9 mM trisodium citrate. The 5 min timepoint
of each filtrate×MPO treatment was analyzed with WLS regression. The same incubation
protocol, CpH = 6.5 dilution buffer, and CpH = 6.0 imaging solutions were used to test bovine
serum albumin (BSA) and human fibronectin as adsorption carriers shown in Figure 3.11. An
MPO dilution factor of 0.2% v/v was used when measuring BSA co-adsorption and 0.4% v/v
was used with fibronectin.
3.2.8 Screening MPO adsorption and imaging conditions
A small screen of adsorption conditions shown in Figure 3.12 was performed with numbered
solutions listed in Table 3.1. Two microcentrifuge tubes received 90 µL of each solution 1–16,
into which 10 µL EDTA-anticoagulated human plasma ±100 µg/L MPO was added. Tubes
containing solutions intended to precipitate plasma components (5–15) were centrifuged
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at 4 ℃, 14,000 × g for 30 min; the remaining tubes were refrigerated at 4 ℃ for 30 min.
From these 10% v/v dilutions or supernatants, 5 µL was added to 495 µL of the matching
solution number (parenthetical solutions in Table 3.1 in the case of supernatants) resulting
in a final dilution factor of 0.1% v/v. Each of the 32 treatment×MPO conditions was loaded
in triplicate 50 µL volumes onto a tissue culture-treated microtiter plate, which was orbitally
shaken for 20 min at 1,000 rpm. Each well was aspirated dry2 and washed four times with
150 µL of the same buffer used for the final dilution stage. After a final dry aspiration, each
well received CpH = 6.0 imaging solution containing 100 µM H2O2, 50 µM L-012, 200 mM
(NH4)2SO4, 20 mM NaBr, 2.28 mM Na2HPO4, and 22.7 mM NaH2PO4. The imaging solution
was shaken at 1,000 rpm on the plate for 1 min before imaging in the ONYX/M. Signal ratios
±95% confidence intervals were calculated using log-linked gamma regression performed on
photon counts from the 5 min timepoint.
A pH survey for optimal adsorption was performed to investigate the findings from the
loading solution screen, as shown in Figure 3.13. Eight solutions with 130 mM NaCl and
total phosphate concentrations of 25 mM spanning CpHs = 6–8 were used to dilute RBP
supplemented with 0, 100, or 300 µg/L human MPO to 0.4% v/v. Each of these solutions
was arrayed as 75 µL volumes in triplicate on a tissue culture-treated microtiter plate and
incubated for 30 min with 1,000 rpm orbital shaking. Each well was aspirated dry and washed
with the corresponding CpH dilution buffer: twice with 150 µL and a third time with 300 µL.
After a final dry aspiration, each well received 150 µL of an imaging solution, CpH = 6.0,
containing 100 µM H2O2, 50 µM L-012, 200 mM (NH4)2SO4, 20 mM NaBr, 3.09 mM citric
acid, and 21.9 mM trisodium citrate. The plate was shaken briefly up to 1,000 rpm on an
2As some of these solutions contained (NH4)2SO4, aspiration was not done into the conventional, bleached
vacuum flask. (A lesson learned the hard way33) A disposable, vacuum-safe biohazard tube was constructed
from conical tubes and paraffin film to be autoclaved at the conclusion of this screen.
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orbital shaker and imaged in the ONYX/M to quantify raw luminescence. Data from the
5 min timepoint were used for WLS regression with pre-dilution MPO concentrations.
A similar screen of imaging conditions shown in Figure 3.14 was performed with solutions
numbered in Table 3.2. Human plasma ±100 µg/L pre-dilution MPO was diluted to 1% v/v
in CpH = 6.5 buffer containing 130 mM NaCl, 6.29 mM Na2HPO4, and 18.7 mM NaH2PO4.
Each plasma series was arrayed in 50 µL volumes into 48 of 96 wells on a tissue culture-treated
microtiter plate which was shaken for 15 min at 1,000 rpm. Each well was aspirated dry and
washed four times with 150 µL of the dilution buffer. After a final dry aspiration, triplicate
wells of each plasma series received 150 µL of one of 16 imaging solutions. The screened
solutions were shaken at 1,000 rpm on the plate for 1 min before imaging in the ONYX/M.
Signal ratios ±95% confidence intervals were calculated using log-linked gamma regression
performed on photon counts from the 5 min timepoint.
3.2.9 Enhancing adsorbed MPO bioluminescence
The effect of (NH4)2SO4 observed in the imaging solution screen was further investigated in
experiments shown in Figure 3.15. A titration of (NH4)2SO4 on adsorbed MPO from human
plasma was performed by preparing 0, 100, and 300 µg/L MPO in CpH = 6.5 buffer containing
200 ppm v/v Tween20, 130 mM NaCl, 6.28 mM Na2HPO4, and 18.7 mM NaH2PO4. This
MPO along with human plasma were diluted 0.4% v/v into a CpH = 6.5 plate loading buffer
containing 50 ppm v/v Tween20, 130 mM NaCl, 6.28 mM Na2HPO4, and 18.7 mM NaH2PO4.
Each of the three plasma ± MPO solutions was arrayed as 75 µL volumes evenly into a
microtiter plate, which was shaken at 1,000 rpm for 30 min. Each well was aspirated dry and
washed thrice with 150 µL of the plate loading buffer. After a final dry aspiration, each well
received one of eight imaging solutions with varying (NH4)2SO4 along with 3.05 mM citric
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acid and 22.0 mM trisodium citrate (CpH = 6.03 ) with 100 µM H2O2, 50 µM L-012, 20 mM
NaBr, and 100 ppm v/v Tween20. The plates were shaken briefly up to 1,000 rpm on an
orbital shaker and imaged in the ONYX/M to quantify raw luminescence. Data from the
5 min timepoint were used for regression with the equation
B = Bmin +
(Bmax −Bmin) [(NH4)2SO4]H
[(NH4)2SO4]
H + ECH50
(3.2)
where EC50 is the concentration of half-maximal enhancement effect, H is the Hill coefficient
responsible for the sigmoid shape of the titration curve, and Bmax and Bmin are the asymptotic
maximum and minimum bioluminescence for each MPO concentration.
The enhancer effect was then quantified for (NH4)2SO4 applied to MPO in solution
with whole plasma as shown in Figure 3.15B. Healthy-donor plasma supplemented with
0, 100, or 300 µg/L MPO was diluted to a final reaction concentration of 400 ppm v/v in
CpH = 6.0 buffer containing 3.05 mM citric acid, 22.0 mM trisodium citrate, and 20 mM
NaBr. Serial dilutions of (NH4)2SO4 were made with constant, final concentrations of 50 µM
L-012 and 100 µM H2O2. A microtiter plate was evenly arrayed with 10 µL of each diluted
plasma. The reaction was initiated by adding 100 µL of each (NH4)2SO4 imaging solution
and shaking briefly up to 1,000 rpm on an orbital shaker before imaging in the ONYX/M.
Raw luminescence data from the 5 min timepoint were fit to the equation
B = Bmin +
(Bmax −Bmin) [(NH4)2SO4]
[(NH4)2SO4] + EC50
(3.3)
lacking a Hill coefficient H as there was no statistically significant sigmoidal nature to the
titration. This protocol was modified with Na2SO4 used in place of (NH4)2SO4 as a negative
control for NH4+ as shown in Figure 3.15D, the data from which failed to fit the signal
enhancement model equations.
3 calculation does not consider effects of acidic (NH4)2SO4
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The effect of (NH4)2SO4 on pure MPO was also investigated as shown in Figure 3.15C.
Serial dilutions of (NH4)2SO4 were prepared in a CpH = 6.0 buffer containing 10 mM NaBr,
3.05 mM citric acid, and 22.0 mM trisodium citrate. Each of these solutions was arrayed
as 75 µL volumes along with 50 µL of the buffer ±500 ng/L final concentration MPO. The
reaction was initiated by the final addition of 150 µL buffer containing final concentrations
100 µM H2O2 and 30 µM L-012 before immediate imaging in the ONYX/M. As previously,
data from the 5 min timepoint were quantified.
The detergent Tween20 was tested for its effects on various portions of the adsorbed
MPO bioluminescence assay as shown in Figures 3.17–3.19. To test the effect of Tween20
in the imaging solution, RBP with varying MPO was diluted to 0.4% v/v in CpH = 6.5
buffer containing 130 mM NaCl, 6.28 mM Na2HPO4, and 18.7 mM NaH2PO4. Each of the
four MPO solutions was arrayed as 75 µL volumes evenly into a microtiter plate, which was
shaken at 1,000 rpm for 30 min. Each well was aspirated dry and washed twice initially with
150 µL of the plate loading buffer and finally with 300 µL. After a final dry aspiration, each
well received one of six CpH = 6.0 imaging solutions with varying Tween20, 3.05 mM citric
acid, 22.0 mM trisodium citrate, 100 µM H2O2, 50 µM L-012, and 20 mM NaBr. The plate
was shaken briefly up to 1,000 rpm on an orbital shaker before imaging in the ONYX/M.
The 5 min timepoint of each Tween20 treatment was analyzed with WLS regression using
pre-dilution MPO concentrations.
This protocol was modified to test the effect of Tween20 in the incubation buffer. Tween20
was serially diluted into the CpH = 6.5 buffer containing 130 mM NaCl, 6.28 mM Na2HPO4,
and 18.7 mM NaH2PO4. 500 µL of each Tween20 buffer was added to three cluster tubes,
which then received 2 µL undiluted RBP supplemented with 0, 100, or 300 µg/L human
MPO. After vigorous vortex mixing, each of the 24 MPO×Tween20 solutions was arrayed
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as quadruplicate 75 µL volumes into a tissue culture-treated plate, which was incubated
for 30 min with 1,000 rpm orbital shaking. Each well was aspirated dry and washed twice
initially with 150 µL of the phosphate buffer (without Tween20) and finally with 300 µL.
After a final dry aspiration, each well received CpH = 6.0 imaging solution with 100 ppm v/v
Tween20, 3.05 mM citric acid, 22.0 mM trisodium citrate, 100 µM H2O2, 50 µM L-012, and
20 mM NaBr. The plate was shaken briefly up to 1,000 rpm on an orbital shaker before
imaging in the ONYX/M. The 5 min timepoint of each Tween20 treatment was analyzed
with WLS regression using pre-dilution MPO concentrations.
The third test of Tween20 effects involved the MPO pre-dilution buffer. First, Tween20
was serially diluted into the CpH = 6.5 buffer containing 130 mM NaCl, 6.28 mM Na2HPO4,
and 18.7 mM NaH2PO4. With each from this series of eight Tween20 buffers, three MPO
serial dilutions were made. RBP was diluted to 0.4% v/v in a 50 ppm v/v Tween20 variant
of the phosphate buffer; 500 µL of this solution was added to each of 24 cluster tubes along
with 2 µL of a single Tween20×MPO solution. After vigorous vortex mixing, each of the
24 cluster tubes was used to array a microtiter plate with triplicate 75 µL volumes. Each
well was aspirated dry and washed twice initially with 150 µL of the phosphate buffer (with
50 ppm v/v Tween20) and finally with 300 µL. After a final dry aspiration, each well received
CpH = 6.0 imaging solution with 100 ppm v/v Tween20, 3.05 mM citric acid, 22.0 mM
trisodium citrate, 100 µM H2O2, 50 µM L-012, and 20 mM NaBr. The plate was shaken
briefly up to 1,000 rpm on an orbital shaker before imaging in the ONYX/M. The 5 min
timepoint of each Tween20 treatment was analyzed with WLS regression using pre-dilution
MPO concentrations.
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3.2.10 Bioluminescence robustness and specificity for MPO
RBP was supplemented with varying concentrations of ascorbic acid to confirm that the
previously observed inhibition had been mitigated by the adsorption procedure. First, MPO
was serially diluted to 0, 100, and 300 µg/L in a CpH = 6.5 buffer containing 200 ppm v/v
Tween20, 130 mM NaCl, 6.28 mM Na2HPO4, and 18.7 mM NaH2PO4. Serial dilutions of
ascorbic acid and a 0.4% v/v RBP dilution were made in a 50 ppm v/v Tween20 variant of the
same buffer. Cluster tubes were used to combine 300 µL diluted RBP, 10 µL MPO solutions,
and 100 µL ascorbic acid titration solutions, all of which corresponded to plasma diluted
to 0.4% v/v. Each of the 24 MPO×ascrobic acid solutions was arrayed as quadruplicate
75 µL volumes and incubated with 1,000 rpm orbital shaking for 30 min. The plate was
then aspirated dry and washed twice with 150 µL and once with 300 µL of the 50 ppm v/v
Tween20 buffer variant. After a final dry aspiration, each well received 75 µL of an imaging
solution, CpH = 6.0, containing 100 ppm v/v Tween20, 100 µM H2O2, 50 µM L-012, 200 mM
(NH4)2SO4, 20 mM NaBr, 3.09 mM citric acid, and 21.9 mM trisodium citrate and was shaken
briefly up to 1,000 rpm before imaging in the ONYX/M. Data from the 5 min timepoint are
shown in Figure 3.16 with all concentrations adjusted to their pre-dilution levels.
Bioluminescence specificity for MPO activity was investigated with the specific inhibitor
4-aminobenzoic hydrazide (4-ABH). Serial dilutions of MPO were prepared in the same buffer
used in the ascorbic acid experiments described in the previous method description. Similarly,
the MPO solutions along with RBP were diluted to 0.4% v/v into a 50 ppm v/v Tween20
variant of the MPO dilution buffer. Each of the three MPO/RBP solutions was arrayed
evenly as 75 µL volumes and incubated with 1,000 rpm orbital shaking for 30 min. The plate
was then aspirated dry and washed as described above. Imaging solutions were made with
varying 4-ABH concentrations in CpH = 6.0 buffer containing 100 ppm v/v Tween20, 100 µM
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H2O2, 50 µM L-012, 200 mM (NH4)2SO4, 20 mM NaBr, 3.09 mM citric acid, and 21.9 mM
trisodium citrate. After a final aspiration, 75 µL of the imaging solutions were arrayed evenly
among the different adsorbed MPO concentrations and imaged as described above. Data
from the 5 min timepoint were regressed with the model
B = BmaxIC
H
50
[4-ABH]H + ICH50
(3.4)
where H is the Hill coefficient, IC50 is the 4-ABH concentration of half-inhibition, and Bmax
is the asymptotic maximum bioluminescence. 95% confidence bands were computed with the
delta method.
A similar procedure was used to block MPO with another cationic protein, protamine
sulfate. As previously, RBP and MPO were diluted into 50 and 200 ppm v/v Tween20 buffers
described above, respectively. Additionally, protamine sulfate was serially diluted into the
200 ppm v/v Tween20 variant. Each of 24 cluster tubes then received 490 µL RBP (final
dilution 0.4% v/v), 5 µL of one of the three MPO concentrations, and 5 µL of one of the
eight protamine solutions. Each of the 24 solutions was arrayed evenly as 75 µL volumes and
incubated with 1,000 rpm orbital shaking for 30 min. Imaging solutions were made with
CpH = 6.0 buffer containing 100 ppm v/v Tween20, 100 µM H2O2, 50 µM L-012, 200 mM
(NH4)2SO4, 20 mM NaBr, 3.09 mM citric acid, and 21.9 mM trisodium citrate. The plate
was washed and imaged as described above. Data from the 5 min timepoint were regressed
with the model
B = BmaxIC
H
50
[protamine sulfate]H + ICH50
(3.5)
similar to the 4-ABH analysis using final, in-well protamine concentrations from the incubation
step. 95% confidence bands were computed with the delta method.
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3.3 Results
3.3.1 Passive MPO immobilization on polymer membranes
Protein isolation and analysis on membranes is a staple technique in molecular biology. A
pilot dot-blot experiment demonstrated the feasibility of isolating MPO on nitrocellulose and
imaging its intact activity via L-012 bioluminescence. A range of MPO concentrations in
buffer spotted onto a nitrocellulose membrane remained visible when immersed in a solution
of L-012 and H2O2 after first incubating in clean buffer, demonstrating that MPO is bound by
nitrocellulose with retained activity. The signal distribution was uneven at each spot, making
precise quantification difficult. (Figure 3.1A) A simple, disposable cassette was designed to
solve this problem using common labware. Holes in plastic tip racks, which are normally
lab waste, are spaced evenly with 96-well microtiter plates, providing pressure around the
rims of plate wells. (Figure 3.1B) ΔFBS used to resuspend MPO residue from a stock
tube was diluted into AcDPBS and distributed into a microtiter plate to test the apparatus
for cross-contamination and MPO binding consistency. After inverting the loaded cassette
10 min and washing the membrane for an additional 10 min, imaging with 1 mM luminol
and 10 mM H2O2 in AcDPBS revealed even signal distribution with minimal leaking out of
each well. (Figure 3.1C) Quantification of the membrane at each well location shows ready
discrimination of the two ΔFBS dilutions and the buffer control. (Figure 3.1D) From this
proof of concept, commercial products for isolating MPO on solid substrates were considered.
PVDF was considered for its low chemical reactivity, membrane durability, and ready
availability as a common protein-binding substrate. Pure human MPO in AcDPBS was loaded
into wells of commercial filter plates with PVDF flow-through floors. After incubating for
5 min and washing unbound enzyme, 1 mM luminol and 10 mM H2O2 were unable to resolve
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Figure 3.1: Passively loading MPO onto nitrocellulose. (A) Preliminary demonstration of MPO
sequestration and bioluminescence on a nitrocellulose solid substrate. Each spot on the nitrocellulose
membrane contains 0.5 µL MPO diluted into AcDPBS. Image shows 1 min integration with 500 µM L-012
and 10 mM H2O2 in the same buffer. (B) Schematic for an early prototype membrane loader designed to
bind proteins from plasma and allow removal of small-molecule antioxidants. Samples were loaded into a
microtiter plate and covered with a nitrocellulose membrane secured by a padded, 96-well tip rack. Metal
clamps (not shown) locked the cassette together before inversion to expose the membrane with the contents
of the microtiter plate. (C) Image of a nitrocellulose membrane loaded with the prototype cassette. Whole
ΔFBS, 10% v/v ΔFBS in AcDPBS, or AcDPBS alone were exposed to the membrane for 10 min followed
by a 10 min wash incubation in the same buffer. MPO concentration in ΔFBS was not determined in this
feasibility experiment. The membrane was immersed in the buffer containing 1 mM luminol and 10 mM
H2O2 prior to imaging. (D) Quantification of membrane bioluminescence shown in (C). Each line represents
individual ROIs.
93
Chapter 3: Myeloperoxidase sequestration on solid substrates Results
0.10
0.75
0.50
0.25
0.00
100
100
75
50
25
0
100
41
17
7.1
2.9
1.2
0.50
0
300
120
45
17
6.7
2.6
1.0
0
Time / min Time / min
MPO / µg/L
0 10 20 30 40 50 60 0 10 20 30 40 50 60
Lu
m
in
es
ce
nc
e 
/ p
ix
el
–1
 m
in
–1
Lu
m
in
es
ce
nc
e 
/ p
ix
el
–1
 m
in
–1
MPO / µg/L MPO / µg/L
A B
0 25 50 75 100
Figure 3.2: MPO bioluminescence in PVDF filter plates. (A) Time series of pure MPO loaded into
commercial PVDF-bottom filter plates. Pure MPO was diluted into AcDPBS and incubated on the PVDF
membrane for 5 min before washing and imaging with 1 mM luminol and 10 mM H2O2. Each line represents
raw data from each replicate (n = 3). MPO is annotated as final incubation concentrations. (B) Time series
of pure MPO loaded onto the same PVDF plate and imaged with 500 µM L-012 in place of luminol. MPO
solutions were incubated for 30 min in an attempt to increase retained protein. Inset shows raw data from
the image taken 2 min after adding the imaging solution to the wells. MPO is annotated as final incubation
concentrations.
MPO in the physiological range reported in the literature.12 MPO loaded at the highest
concentration of 300 µg/L was resolvable, albeit poorly. (Figure 3.2A) A longer incubation of
30 min as well as imaging with L-012 in the place of luminol improved resolution of 100 µg/L
MPO, but the lower concentrations were only marginally differentiable from the buffer control.
(Figure 3.2B)
MPO is heavily modified with hydrophilic residues and is itself a cationic protein at
acidic and neutral pH (see page 10), so nitrocellulose filter plates would hypothetically
bind MPO more tightly than would PVDF plates. In general, background luminescence
from nitrocellulose filter plates was much higher than that seen with PVDF, even when
imaging with 80% lower L-012 and 98% lower H2O2 concentrations. Serial dilutions of
plasma supplemented with 50 µg/L MPO into DPBS were poorly resolvable from native
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plasma. Serially diluting pure MPO into DPBS free from plasma did not improve resolution.
(Figure 3.3A) Although background luminescence from the nitrocellulose plates was reduced
by imaging in AcDPBS, neither resolution of pure MPO nor of plasma supplemented MPO
was improved over what was seen with neutral DPBS. (Figure 3.3B)
Additional nitrocellulose formats were also tested as MPO assay platforms. These included:
nitrocellulose films deposited onto microscopy slides, membrane dipsticks modeled after
modern blood glucose tests, nitrocellulose disks incubated in plasma and imaged in microtiter
plate wells, and powdered nitrocellulose slurries centrifuged out of plasma suspensions for
imaging. Unfortunately, each method was wildly inconsistent and failed to differentiate
MPO-spiked plasmas from native controls. (Data not shown)
3.3.2 Vacuum-driven MPO immobilization on nitrocellulose
Protein blotting membranes are usually loaded using electromagnetic fields to drive proteins
to the membrane surface. This is performed by first denaturing the proteins before they are
coated with an ionic detergent such as sodium dodecyl sulfate. In order to maintain native
protein function, vacuum pressure was instead used to draw samples through a nitrocellulose
membrane loaded into a Bio-Dot apparatus. Pure MPO adhered to the membrane and
resulted in better resolution when imaged directly in the Bio-Dot apparatus with 10 µM
L-012 and 100 µM H2O2 in DPBS. Unfortunately, the kinetic variability between replicates
was consistently high. (Figure 3.4A) Additionally, standard curves constructed with this
method were not linear over a wide MPO concentration range. (Figure 3.4B)
To determine if MPO bioluminescence was linear with concentration in plasma, ΔFBS
supplemented with pure human MPO was diluted to 1% v/v in DPBS and similarly drawn
through a nitrocellulose membrane by a vacuum. Although the final MPO concentrations were
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Figure 3.3: MPO bioluminescence in nitrocellulose filter plates. (A) Plasma ± 50 µg/L MPO and
serially diluted into DPBS and incubated in a nitrocellulose-bottom microtiter plate. Wells were washed
with DPBS and imaged with 200 µM H2O2 and 100 µM L-012 in DPBS supplemented with NaCl to a
final concentration of 500 mM. Individual replicates (n = 3) are shown from the 2 min timepoint after the
imaging solution was added to the plate. (B) Data from a variation of the experiment shown in (A) using
DPBS without additional NaCl and adjusted with HCl to pH = 6.0 for the imaging solution. The acidic
imaging buffer reduced the high background luminescence from the nitrocellulose plate but also reduced
MPO resolution.
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matched to those used in pure-buffer membrane loading, ΔFBS-diluted bioluminescence was
more consistent. (Figure 3.4C) Although standard curves were reproducible, the non-linear
relationship between loaded MPO and bioluminescence remained. (Figure 3.4D)
3.3.3 Co-adsorption of MPO and carrier proteins onto
polystyrene
Although used to prepare ELISA plates by tightly adsorbing immunoglobulins with affinity
for the desired analyte, imaging high-affinity protein binding plates did not show any MPO-
dependent bioluminescence after a wide variety of adsorption incubation conditions. (Data
not shown) Although not intended for this purpose, tissue culture-treated polystyrene on a
96-well microtiter plate retained MPO diluted into human plasma. Buffer washes prior to
imaging with 100 µM H2O2 and 50 µM L-012 in a mildly acidic phosphate buffer mitigated
the effects of plasma inhibitors (see page 60). This adsorption required the presence of
plasma; pure MPO similarly diluted and incubated in the same buffer did not exhibit the
MPO dose-response with L-012 bioluminescence (Figure 3.5A) Although pure MPO adhered
to polystyrene was detectable, calibration curves prepared from it were very shallow (5 min
limit of detection = 97 µg/L MPO, R2 = 0.847) compared to those from MPO incubated
with human plasma (5 min limit of detection = 3.7 µg/L MPO, R2 = 0.995). (Figure 3.5B)
Published ELISA plate adsorption protocols generally call for incubations spanning many
hours to reliably retain immunoglobulins; MPO adsorption from ΔFBS was more rapid.
Applying ΔFBS supplemented with human MPO and immediately aspirating and washing
was adequate to coarsely resolve MPO concentration upon imaging with 50 µM L-012 and
100 µM H2O2. (Figure 3.6A) Quantifying the dose response with WLS regression showed
that peak MPO resolution is achieved by a 15 min incubation and longer durations did not
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Figure 3.4: Vacuum cassette filtration of MPO through nitrocellulose. (A) Bioluminescence time
series and (B) 2 min timepoint of purified MPO serially diluted into DPBS and drawn through a nitrocellulose
membrane in a Bio-Dot cassette. Cassette wells were washed by drawing DPBS through after the MPO
solutions. The membrane was then imaged in the cassette by addition of 10 µM L-012 and 100 µM H2O2 in
DPBS. MPO is annotated with final concentrations drawn through the membrane. (C) Bioluminescence
time series and (D) 2 min timepoint of MPO serially diluted into ΔFBS before further 1:100 dilution into
DPBS and similarly loaded onto nitrocellulose. Each well was imaged with 10 µM L-012 and 100 µM H2O2.
MPO is annotated with pre-dilution concentrations in whole ΔFBS. Regression with equation (3.1), shown as
a dashed line ± 95% confidence bands in gray, suggests that this method is only linear between 40–80 ng/L
MPO. Raw data (n = 4) are shown in (A)–(C), mean ± standard deviation in (D).
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Figure 3.5: Adsorption of MPO from human plasma onto tissue culture-treated polystyrene.
(A) Bioluminescence time series of MPO ± human plasma incubated on tissue culture-treated polystyrene
plates prior to imaging with 50 µM L-012 and 200 µM H2O2. Both solution series were diluted to 0.5% v/v in
a CpH = 6.5 phosphate buffer with 130 mM NaCl. Data are shown as individual replicates (n=4). (B) WLS
regression on data from the 5 min timepoint of the time series shown in (A). The limit of detection when
plasma was added as an adsorption carrier was 3.7 µg/L MPO with R2 = 0.995, while regression with MPO
alone resulted in a limit of 97 µg/L MPO with R2 = 0.847. Data are plotted as mean ± standard deviation.
WLS results are shown as dashed lines ± gray 95% confidence bands. Quadruplicate 95% prediction bands
are shown as long-dashed lines.
substantially reduce the quality of the calibration curves, which consistently achieved values
of R2 > 0.995. (Figure 3.6B)
The anticoagulant used at plasma collection had a dramatic effect on MPO adsorption
onto polystyrene. Plasma collected in vacuum phlebotomy tubes coated in lithium heparin
reduced adsorbed MPO bioluminescence to a constant baseline level, slightly below that of
healthy donor plasma collected in K2EDTA vacuum tubes. Supplementing this heparinized
plasma with exogenous MPO had no effect on resulting bioluminescence. (Figure 3.7A) Unlike
pure MPO adsorbed onto the microtiter plates from buffer, which resulted in a poor but
quantifiable bioluminescence response (see Figure 3.5B), MPO adsorption from heparinized
plasma had no quantifiable correlation with loaded MPO concentration as determined by
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Figure 3.6: Rapid kinetics of MPO adsorption onto polystyrene. (A) MPO diluted into ΔFBS
and incubated on tissue culture-treated polystyrene microtiter plates for different durations before imaging.
All ΔFBS samples were diluted to 0.5% v/v in a CpH = 6.5 phosphate buffer with 130 mM NaCl. Imaging
solution in a CpH = 6.0 phosphate buffer containing 50 µM L-012, 200 µM H2O2, 20 mM NaBr, and 500 mM
NaCl was added to the plate after multiple washes removed any non-adsorbed ΔFBS and MPO. Raw data
(n = 3) are shown. (B) WLS regression on data from the 5 min timepoint of (A). Triplicate 95% prediction
bands are shown as long-dashed lines outside the regression mean and shaded 95% confidence bands. Data
are shown as mean ± standard deviation.
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Figure 3.7: Anticoagulant heparin blocking MPO adsorption. (A) Bioluminescence time series of
human plasma drawn with different anticoagulants, supplemented with purified human MPO, and adsorbed
onto polystyrene. Plasma ± MPO was diluted to 1% v/v in DPBS and incubated for 30 min before the plate
was washed free of unadsorbed material and imaged with 200 µM H2O2, 50 µM L-012, and 20 mM NaBr in
an acidic phosphate buffer. MPO was unresolvable in the heparinized plasma. Each line is an individual well
(n = 4). (B) Data from the 5 min timepoint analyzed with WLS regression. Mean ± standard deviation are
shown. Long-dashed lines are triplicate 95% prediction intervals around the WLS mean (dashed line) and
95% confidence bands (gray). Heparinized plasma could not be fit with the regression method.
WLS regression. (Figure 3.7B) Blood anticoagulated with citrate also allowed for MPO
adsorption, but K2EDTA was exclusively used for consistency. (Data not shown)
Although MPO reliably adsorbed in a near-linear manner when incubated with either
ΔFBS or human plasma on tissue culture-treated polystyrene, the resulting bioluminescence
was not reproducibly equivalent with the two carriers. Generally, ΔFBS resulted in greater
signal from equivalent MPO in human plasma. (Figure 3.8A) Modifying sample preparation
techniques counteracted this discrepancy, but the results of this strategy were extremely
sensitive to slight variations in the duration and extent of pipette transfers, sequence of sample
dilutions, and even the type of liquid vessel used to mix each solution. (Data not shown)
MPO in human plasma was linearly underestimated when measured using ΔFBS-based
standards for WLS regression. (Figure 3.8B)
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Figure 3.8: ΔFBS and human plasma as MPO adsorption carriers. (A) Bioluminescence of MPO
adsorbed onto polystyrene in the presence of ΔFBS or human plasma. Data from the 5 min timepoint are
shown as mean ± standard deviation (n = 4). WLS regression mean ± 95% confidence bands are shown as
dashed lines and gray areas, respectively. Quadruplicate prediction intervals are shown in long-dashed lines.
MPO is annotated as pre-dilution concentrations in each carrier tissue. (B) WLS regression results of MPO
in human plasma calibrated against MPO standards in ΔFBS. Data are shown as mean ± 95% confidence
interval. Dashed line represents 1:1 agreement between supplemented and regressed MPO.
Anticoagulated human plasma and ΔFBS differ greatly in protein content as measured by
the bicinchoninic acid protein assay (data not shown) as would be expected after the removal
of clotting factors, fibrinogen, and co-aggregated proteins during the plasma-serum conversion.
Additionally, ΔFBS is heat-treated with the intention of denaturing serum proteins, further
differentiating it from plasma. From this, RBP was tested as an alternative carrier to ΔFBS
for assaying human MPO. As seen with human plasma, RBP co-adsorbed with exogenous
human MPO with reproducible signal and kinetics. (Figure 3.9A) Calibration curves prepared
from MPO in RBP were linear or slightly convex and had narrow prediction intervals, both
desirable traits in an assay standard. (Figure 3.9B) Most importantly, human plasma
supplemented with exogenous MPO were reliably assayed against RBP-based standards;
the WLS regression results agreed within 95% confidence limits with supplemented MPO
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Figure 3.9: RBP and human plasma as MPO adsorption carriers. (A) Time series of human MPO
serially diluted into human plasma or RBP before dilution to 0.4% v/v and incubating for 30 min in a
polystyrene microtiter plate. Unadsorbed material was washed from the plate before imaging with 100 µM
H2O2, 50 µM L-012, and 200 mM (NH4)2SO4 in an acidic citrate buffer. Individual wells (n = 4) are shown.
(B) WLS calibration curve of data from the RBP solutions at the 5 min timepoint. This standard curve
had a limit of detection = 1.8 µg/L MPO with R2 > 0.998. Data are shown as mean ± standard deviation.
Quadruplicate 95% prediction bands are shown as long-dashed lines about the dashed WLS mean and gray
95% confidence bands. (C) Human plasma calibrated against the RBP curve. Solutions were accurately
predicted within experimental error. Dashed line represents perfect 1:1 agreement between supplemented
MPO and inverse regression results. Data are shown as regression estimate ± 95% confidence interval.
concentrations in plasma from a healthy donor. (Figure 3.9C) The utility of RBP as a human
plasma substitute was confirmed with two product lots obtained independently. (Data not
shown)
RBP was roughly fractionated by membrane ultrafiltration with 5, 30, and 100 kDa
exclusions to determine if specific proteins were necessary or sufficient for MPO adsorption.
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Figure 3.10: Plasma size fractionation and MPO adsorption. RBP was fractionated by centrifugal
ultrafiltration before both the filtrate and retained feed from each size-cutoff was used as a carrier solution for
MPO adsorption. Each filtrate was diluted to 0.5% v/v in a CpH = 6.5 phosphate buffer and incubated in a
polystyrene microtiter plate for 30 min. After washing unadsorbed material from the plate, it was imaged
with 100 µM H2O2, 50 µM L-012, 20 mM NaBr, and 200 mM (NH4)2SO4. Data from the 5 min timepoint
are shown as mean ± standard deviation (n = 4). WLS results are shown as dashed lines ± gray 95%
confidence bands. Quadruplicate 95% prediction bands are shown as long-dashed lines. MPO axis represents
pre-dilution concentration.
Of the retained feeder plasma components, only the >100 kDa cutoff showed slightly reduced
bioluminescence. The matched <100 kDa filtrate likewise allowed MPO adsorption above
that of buffer or the smaller molecular weight cutoff filtrates. Although the >5 and >30 kDa
fractions showed slightly increased signal compared to that of whole RBP control, it is
uncertain if this resulted from the loss of the <5 kDa fraction or if it was an artifact of
differences in sample dilution due to the uncertain retention volume of the centrifugal filter
units. (Figure 3.10)
A homogeneous and consistent MPO carrier is desirable to reduce the number of possible
confounding assay components. While both human plasma and RBP evenly coated the floor
surface of microtiter plate wells, there are many unknown parameters in such complex protein
mixtures. (Figure 3.11A) Plasma proteins known to bind to MPO were thus tested as pure
co-adsorption additives. BSA has been shown to bind to human MPO and adsorb onto
polystyrene surfaces.34,35 If sufficient to cause MPO adsorption, BSA would be an inexpensive
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Figure 3.11: MPO co-adsorption with pure plasma proteins. (A) Tissue culture-treated polystyrene
wells imaged after MPO adsorbed in the presence of 0.4% v/v human plasma and RBP. Images are 1 min
integrations taken 5 min after the addition of the imaging solution containing 100 µM H2O2, 50 µM L-012,
20 mM NaBr and 200 mM (NH4)2SO4. The even distribution of signal across the well-bottom surface is
typical of MPO coadsorbed with whole plasma after citrate or EDTA anticoagulation. MPO is labeled as
pre-dilution concentration in whole plasmas. (B) Wells imaged with pure BSA as an MPO adsorption carrier.
MPO solutions were diluted to 0.2% v/v before incubation in a similar manner as used in (A). Signal rings
around the well periphery is typical of residual solution desiccating during the washing steps, precipitating
MPO and other proteins as opposed to uniform adsorption onto the polystyrene surface. MPO is annotated
with pre-dilution concentrations, BSA with final incubation concentrations. (C) Wells imaged with pure
human serum fibronectin as an MPO adsorption carrier. MPO solutions were diluted to 0.4% v/v before
incubation in a similar manner as used in (A) and (B). As in (B), ringing indicates poor adsorption compared
to that from MPO + plasma mixtures. MPO is annotated with pre-dilution concentrations, fibronectin with
final incubation concentrations.
and consistent assay component. However, MPO and BSA proved insufficient to evenly
coat wells, with signal rings typical of drying artifacts during plate washes composing most
of the measurable signal. (Figure 3.11B) Fibronectin has also been shown to bind MPO
and is known to adsorb readily onto modified polystyrene.34,36–38 Fibronectin exists freely in
plasma as well as in the extracellular matrix and, unlike BSA, is far larger than 100 kDa
and compatible with the size fractionation data shown in Figure 3.10.39 Although purified
human fibronectin did cause increased adsorbed MPO bioluminescence more than observed
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with BSA, even at high concentrations it was still insufficient to produce the even, consistent
adsorption seen with whole human plasma or RBP. (Figure 3.11C)
3.3.4 MPO adsorption across solution conditions
There are no reports of MPO adsorption conditions in the literature, so a small screen was
performed to coarsely investigate several solution and processing parameters for guidance
in further assay optimization. Incubation buffer parameters included pH, buffering agent,
and NaCl concentration. Based on the observed discrepancy between ΔFBS and RBP (see
Figure 3.8 and Figure 3.9), attempts to selectively remove plasma proteins other than MPO and
those required for its adsorption were made. Pre-incubation and centrifugation with varying
CaCl2 was explored to saturate the anticoagulant K2EDTA and remove polymerized fibrin
and associated proteins prior to polystyrene incubation. Pre-incubation and centrifugation
with concentrated (NH4)2SO4 was also investigated, as (NH4)2SO4 is known to precipitate
many abundant plasma proteins while MPO remains soluble.40–42 Treatment and solution
conditions are summarized in Table 3.1.
Although precipitate pellets were visible after centrifugation with (NH4)2SO4, it had no
beneficial effect on MPO adsorption from the supernatants. Of note, each of the supernatants
still contained 10% of the centrifuge (NH4)2SO4 concentration after dilution into the plate
incubation buffer. This was an unavoidable consequence of the precipitation step and must
be interpreted as part of each treatment. (Figure 3.12A) Similarly, CaCl2 pretreatment
consistently had no effect on bioluminescence of adsorbed MPO despite a visible pellet present
after centrifugation. (Figure 3.12B) Further experimentation with plasma fractionation
via selective precipitation with (NH4)2SO4, CaCl2, and purified bovine thrombin similarly
produced only negative results. (Data not shown) Of the conditions without a precipitation
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Table 3.1: Multi-parameter survey of treatments for MPO adsorption. Human plasma ± exogenous
human MPO was diluted to 10% v/v into each of the 16 test solutions. Preceding experiments suggested that
pH, buffering agent, buffer concentration, coagulation cascade activation, and ionic strength had potentially
important effects on MPO adsorption onto tissue culture-treated polystyrene. Blocks of conditions designed
to test a particular parameter are shown. Conditions 5–15 were designed to precipitate plasma proteins
such as fibrin(ogen) and thus were subjected to centrifugation; the resulting supernatant was transferred at
the appropriate dilution into a matched loading solution shown in parentheses. Control solutions used in
multiple comparison blocks are denoted by bold condition labels. Data from this adsorption screen are shown
in Figure 3.12.
solute / mM
condition buffer CpH (NH4)2SO4 (spin) CaCl2 (spin) NaCl (plate)
1 citrate 6.0 – – –
2 citrate 6.0 – – 150
3 PO43– 6.5 – – –
4 PO43– 6.5 – – 150
5→(3) PO43– 6.5 800 – –
6→(3) PO43– 6.5 1,200 – –
7→(3) PO43– 6.5 1,600 – –
8→(1) citrate 6.0 800 – –
9→(1) citrate 6.0 1,200 – –
10→(1) citrate 6.0 1,600 – –
11→(3) PO43– 6.5 – 50 –
12→(3) PO43– 6.5 – 20 –
13→(16) PO43– 7.0 800 – –
14→(16) PO43– 7.0 1,200 – –
15→(16) PO43– 7.0 1,600 – –
16 PO43– 7.0 – – –
step, only pH = 6.5 with 150 mM NaCl resulted in a substantial improvement in both absolute
and relative difference between native plasma and plasma + 100 µg/L MPO. (Figure 3.12C)
The signal ratios of each condition corresponding with Table 3.1 are shown in Figure 3.12D.
From this survey, pH and NaCl concentration stood out as important adsorption solution
parameters. To find the optimum pH for adsorbed MPO retention, a ratio titration of mixed
NaH2PO4 and Na2HPO4 totaling 25 mM was performed in the presence of 130 mM NaCl.
pH strongly influenced adsorption with optimal bioluminescence at CpH = 6.6, agreeing
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Figure 3.12: Multi-parameter survey of treatments for MPO adsorption. All data represent the
1 min image taken at the 5 min imaging timepoint (n = 3). Solution numbers are also annotated on each
horizontal axis. (A) Effects of (NH4)2SO4 pre-incubation and centrifugation in three buffer conditions
before further diluting the supernatant into the matching 0 mM (NH4)2SO4 buffer for adsorption. Although
some precipitate remained after centrifugation with >1 M (NH4)2SO4, pretreatment did not improve MPO
resolution in any of the buffer conditions. (B) Varying CaCl2 to reverse K2EDTA anticoagulation from the
phlebotomy tubes. Some visible precipitate remained after centrifugation, but there was little improvement
over the Ca2+ control solution (#3). (C) Citrate buffer with a CpH = 6.0 or phosphate buffers with CpH = 6.5
or 7.0 with 0 or 150 mM NaCl. These conditions did not involve centrifugation and were kept at 4 ℃ while
other solutions were centrifuged so that they could serve as controls when applicable. The effects of pH are
discussed further in Figure 3.13. Of the different pH and NaCl permutations, only 150 mM NaCl at pH = 6.5
stood out with improved MPO resolution. (D) The signal ratio of MPO-supplemented plasma to untreated
plasma after each of the 16 adsorption conditions. Ratios were determined by log-linked gamma regression
and are displayed as mean ± 95% confidence intervals. For solution conditions included in this survey, see
Table 3.1.
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Figure 3.13: Optimal pH for MPO adsorption. RBP with varying MPO was diluted to 0.4% v/v into
phosphate buffers with 130 mM NaCl and different CpHs (total PO43– = 25 mM). Wells were washed with
the same phosphate buffer after plasma adsorbed over a 30 min incubation. The plate was imaged with
50 µM L-012, 100 µM H2O2, 200 mM (NH4)2SO4, and 20 mM NaBr. (A) Data from the 5 min timepoint are
shown as mean ± standard deviation (n = 4). WLS results are shown as dashed lines ± gray 95% confidence
bands. Quadruplicate 95% prediction bands are shown as long-dashed lines. MPO axis represents pre-dilution
concentration. (B) Data arranged to show bioluminescence across all tested pH values. Raw bioluminescence
measurements shown.
with the previous data from the condition survey. (Figure 3.13) Further pH testing showed
dramatic decreases in adsorbed MPO activity in citrate buffers with pH < 6.0 and at pH > 8
buffered by CAPS. (Data not shown)
3.3.5 Optimizing adsorbed MPO-dependent bioluminescence
Imaging MPO-dependent bioluminescence with L-012 requires optimization beyond simply
maximizing MPO halogenation activity; releasing adsorbed MPO from the polystyrene
surface must also be considered, as must the elimination of any inhibition activity present
in co-adsorbed proteins from plasma. Relevant parameters were first surveyed similarly
to what is described on page 106: pH, NaCl concentration, (NH4)2SO4 concentration with
Na2SO4 as a control for NH4+, and total buffer phosphate. Chance observations from an
attempt to precipitate plasma proteins suggested that (NH4)2SO4 mitigated some of the MPO
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Table 3.2: Multi-parameter survey of adsorbed MPO imaging solutions. Human
plasma ± exogenous human MPO was diluted to 1% v/v and incubated for 30 min on tissue culture-
treated polystyrene, washed, and imaged with 16 solutions designed to survey different parameter effects on
MPO resolution. Each solution also contained 20 mM NaBr, 50 µM L-012, and 100 µM H2O2. Preceding
experiments suggested that phosphate buffer concentration, pH, ionic strength, and NH4+ affected resolution
of adsorbed MPO. Blocks of conditions designed to test a particular parameter are shown. Control solutions
used in multiple comparison blocks are denoted by bold condition labels. Data from this imaging solution
screen are shown in Figure 3.14.
solute / mM
condition CpH PO43– NaCl (NH4)2SO4 Na2SO4
1 6.0 10 – – –
2 6.0 25 – – –
3 6.0 40 – – –
4 6.0 25 150 – –
5 6.0 25 300 – –
6 6.0 25 500 – –
7 6.0 25 – 50 –
8 6.0 25 – 100 –
9 6.0 25 – 200 –
10 6.0 25 – – 75
11 7.0 10 – – –
12 7.0 25 – – –
13 7.0 25 300 – –
14 7.0 25 – 50 –
15 7.0 25 – 100 –
16 7.0 25 – 200 –
bioluminescence inhibition caused by plasma components such as ceruloplasmin. Additionally,
previous literature suggested that NaCl added to increase ionic strength could disrupt the
interaction between MPO and ceruloplasmin.25 Because previous data had shown Cl– to inhibit
HOBr-dependent MPO bioluminescence (see Figure 2.6 on page 55), varying concentrations
of buffer phosphate were also used to independently adjust ionic strength. Preliminary data
had also suggested that higher-capacity buffers prevented diluted plasma from increasing the
imaging solution pH and minimizing MPO-independent L-012 oxidation. (Data not shown)
The imaging solution parameters tested are detailed in Table 3.2.
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Of the parameters tested, (NH4)2SO4 had the most profound effect. Bioluminescence
from native plasma decreased with increasing (NH4)2SO4. The same was true with MPO-
supplemented plasma imaged with pH = 7 buffer; this was likely due to its effect on pH. For
example, measurements with an electronic pH meter showed that 200 mM (NH4)2SO4 lowered
the pH of 25 mM phosphate buffer from 6.0 to 5.5. Despite the overall decrease in signal at
buffer pH = 7, the absolute and relative difference between MPO-supplemented and native
plasma increased with (NH4)2SO4 concentration in both buffers. Additionally, absolute
MPO-dependent bioluminescence in acidic phosphate buffer increased with (NH4)2SO4.
(Figure 3.14A) This boost in MPO resolution was greater than the improvement due to
increasing NaCl. (Figure 3.14B) While total phosphate concentration was correlated with
overall bioluminescence intensity, MPO resolution did not improve with increasing phosphate
alone. (Figure 3.14C) The signal ratios of each condition corresponding with Table 3.2 are
shown in Figure 3.14D.
A higher-resolution titration of (NH4)2SO4 in the imaging solution was performed to
characterize its effect. When applied to MPO-supplemented human plasma adsorbed onto
polystyrene, (NH4)2SO4 enhanced bioluminescence with a sigmoid relationship described by
equation (3.2). This gave an EC 50 = 34 mM (95% confidence interval 32–36 mM) and a
Hill coefficient H = 2.3 (95% confidence interval 2.0–2.5) at all levels of supplemented MPO.
Supplemented plasma showed an ~10-fold asymptotic increase in bioluminescence intensity.
(Figure 3.15A) When a similar experiment was performed with MPO-supplemented plasma
diluted directly into imaging buffer, (NH4)2SO4 did not cause a quantifiably sigmoid response
curve. Analysis with equation (3.3) showed that although (NH4)2SO4 in plasma gave a similar
EC 50 to that seen with adsorbed MPO, 23 mM (95% confidence interval 11–35 mM), the
asymptotic maximum was <2-fold higher than baseline. (Figure 3.15B) The enhancing effect
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Figure 3.14: Multi-parameter survey of adsorbed MPO imaging solutions. All data represent the
1 min image taken at the 5 min imaging timepoint (n = 3). Solution numbers are also annotated on each
horizontal axis. (A) Titration of (NH4)2SO4 at CpH = 6.0 or 7.0. The effect trend was the same in both
buffer systems: (NH4)2SO4 substantially increased overall MPO resolution. Decreased total luminescence
in the pH = 7.0 buffer may be due to the pH shift from NH4+. The effects of (NH4)2SO4 are discussed
further in Figure 3.15. (B) NaCl concentration at two CpHs, 6.0 and 7.0. At high NaCl concentrations, the
MPO inhibitor ceruloplasmin has been reported to dissociate from MPO.25 Previous data also demonstrates
that Cl– inhibits Br–-dependent MPO bioluminescence at concentrations adequate to dissociate MPO and
ceruloplasmin. (see Figure 2.6) As expected from this, increasing Cl– decreases total luminescence at both
pHs but slightly improves MPO resolution. (C) Total phosphate concentration at two CpHs, 6.0 and 7.0. In
addition to improved buffering capacity, increasing the total phosphate concentration also has a large effect
on ionic strength. Increasing phosphate increased the overall luminescence, but did not have a substantial
effect on MPO resolution. (D) The signal ratio of MPO-supplemented plasma to untreated plasma after
each of the 16 imaging conditions. Ratios were determined by log-linked gamma regression and are displayed
as mean ± 95% confidence intervals. For solution conditions included in this survey, see Table 3.2.
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of (NH4)2SO4 was absent when MPO was diluted into imaging solution in the absence of
human plasma. (Figure 3.15C) To determine if the key solute was either NH4+ or SO42–
individually, Na2SO4 was titrated in imaging solution into which human plasma with varying
supplemented MPO were added. Unlike the mild enhancement seen with (NH4)2SO4 in
Figure 3.15B, Na2SO4 did not increase MPO bioluminescence. (Figure 3.15D)
The different effects of (NH4)2SO4 when used with adsorbed plasma versus plasma diluted
into buffer could be explained by the presence or absence of antioxidants, the removal of
which was the rationale behind the development of the solid-state MPO assay. To test the
removal of small molecule antioxidants, the potent bioluminescence inhibitor ascorbic acid
(see Figure 2.12 on page 63) was added to RBP with varying human MPO before adsorption
onto polystyrene. After washing unadsorbed material free from the plate, ascorbic acid did
not show the potent inhibitory effect seen with MPO in solution. (Figure 3.16)
Tween20 was also discovered to have a profound effect on adsorbed MPO-dependent
bioluminescence at multiple stages in the assay protocol. When added to pure MPO in solution,
Tween20 did not affect MPO-dependent bioluminescence. (Data not shown) When added to
the imaging solution applied to MPO adsorbed in conjunction with RBP, Tween20 caused
a slight increase in bioluminescence at a final concentration ~100 ppm v/v. (Figure 3.17)
An ~2-fold increase was observed when Tween20 was added at 65–130 ppm v/v to the RBP
dilution and incubation buffer. (Figure 3.18) Most striking by far was the improvement
seen by 200 ppm v/v Tween20 in the MPO standard curve dilution buffer, which not only
increased the signal by a factor >4, but also dramatically reduced the intra- and inter-assay
variance of prepared standard curves. (Figure 3.19)
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Figure 3.15: Increasing adsorbed plasma MPO activity with (NH4)2SO4. Data are from the 5 min
timepoint and are shown as mean ± standard deviation (n = 4). (A) Titration curves of (NH4)2SO4 in
imaging solutions for adsorbed MPO. (NH4)2SO4 was titrated in the presence of 50 µM L-012, 100 µM
H2O2, 20 mM NaBr, and 200 ppm v/v Tween20 in an acidic citrate buffer. MPO concentrations are in
whole plasma before dilution to 0.4% v/v in loading buffer for adsorption onto polystyrene. Regression
results ± 95% confidence bands from equation (3.2) are shown as dashed lines and gray areas, respectively.
(NH4)2SO4 enhanced MPO bioluminescence with EC 50 = 34 mM (95% confidence interval 32–36 mM).
The regression Hill coefficient and EC 50 did not vary significantly between the three MPO concentrations.
(B) Titration curves of (NH4)2SO4 in imaging solutions for MPO in human plasma. (NH4)2SO4 was titrated
in the presence of 50 µM L-012, 100 µM H2O2, 20 mM NaBr in an acidic citrate buffer. MPO concentrations
are in whole plasma before dilution to 400 ppm v/v in imaging buffer. Regression results ± 95% confidence
bands from equation (3.3) are shown as dashed lines and gray areas, respectively. (NH4)2SO4 enhanced
MPO bioluminescence in the 300 µg/L and 100 µg/L solutions with EC 50 = 23 mM (95% confidence interval
11–35 mM). The regression EC 50 did not vary significantly between the two MPO concentrations that could
be fit to equation (3.3). (C) Titration curves of (NH4)2SO4 in imaging solutions for pure MPO in acidic
citrate buffer with 20 mM NaBr, 30 µM L-012, and 100 µM H2O2. Unlike in (A) and (C), (NH4)2SO4 did not
substantially enhance MPO bioluminescence. (D) Modification of the experiment used in (B) using Na2SO4
in place of (NH4)2SO4 to control for ionic strength and SO42– concentration. Na2SO4 did not enhance
MPO bioluminescence and could not be fit to standard models of either enhancement or inhibition. MPO
concentrations are in whole plasma before dilution to 400 ppm v/v in imaging buffer.
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Figure 3.16: Ascorbic acid washed from adsorbed MPO. Bioluminescence from RBP supplemented
with human MPO and varying ascorbic acid prior to adsorption and imaging on polystyrene. Black bar
represents the physiological reference range for plasma ascorbic acid. Unlike when applied directly to MPO
in imaging solution, ascorbic acid has no substantial effect on adsorbed MPO bioluminescence. Data from
the 5 min imaging timepoint are shown as mean ± standard deviation (n = 4). MPO and ascorbic acid are
annotated with pre-dilution concentrations. Physiologic reference range from McPherson & Pincus.43
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Figure 3.17: Effects of Tween20 in bioluminescence imaging buffer applied to adsorbed MPO.
MPO co-adsorbed with RBP after dilution to 0.4% v/v in CpH = 6.5 phosphate buffer and imaged with
100 µM H2O2, 50 µM L-012, 200 mM (NH4)2SO4, 20 mM NaBr, and varying Tween20. Tween20 had a
minimal effect on MPO resolution with peak improvement at ~50–140 ppm v/v. All data are from the 5 min
timepoint of their respective time series and are shown as mean ± standard deviation (n = 4). WLS results
are shown as dashed lines ± gray 95% confidence bands. Quadruplicate 95% prediction bands are shown as
long-dashed lines. MPO axis represents pre-dilution concentration.
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Figure 3.18: Improved adsorption of MPO in the presence of Tween20. Modification of the
experiment used in Figure 3.17 using Tween20 in the loading buffer into which RBP ± MPO was diluted
to 0.4% v/v and incubated on the polystyrene plate. ~29–65 ppm v/v Tween20 resulted in the greatest
improvement in MPO resolution. All data are from the 5 min timepoint of their respective time series and are
shown as mean ± standard deviation (n = 4). WLS results are shown as dashed lines ± gray 95% confidence
bands. Quadruplicate 95% prediction bands are shown as long-dashed lines. MPO axis represents pre-dilution
concentration.
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Figure 3.19: Tween20 reducing MPO loss during serial dilutions. Modification of the experiment
used in Figure 3.17 and Figure 3.18 using Tween20 in the MPO serial dilution buffer. Using this method, pure
MPO was combined with pre-diluted RBP rather than premixing the two before dilution. MPO resolution
improved dramatically and plateaued by 200 ppm v/v Tween20. All data are from the 5 min timepoint of
their respective time series and are shown as mean ± standard deviation (n = 4). WLS results are shown as
dashed lines ± gray 95% confidence bands. Quadruplicate 95% prediction bands are shown as long-dashed
lines. MPO axis represents pre-dilution concentration.
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3.3.6 Bioluminescence specificity for adsorbed MPO
The specific MPO inhibitor 4-ABH was used to verify that the bioluminescence from adsorbed
plasma supplemented with exogenous MPO was from active enzyme.44 Titrating 4-ABH into
the imaging solution applied to adsorbed RBP with human plasma inhibited bioluminescence
fitting the model described by equation (3.4) with an IC 50 = 25 nM (95% confidence interval
22–28 nM). This also provided further evidence that RBP is a suitable baseline carrier for
an MPO assay: native RBP bioluminescence cannot be fit to equation (3.4) and remained
at a steady baseline across the entire titration concentration range. (Figure 3.20A) To
further test that MPO was adsorbed onto the polystyrene surface, the highly cationic protein
protamine sulfate was co-incubated at increasing concentrations with RBP supplemented with
human MPO. Protamine sulfate blocked MPO adsorption with an IC 50 = 590 µg/L (95%
confidence interval 560–620 µg/L). (Figure 3.20B) This effect was confirmed to be caused by
competitive adsorption by testing protamine sulfate for intrinsic inhibition activity against
MPO bioluminescence. Even when applied at concentrations over many orders of magnitude,
protamine sulfate had no effect on MPO bioluminescence in solution. (Figure 3.20C)
3.4 Discussion
Plasma MPO content is a recently discovered biomarker for subclinical CVD progression, risk
of MACEs in patients with known coronary artery disease (CAD), and short- and long-term
prognosis after clinical presentation with a MACE.9–20 At present, plasma MPO is measured
with ELISAs, which are costly, time-consuming, and do not utilize the enzymatic properties of
MPO in its detection. Luminol and its analogue L-012 serve as bioluminescence substrates for
MPO activity by means of chemiluminescent oxidation caused by hypohalous acids produced
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Figure 3.20: Bioluminescence specificity for adsorbed MPO. All MPO is annotated with pre-
dilution concentrations. (A) Titration of the specific MPO inhibitor 4-ABH in imaging solutions applied
to MPO adsorbed in the presence of RBP. Regression of the data from MPO-supplemented RBP with
equation (3.4) showed that 4-ABH inhibited bioluminescence with an IC 50 = 25 nM (95% confidence interval
22–28 nM). Native RBP did not fit the inhibition model and signal remained at the baseline across all 4-ABH
concentrations. Data from the 5 min imaging timepoint are shown as mean ± standard deviation (n = 4).
Nonlinear regression and 95% confidence bands are shown as dashed lines and shaded areas, respectively.
(B) Titration curves of protamine sulfate co-incubated with RBP supplemented with varying MPO and diluted
to 0.4% v/v. Protamine sulfate is a cationic protein much like MPO and can compete for adsorption surface
area. Regression with equation (3.5) gave an IC 50 = 590 µg/L (95% confidence interval 560–620 µg/L). Data
from the 5 min imaging timepoint are shown as mean ± standard deviation (n = 4). Nonlinear regression
and 95% confidence bands are shown as dashed lines and shaded areas, respectively. (C) Protamine sulfate
titrated with human plasma supplemented with exogenous MPO and diluted to 500 ppm v/v. Unlike with
bioluminescence from adsorbed MPO seen in (B), protamine sulfate does not affect MPO bioluminescence in
solution. Raw data from the 5 min imaging timepoint are shown (n = 4).
by MPO halogenation cycles.45–47 As shown in Chapter 2, assaying MPO activity with L-012
and H2O2 added directly to plasma is not a feasible strategy; nonspecific antioxidants and
endogenous MPO inhibitors are confounding variables with non-linear relationships to MPO
bioluminescence and can vary widely between samples. This chapter describes the inception
and optimization of a novel bioluminescence assay for MPO activity from whole human
plasma. The objectives in developing the assay were to measure human MPO activity with
similar precision and reproducibility compared to current commercial ELISA kits but with
great reductions in monetary cost, required time, and procedural steps.
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Enzyme peroxidase activity is commonly measured on various polymer membrane surfaces,
often to visualize protein bands with immunoconjugated HRP targeting a desired epitope.
The ubiquity, low cost, and simplicity of protein isolation on nitrocellulose or PVDF
membranes made the technique an intuitive platform to utilize for MPO retention. As
expected from the hydrophilic oligosaccharides adorning its surface and strong cationic
charge of the core protein, MPO was retained after direct application to nitrocellulose with
concentration-dependent bioluminescence visible after buffer washes. (Figure 3.1A) Such dot-
blot techniques are generally used when the analyte concentration spans orders of magnitude
or when precise quantification is unnecessary, as is not the case with plasma MPO. With an
improvised apparatus for applying solutions to a nitrocellulose membrane, the distribution of
bioluminescence from each sample became more heterogeneous with sharp boundaries for
improved quantification. (Figures 3.1B–3.1D)
The functionality of the nitrocellulose cassette proof-of-concept is similar to commercially
available protein analysis products, which have the advantage of consistency and quality
control far exceeding that of re-purposed laboratory plastic waste. PVDF-floored microtiter
plates did not produce linear bioluminescence with either luminol or L-012, likely due
to decreased affinity for hydrophilic macromolecules compared to that of nitrocellulose.
(Figure 3.2) Contrary to expectations, nitrocellulose-floored plates also performed poorly
when used to distinguish MPO from a negative control solution with L-012 bioluminescence
imaging, both in the presence and absence of diluted human plasma. (Figure 3.3A) As
shown in Figure 2.9B on page 60, acidification of the imaging solution improves the signal
ratio of MPO:H2O2-dependent L-012 oxidation. This strategy did not improve the utility
of the nitrocellulose plate in measuring MPO; although background signal decreased as
expected, the same was equally true of MPO bioluminescence. (Figure 3.3B) Unlike the free
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nitrocellulose membranes previously used successfully, the undersides of the filter plates were
covered in a hydrophobic film intended to assist in vacuum filtration of fluid through each
well. Although vacuum filtration through the plates required a manifold built to the plate
specifications, a similar product allowed for vacuum filtration through free nitrocellulose
membranes. Using atmospheric pressure to force MPO-laden solutions through the membrane
greatly improved bioluminescence detection compared to that with passive plate loading,
but this also revealed new disadvantages. Bioluminescence kinetics were extremely variable,
even with pure solutions of MPO in buffer. (Figure 3.4A and 3.4B) Rigorous washing of
the cassette before imaging mitigated this somewhat, especially at lower concentrations of
MPO and allowed progression to testing with MPO diluted into ΔFBS. (Figure 3.4C) In
the end, however, nitrocellulose imaging proved to have high MPO resolution in a narrow
concentration range, with dilute MPO likely inhibited by other plasma components bound
to the membrane, and higher concentrations saturating the available binding interface; the
resulting sigmoid calibration curves were not amenable to inverse regression of unknown
MPO solutions. (Figure 3.4D)
Plastics offer an alternative to polymer membranes for protein immobilization. They
also have the advantages of precision manufacturing and chemical modifications that can be
incorporated reproducibly into the well surfaces to increase protein binding. Sandwich ELISA
plates are prepared in this manner by first incubating the desired immunoglobulin in buffers
designed to maximize adsorption through non-covalent interactions at the protein/polymer
interface. Initial attempts at coating various “high protein-binding” commercial microtiter
plates with purified human MPO were discouraging; even conditions that resulted in near-
linear relationships between loaded MPO concentration and measured bioluminescence
had dynamic ranges unsuitable for a clinical assay. (Figure 3.5A) Dilute human plasma
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supplemented with exogenous MPO paradoxically produced bioluminescence calibration
curves with less variance than any solution-based MPO titrations (such as those in Chapter 2)
and exceeding the quality of those from commercial ELISA kits. (Figure 3.5B) Tissue
culture-treated polystyrene, while not marketed for this purpose, outperformed plastic
surfaces designed for ELISA adsorption. (Data not shown) Additionally, MPO adsorption was
complete in far less time than the 5–10 h or overnight incubations suggested by ELISA coating
protocols.48 Although peak adsorption was achieved in 5–15 min, 30 min was chosen for all
adsorptive incubations for consistency and to give adequate time to prepare any experimental
imaging solutions during the optimization stages of assay development. (Figure 3.6)
Although human plasma from healthy volunteers was used extensively throughout the
development of this assay, it has many disadvantages precluding its use as a standard carrier
for MPO calibration solutions: it has greater associated biohazard risk than plasmas from
other species, it is more costly to obtain, and by definition has the possibility of confounding
endogenous human MPO. Another consideration in testing carrier plasmas was the means
of anticoagulation. After a long series of failed experiments with fresh human plasma, the
use heparinized phlebotomy tubes was found to prevent adsorption of any supplemented
MPO. (Figure 3.7) This is agrees with the literature reports of MPO associating with
heparin and other glycosaminoglycans.37,49,50 ΔFBS is another adsorption carrier used in
assay development, but it often failed to accurately calibrate MPO added to human plasma.
(Figure 3.8) The primary difference between human plasma and ΔFBS is the presence of
fibrinogen and other proteins associated with thrombus formation. However, treating human
plasma with bovine thrombin or CaCl2 to initiate the fibrinogen→fibrin conversion had no
effect on adsorbed MPO bioluminescence.
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Reconstituted bovine plasma (RBP) anticoagulated with citrate reproducibly matched
fresh human plasma anticoagulated with K2EDTA as a human MPO adsorption carrier.
(Figure 3.9) Calibration curves analyzed with WLS regression routinely produced R2 > 0.99
and resulted in accurately regressed MPO adsorbed with human plasma within 95% confidence
limits. RBP size fractionation was used to determine what plasma components are important
to MPO adsorption. (Figure 3.10) Of the fractions above their respective molecular weight
cutoffs that were tested, only the >100 kDa components showed slightly reduced co-adsorption
utility. Removing the <5 kDa fraction appeared to increase MPO bioluminescence, but
this may be an artifact of the filtration procedure, which could not be exactly replicated
with unfiltered RBP, only approximated by incubating diluted RBP at 4 ℃ for the duration
of the filtration spins. Still, BSA and human fibronectin were forerunner candidates for
co-adsorption proteins given literature on both their interaction with MPO and adsorption
onto activated polystyrene.34–38 Neither proved sufficient to allow MPO adsorption, however,
and after two independently obtained lots of RBP gave consistent results, efforts were shifted
instead to optimizing the assay using whole RBP as the MPO carrier. (Figure 3.11)
Solution parameter surveys for both the adsorption and imaging solutions were performed
to guide further optimization. Of the MPO binding treatments and solutions summarized in
Table 3.1, those based on precipitating fibrin via addition of CaCl2 to activate thrombin had
the least effect on MPO bioluminescence. (Figure 3.12B) Additionally, all solutions with no
NaCl performed poorly, suggesting that electrostatically driven protein aggregation at low ionic
strength prevents MPO adsorption, but whether this is due to surface saturation by competing
proteins or sequestration of MPO by other free proteins is not known. (Figure 3.12A) The
most noteworthy comparison was between 150 mM NaCl buffered with citrate at pH = 6.0
and phosphate at pH = 6.5. (Figure 3.12C) The difference in buffer caused an ~2-fold
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change in the signal ratio of MPO-supplemented plasma to native control, suggesting that
protonation was the primary determinant of MPO adsorption. (Figure 3.12D) Titrating
the ratio of NaH2PO4 to Na2HPO4 in a 25 mM phosphate buffer revealed the narrow pH
optimum for MPO retention. (Figure 3.13) By chance, this maximum coincided to the pH
used most often for plasma dilution in preceding experiments.
The most important finding made prior to testing the assay with clinical plasma samples
involved abatement of co-adsorbed MPO inhibitors. The plasma protein ceruloplasmin
is known to tightly bind to MPO and potently inhibit its activity in vivo and in vitro
and also adsorbs onto oxidized polystyrene.26,27,34,51,52 The interaction between MPO and
ceruloplasmin can be disrupted by concentrated NaCl, but this is counterproductive to a
bioluminescence assay optimized for bromination (see Figure 2.6 on page 55). As expected,
increasing NaCl moderately improved adsorbed MPO bioluminescence at acidic and neutral
pH. (Figure 3.14B)
An alternative salt to increase ionic strength is (NH4)2SO4, which is commonly used by
crystallographers and biochemists to “salt-out” proteins for purification or lattice formation
due to its high solubility and the position of SO42– along the Hofmeister series.53 Although one
publication documented SO42– as an enhancer of luminol chemiluminescence, few published
reports mention NH4+ in the context of MPO biochemistry, none of which investigate the
interactions in a way directly applicable to bioluminescence.Beilke1989a, 54–57 Interestingly,
(NH4)2SO4 has been reported as a potent inhibitor of HRP-dependent bioluminescence of
luminol.58 This made the discovery that (NH4)2SO4 was a potent MPO bioluminescence
enhancer rather unexpected. (Figure 3.14D) Acidification from NH4+ ions concentrated at
2–8 times the total buffering capacity accounts for the drop in overall luminescence in the
CpH = 7 solutions, but this did not adversely affect MPO differentiation. Further investigation
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of (NH4)2SO4 enhancement after other optimization showed that (NH4)2SO4 could increase
MPO-dependent bioluminescence in the presence of co-adsorbed plasma proteins by a factor
of ~10 and the effect was sharply saturable. (Figure 3.15A) When titrated into diluted plasma
supplemented with MPO, (NH4)2SO4 enhancement was muted. (Figure 3.15B) This suggests
that the antioxidants removed by the washes after MPO and other proteins adsorb to the plate
are not affected by (NH4)2SO4; its effect is on specific MPO inhibitors such as ceruloplasmin.
From this, (NH4)2SO4 would not be expected to enhance MPO bioluminescence in the
absence of any inhibitors. This was confirmed experimentally. (Figure 3.15C) Additionally,
the effect was dependent not on ionic strength of SO42– concentration; titrating Na2SO4
into diluted plasma supplemented with MPO showed no enhancement and actually reduced
bioluminescence slightly. (Figure 3.15D)
Before applying the assay to clinical samples, it was first tested for specificity to MPO
and robustness to small-molecule antioxidants. The potent inhibition observed from ascorbic
acid titrated in the presence of pure MPO (see Figure 2.12A on page 63) was absent
when RBP supplemented with human MPO and increasing ascorbic acid was incubated on
polystyrene and washed free of unadsorbed material before imaging. (Figure 3.16) Even at the
physiological reference range, ascorbic acid did not appreciably quench L-012 bioluminescence.
The source of the bioluminescence was also determined to be functional MPO by two different
lines of evidence. The specific MPO inhibitor 4-ABH quenched bioluminescence with an
IC 50 = 25 nM (95% confidence interval 22–28 nM), consistent with pharmacological inhibition.
(Figure 3.20A) The effect of co-incubation with a competing cationic protein also supports
the conclusion that MPO is adsorbing from plasma onto the polystyrene; protamine sulfate
blocked MPO adsorption with an IC 50 = 590 µg/L (95% confidence interval 560–620 µg/L)
despite having no effect on MPO bioluminescence in solution. (Figure 3.20B and 3.20C) Both
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of these experiments also confirm that RBP is a suitable standard MPO carrier, as native
RBP did not fit the inhibition model with either experiment and remained at a constant
baseline signal across both inhibitor titrations.
The final discovery important for the clinical assay was the effect of the detergent Tween20
on different stages of the protocol. Although RBP enabled accurate inverse regression of
supplemented MPO in human plasma, both of these solution series were prepared by serially
diluting MPO into the respective carriers. MPO was being lost at each serial dilution stage,
but the effect was equal in the two series. As clinical plasma samples are not subject to this
manipulation, early attempts to assay clinical samples were discordant from ELISA estimates
of MPO concentration. (Data not shown) This MPO loss is apparent when Tween20 is
added to the standard curve dilution buffer, resulting in a sharp rise in bioluminescence with
Tween20 as dilute as 100 ppm v/v. (Figure 3.19) Additional adsorption is also apparent when
Tween20 is added to the dilution buffer to which plasma is added before incubation in the
microtiter plate wells. (Figure 3.18) Lastly, there is a slight increase bioluminescence from
Tween20 in the imaging solution, perhaps preventing residual interactions between MPO and
co-adsorbed inhibitors.
In conclusion, the work described in this chapter was aimed toward overcoming the
obstacles to a clinical bioluminescence assay for plasma MPO activity described in Chapter 2.
The primary achieved objectives were to isolate MPO from whole human plasma, remove or
otherwise negate exogenous MPO inhibitors and antioxidants, and measure remaining MPO
activity using calibration standards with known MPO activity. Nitrocellulose traditionally
used for visualizing immunoconjugated HRP chemiluminescence limited the detectable
concentration range of retained MPO due to high background signal, a saturable membrane
interface, and retention of exogenous inhibitors. Although commercial plastic surfaces
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intended to bind immunoglobulins for ELISA failed to linearly adsorb MPO, tissue culture-
treated polystyrene proved apt for rapid MPO binding when incubated in the presence
of human or bovine blood plasma. Human plasma MPO was accurately regressed using
RBP standards with known MPO activity. Co-adsorbed inhibitors were neutralized with
concentrated (NH4)2SO4, increasing bioluminescence signal by an order of magnitude. The
technique resulting from the work in this chapter, hereafter referred to as the ‘MPO activity
on a polymer surface (MAPS) assay,’ produces calibration curves superior to those from
ELISA at <5% of the cost and can be executed in 30 min. The next chapter will discuss a
pilot clinical study on the accuracy and reproducibility of the MAPS assay in contrast to
ELISA, the current clinical standard for measuring plasma MPO.
3.5 References
1. Ross, R. Atherosclerosis–an inflammatory disease. N. Engl. J. Med. 340, 115–26 (Jan.
1999).
2. Libby, P. Inflammation in atherosclerosis. Nature 420, 868–74 (2002).
3. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J.
Med. 352, 1685–95 (July 2005).
4. Nieto, F. J. in Inflamm. Atheroscler. (eds Wick, G. & Grundtman, C.) 1–17 (Springer
Vienna, Vienna, 2012).
5. Kemp, M., Donovan, J., Higham, H. & Hooper, J. Biochemical markers of myocardial
injury. Br. J. Anaesth. 93, 63–73 (July 2004).
6. Hellings, W. E., Peeters, W., Moll, F. L. & Pasterkamp, G. From vulnerable plaque
to vulnerable patient: the search for biomarkers of plaque destabilization. Trends
Cardiovasc. Med. 17, 162–71 (July 2007).
7. McDonnell, B., Hearty, S., Leonard, P. & O’Kennedy, R. Cardiac biomarkers and the
case for point-of-care testing. Clin. Biochem. 42, 549–61 (2009).
8. Scolletta, S., Donadello, K., Santonocito, C., Franchi, F. & Taccone, F. S. Biomarkers
as predictors of outcome after cardiac arrest. Expert Rev. Clin. Pharmacol. 5, 687–99
(Nov. 2012).
126
Chapter 3: Myeloperoxidase sequestration on solid substrates References
9. Zhang, R., Brennan, M. L., Fu, X., Aviles, R. J., Pearce, G. L., Penn, M. S., Topol, E. J.,
Sprecher, D. L. & Hazen, S. L. Association between myeloperoxidase levels and risk of
coronary artery disease. JAMA 286, 2136–42 (Nov. 2001).
10. Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Münzel, T.,
Simoons, M. L. & Hamm, C. W. Myeloperoxidase serum levels predict risk in patients
with acute coronary syndromes. Circulation 108, 1440–5 (Sept. 2003).
11. Brennan, M.-L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J.,
Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E. & Hazen, S. L.
Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349,
1595–604 (Oct. 2003).
12. Mocatta, T. J., Pilbrow, A. P., Cameron, V. a., Senthilmohan, R., Frampton, C. M.,
Richards, a. M. & Winterbourn, C. C. Plasma concentrations of myeloperoxidase
predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49, 1993–2000
(2007).
13. Khan, S. Q., Kelly, D., Quinn, P., Davies, J. E. & Ng, L. L. Myeloperoxidase aids
prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk
patients with acute ST elevation myocardial infarction. Heart 93, 826–31 (July 2007).
14. Ndrepepa, G., Braun, S., Mehilli, J., von Beckerath, N., Schömig, a. & Kastrati, a.
Myeloperoxidase level in patients with stable coronary artery disease and acute coronary
syndromes. Eur. J. Clin. Invest. 38, 90–6 (Mar. 2008).
15. Karadag, B., Vatan, B., Hacioglu, Y., Duman, D., Baskurt, M., Keles, I., Ongen, Z.
& Vural, V. A. Serum myeloperoxidase level predicts reperfusion in patients with
myocardial infarction receiving thrombolytic therapy. Heart Vessels 24, 247–53 (July
2009).
16. Roman, R. M., Camargo, P. V., Borges, F. K., Rossini, A. P. & Polanczyk, C. A.
Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable
and stable angina patients. Coron. Artery Dis. 21, 129–36 (May 2010).
17. Nicholls, S. J., Tang, W. H. W., Brennan, D., Brennan, M.-L., Mann, S., Nissen, S. E.
& Hazen, S. L. Risk prediction with serial myeloperoxidase monitoring in patients with
acute chest pain. Clin. Chem. 57, 1762–70 (Dec. 2011).
18. Tretjakovs, P., Jurka, A., Bormane, I., Mikelsone, I., Elksne, K., Krievina, G., Reihmane,
D., Verbovenko, J. & Bahs, G. Circulating adhesion molecules, matrix metalloproteinase-
9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease
patients with stable and unstable angina. Clin. Chim. Acta. 413, 25–9 (Jan. 2012).
127
Chapter 3: Myeloperoxidase sequestration on solid substrates References
19. Stankovic, S., Asanin, M., Trifunovic, D., Majkic-Singh, N., Ignjatovic, S., Mrdovic, I.,
Matic, D., Savic, L., Marinkovic, J., Ostojic, M. & Vasiljevic, Z. Time-dependent
changes of myeloperoxidase in relation to in-hospital mortality in patients with the first
anterior ST-segment elevation myocardial infarction treated by primary percutaneous
coronary intervention. Clin. Biochem. 45, 547–51 (May 2012).
20. Granér, M., Tikkanen, E., Rimpilä, O., Tikkanen, H., Ripatti, S., Lokki, M.-L.,
Nieminen, M. S., Taskinen, M.-R. & Sinisalo, J. Diagnostic efficacy of myeloperoxidase
to identify acute coronary syndrome in subjects with chest pain. Ann. Med. 322–327
(May 2013).
21. Hampton, M. B., Kettle, a. J. & Winterbourn, C. C. Inside the neutrophil phagosome:
oxidants, myeloperoxidase, and bacterial killing. Blood 92, 3007–17 (Nov. 1998).
22. Klebanoff, S. J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598–625 (May
2005).
23. Winterbourn, C. C. Comparative reactivities of various biological compounds
with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to
hypochlorite. Biochim. Biophys. Acta 840, 204–10 (July 1985).
24. Lindvall, S. & Rydell, G. Influence of thiols on the chlorinating effect of a
myeloperoxidase system. Chem. Biol. Interact. 97, 53–62 (July 1995).
25. Sokolov, A. V., Pulina, M. O., Ageeva, K. V., Ayrapetov, M. I., Berlov, M. N.,
Volgin, G. N., Markov, A. G., Yablonsky, P. K., Kolodkin, N. I., Zakharova, E. T.
& Vasilyev, V. B. Interaction of ceruloplasmin, lactoferrin, and myeloperoxidase.
Biochemistry 72, 409–415 (Apr. 2007).
26. Sokolov, A. V., Ageeva, K. V., Pulina, M. O., Cherkalina, O. S., Samygina, V. R.,
Vlasova, I. I., Panasenko, O. M., Zakharova, E. T. & Vasilyev, V. B. Ceruloplasmin
and myeloperoxidase in complex affect the enzymatic properties of each other. Free
Radic. Res. 42, 989–98 (Nov. 2008).
27. Chapman, A. L. P., Mocatta, T. J., Shiva, S., Seidel, A., Chen, B., Khalilova, I.,
Paumann-Page, M. E., Jameson, G. N. L., Winterbourn, C. C. & Kettle, A. J.
Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J. Biol. Chem. 288,
6465–77 (Mar. 2013).
28. Franck, T., Kohnen, S., Deby-Dupont, G., Grulke, S., Deby, C. & Serteyn, D. A Specific
Method for Measurement of Equine Active Myeloperoxidase in Biological Samples and
in in Vitro Tests. J. Vet. Diagnostic Investig. 18, 326–334 (July 2006).
29. Franck, T., Kohnen, S., Boudjeltia, K. Z., Van Antwerpen, P., Bosseloir, a., Niesten, a.,
Gach, O., Nys, M., Deby-Dupont, G. & Serteyn, D. A new easy method for specific
measurement of active myeloperoxidase in human biological fluids and tissue extracts.
Talanta 80, 723–9 (Dec. 2009).
128
Chapter 3: Myeloperoxidase sequestration on solid substrates References
30. Green, A. A. & Hughes, W. L. in Methods Enzymol. (eds Colowick, S. P. & Kaplan,
N. O.) 67–90 (Academic Press, Inc, San Diego, California, 1955).
31. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.-Y., White, D. J.,
Hartenstein, V., Eliceiri, K., Tomancak, P. & Cardona, A. Fiji: an open-source platform
for biological-image analysis. Nat. Methods 9, 676–82 (July 2012).
32. Cox, C. & Ma, G. Asymptotic confidence bands for generalized nonlinear regression
models. Biometrics 51, 142–50 (Mar. 1995).
33. Chapin, R. M. The influence of pH upon the formation and decomposition of the chloro
derivatives of ammonia. J. Am. Chem. Soc. 53, 912–920 (1931).
34. Curtis, A. S. G. & Forrester, J. V. The competitive effects of serum proteins on cell
adhesion. J. Cell Sci. 71, 17–35 (Oct. 1984).
35. Tiruppathi, C., Naqvi, T., Wu, Y., Vogel, S. M., Minshall, R. D. & Malik, A. B. Albumin
mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells.
Proc. Natl. Acad. Sci. U. S. A. 101, 7699–704 (May 2004).
36. Baldus, S., Eiserich, J. P., Mani, A., Castro, L., Figueroa, M., Chumley, P., Ma, W.,
Tousson, A., White, C. R., Bullard, D. C., Brennan, M. L., Lusis, A. J., Moore, K. P.
& Freeman, B. A. Endothelial transcytosis of myeloperoxidase confers specificity to
vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108, 1759–70
(Dec. 2001).
37. Baldus, S., Rudolph, V., Roiss, M., Ito, W. D., Rudolph, T. K., Eiserich, J. P.,
Sydow, K., Lau, D., Szöcs, K., Klinke, A., Kubala, L., Berglund, L., Schrepfer, S.,
Deuse, T., Haddad, M., Risius, T., Klemm, H., Reichenspurner, H. C., Meinertz, T.
& Heitzer, T. Heparins increase endothelial nitric oxide bioavailability by liberating
vessel-immobilized myeloperoxidase. Circulation 113, 1871–8 (2006).
38. Shen, M. & Horbett, T. a. The effects of surface chemistry and adsorbed proteins
on monocyte/macrophage adhesion to chemically modified polystyrene surfaces. J.
Biomed. Mater. Res. 57, 336–45 (Dec. 2001).
39. Pankov, R. Fibronectin at a glance. J. Cell Sci. 115, 3861–3863 (Oct. 2002).
40. Hur, S. J., Toda, H. K. & Yamada, M. Isolation and characterization of an unprocessed
extracellular myeloperoxidase in HL-60 cell cultures. J. Biol. Chem. 264, 8542–8 (May
1989).
41. Yamada, M., Hur, S. J. & Toda, H. Isolation and characterization of extracellular
myeloperoxidase precursor in HL-60 cell cultures. Biochem. Biophys. Res. Commun.
166, 852–9 (Jan. 1990).
129
Chapter 3: Myeloperoxidase sequestration on solid substrates References
42. Mahn, A. & Ismail, M. Depletion of highly abundant proteins in blood plasma by
ammonium sulfate precipitation for 2D-PAGE analysis. J. Chromatogr. B. Analyt.
Technol. Biomed. Life Sci. 879, 3645–8 (Dec. 2011).
43. McPherson, R. A. & Pincus, M. R. Henry’s Clinical Diagnosis and Management by
Laboratory Methods 22nd (Saunders, Philadelphia, PA, 2011).
44. Kettle, A. J., Gedye, C. A., Hampton, M. B. & Winterbourn, C. C. Inhibition of
myeloperoxidase by benzoic acid hydrazides. Biochem. J. 308, 559–63 (June 1995).
45. Gross, S., Gammon, S. T., Moss, B. L., Rauch, D., Harding, J., Heinecke, J. W.,
Ratner, L. & Piwnica-Worms, D. Bioluminescence imaging of myeloperoxidase activity
in vivo. Nat. Med. 15, 455–61 (2009).
46. Ashkenazi, A. & Marks, R. S. Luminol-dependent chemiluminescence of human
phagocyte cell lines: comparison between DMSO differentiated PLB 985 and HL
60 cells. Luminescence 24, 171–7 (2009).
47. Zhou, J., Tsai, Y.-T., Weng, H. & Tang, L. Noninvasive assessment of localized
inflammatory responses. Free Radic. Biol. Med. 52, 218–26 (Jan. 2012).
48. Hornbeck, P., Winston, S. E. & Fuller, S. A. in Curr. Protoc. Mol. Biol. 1991, 11.2.1–
11.2.22 (John Wiley & Sons, Inc., May 2001).
49. Daphna, E. M., Michaela, S., Eynat, P., Irit, a. & Rimon, S. Association of
myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of
endothelial cells by the bound enzyme. Mol. Cell. Biochem. 183, 55–61 (June 1998).
50. Borawski, J., Naumnik, B. & Mysliwiec, M. Heparin, myeloperoxidase, and
atherosclerosis: a new focus on an old drug. Clin. Appl. Thromb. 13, 219–20 (Apr.
2007).
51. Sokolov, A. V., Prozorovskii, V. N. & Vasilyev, V. B. Study of interaction of
ceruloplasmin, lactoferrin, and myeloperoxidase by photon correlation spectroscopy.
Biochemistry 74, 1225–7 (Nov. 2009).
52. Sokolov, A. V., Ageeva, K. V., Cherkalina, O. S., Pulina, M. O., Zakharova, E. T.,
Prozorovskii, V. N., Aksenov, D. V., Vasilyev, V. B. & Panasenko, O. M. Identification
and properties of complexes formed by myeloperoxidase with lipoproteins and
ceruloplasmin. Chem. Phys. Lipids 163, 347–55 (May 2010).
53. Zhang, Y. & Cremer, P. S. Interactions between macromolecules and ions: The
Hofmeister series. Curr. Opin. Chem. Biol. 10, 658–63 (Dec. 2006).
54. Bause, D. E. & Patterson, H. H. Enhancement of luminol chemiluminescence with
halide ions. Anal. Chem. 51, 2288–2289 (Nov. 1979).
55. Thomas, E. L. Myeloperoxidase-hydrogen peroxide-chloride antimicrobial system: effect
of exogenous amines on antibacterial action against Escherichia coli. Infect. Immun.
25, 110–6 (July 1979).
130
Chapter 3: Myeloperoxidase sequestration on solid substrates References
56. Buys, J., Wever, R. & Ruitenberg, E. J. Myeloperoxidase is more efficient than eosinophil
peroxidase in the in vitro killing of newborn larvae of Trichinella spiralis. Immunology
51, 601–7 (Mar. 1984).
57. Gottardi, W. & Nagl, M. Chlorine covers on living bacteria: the initial step in
antimicrobial action of active chlorine compounds. J. Antimicrob. Chemother. 55,
475–82 (Apr. 2005).
58. Misra, H. P. & Squatrito, P. M. The role of superoxide anion in peroxidase-catalyzed
chemiluminescence of luminol. Arch. Biochem. Biophys. 215, 59–65 (Apr. 1982).
131
Chapter 4
Clinical ELISA and MAPS assays
4.1 Introduction
Chapter 3 demonstrated the development and optimization of a novel method to measure
myeloperoxidase (MPO) in plasma, dubbed the ‘MPO activity on a polymer surface (MAPS)
assay.’ This research was motivated by the increasing need for cardiovascular disease (CVD)
biomarkers, as the burden of the disease is rising both nationally and globally.1–3 Assessing
the extent of CVD through plasma biomarkers is a desirable strategy as they can be measured
with less risk and cost than invasive imaging techniques. Biomarkers of the inflammatory
processes that drive atherosclerosis progression are a newer class under investigation to
potentially join traditional analytes such as cardiac troponins.4–7 Plasma MPO concentration
is a potentially useful biomarker in predicting CVD risk as indicated by a growing body
of literature.8–30 Unlike the enzyme-linked immunosorbent assays (ELISAs) performed in
these previous studies, the MAPS assay can detect a broad range of MPO in human plasma
without the use of costly immunological reagents. It can also be performed in ~30 min, as
opposed to the many hours required by ELISA protocols, and costs <5% of the per-sample
ELISA cost. The MAPS assay has proven to be reproducible in simulated assays of clinical
samples, but a trial with patient plasma was required to directly compare the results to
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those from ELISA. In this chapter, MAPS assay data from a cohort of 72 cardiology patients
presenting for elective central catheterization is compared to matched ELISA measurements.
The two assays are compared with traditional methods of assay validation, including both a
side-by-side ELISA and a Food and Drug Administration (FDA)-approved ELISA performed
by a Clinical Laboratory Improvement Amendments (CLIA)- and College of American
Pathologists (CAP)-accredited laboratory, the Cleveland HeartLab (CHL). Additionally, the
MAPS assay is independently replicated four times with the entire cohort in order to quantify
the inter-assay variance with a robust statistical method of quantifying reproducibility.
4.2 Methods
4.2.1 Reagents and materials
Lyophilized L-012 was provided by Wako Chemicals USA (Richmond, Virginia; product
number 120-04891) was resuspended to 16.1 mM in ultrapure water and stored in 200 µL
aliquots at −20 ℃. Lyophilized human MPO from EMD Millipore/Calbiochem (Darmstadt,
Germany; product number 475911) was resuspended in pH = 6.0 buffer containing 100 mM
NaCl and 50 mM acetate, as recommended by the supplier, with final concentration 100 mg/L.
Single-use 10 µL aliquots were stored at −20 ℃. Lyophilized citrated bovine plasma from
Sigma Aldrich (Saint Louis, Missouri; product number P4639) was resuspended to the original
10 mL with ultrapure water and gently agitated at room temperature until particulates had
dispersed. Reconstituted bovine plasma (RBP) was stored at −20 ℃. All other reagents
were supplied by Sigma Aldrich. Human MPO ELISA kits were provided by Enzo Life
Sciences, Inc. (Farmingdale, New York; product number ADI-900-115) All bioluminescence
experiments were performed using 96-well, black-walled, flat-bottom, tissue culture-treated
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polystyrene microtiter plates (Corning Inc.; Corning, New York; product number 3603).
Samples were prepared for MAPS assays in 1.2 mL polypropylene cluster tubes (Corning Inc;
product numbers 4401 and 4418).
4.2.2 Human plasma samples
Prior to elective cardiac catheterization, patients in the experimental cohort provided written
and informed consent to allow collection of ~10 mL blood by a physician after successful
arterial cannulation. Blood was transported on ice in K2EDTA vacuum tubes for plasma
isolation. This was accomplished by two-stage centrifugation at 4 ℃: 1,000 × g in the
collection tubes for 15 min followed by 14,000 × g in microcentrifuge tubes for 10 min.
Plasma was stored at −80 ℃ and thawed at 4 ℃ before use. The plasma samples sent to CHL
were stripped of any personal identifying information and assigned identifiers (name, date of
birth, and sex) generated by an online name generator and random number generator.31,32
Per the CHL protocol, samples were divided into aliquots with a minimum volume of 500 µL
and shipped overnight at 4 ℃; only 67 of the 72 samples met this volume requirement. The
Institutional Review Board at Washington University in St. Louis approved these study
protocols.
4.2.3 Bioluminescence imaging
All images were acquired with the ONYX/M imaging system with a XR/MEGA-10Z camera
(Stanford Photonics; Palo Alto, California) at 55 frames/s with no optical filter. Images
were integrated for 10 s to prevent camera saturation and compiled into 1 min exposures for
quantification with the Fiji distribution of ImageJ analysis software.33 All bioluminescence
data are presented in dimensionless intensity units and are uniformly scaled throughout to
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allow direct comparison between experiments. MAPS assay data were quantified at the 5 min
timepoint.
4.2.4 Data analysis and statistics
Bioluminescence data were quantified with the Fiji distribution of ImageJ image analysis
software.33 Images were processed to correct for optical vignetting as detailed in the Appendix
Section §7.4.2 on page 229. Regions of interest (ROIs) were created in microtiter plate arrays
using the Quadrangular ROI array program, the source code of which can be found on
page 226. Quantifications were normalized to image ROI pixel area to account for inter-
experiment differences in ROI layout. All statistical analyses were performed in IBM SPSS
Statistics 21 (Armonk, New York) unless otherwise noted.
4.2.5 WLS calibration of plasma MPO
Throughout this project, data were analyzed with a weighted least squares (WLS) regression
algorithm adapted from multiple literature reports on calibration methods.34–37 A detailed
description of the WLS calibration methods can be found in the Appendix Section §7.2 on
page 202. Briefly, the method constructs a standard curve by weighting each calibration
standard according to the inter-replicate variance and comparing first- and second-order
models on the basis of degrees of freedom and regression residuals. Assay data are usually
heteroscedastic with a positive correlation between signal and variance. When assays are
calibrated using ordinary least squares (OLS) regression,1 measurement heteroscedasticity
artificially increases the calculated uncertainty at the lower range of analyte standards.
1Often forgotten in biology literature, there is an intrinsic assumption with OLS regression that the data are
homoscedastic. Although regression coefficients are not systematically biased by violating this assumption,
estimates of dispersion such as the standard error of the mean are strongly biased. This is one of many
reasons to take p-values lightly.
135
Chapter 4: Clinical ELISA and MAPS assays Methods
WLS regressionOLS regression
Replicate Measurement
95% Confidence Interval
Single Measurement
95% Confidence Interval
OLS regression
WLS regression
OLS regression
WLS regression
Figure 4.1: Comparing OLS and WLS regression. Simulated calibration data generated to compare
uncertainty between OLS and WLS regression. Standard curves made from 7 concentrations generated in
triplicate with measurement-dependent variance were used in calibration (or inverse regression) of triplicate
(gray) or single (black) unknown samples. OLS regression assumes homoscedasticity, and thus uncertainty of
both the regression curve (gray bands) and predictions based on the curve (dashed lines) only vary slightly
with distance from the mean calibration value. WLS curves are more precise where calibration standards
have low variance, as was always observed with low MPO in both ELISA and MAPS assays. Although
single-measurement prediction bands are shown in this simulation, replicate measurements are calibrated
based on their t-distribution, thus incorporating variance of unknown samples into the overall prediction
uncertainty. For a detailed explanation of the method, see Appendix Section §7.2, page 202.
It also increases overall variance by giving disproportionately equal weight to uncertain
measurements. Alternatively, WLS regression gives more weight to measurement replicates
with low variance with the assumption that deviation from the regression model in replicates
with high variance is due to random processes. (Figure 4.1) The method used to analyze
data from both assays is automated in regression model selection, weight assignments, and
final prediction outputs to prevent any experimenter bias. For all comparisons in these
experiments, WLS regression used technical triplicates (m = 3), 95% confidence intervals
(α = 0.05), and 95% power (β = 0.05).
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4.2.6 Assay reproducibility metrics
The reproducibility of the MAPS assay was determined taking into consideration the
uncertainty in each independent replicate. In place of traditional estimates of reproducibility,
standard deviation s and coefficient of variation cv, variance-adjusted parameters variability s¨
and coefficient of variability ω were used to quantify inter-assay dispersion. These parameters
were calculated by adapting methods designed to combine variances from independent
experiments for meta-analyses.38,39 A detailed explanation of these calculations can be found
in the Appendix Section §7.3 on page 223.
4.2.7 MPO ELISA
ELISAs on clinical samples were performed with slight modification to the protocol suggested
by the manufacturer to provide data “in parallel” with MAPS. The standard curve dilution
series was matched to that used in MAPS assays: 300, 225, 161, 107, 64.3, 32.1, 10.7,
and 0 µg/L pre-dilution MPO. Plasma and MPO standard curve samples were loaded and
analyzed in triplicate. All ELISA measurements were maintained as raw absorbance values
throughout analysis. Additional ELISAs were performed by the CHL (Cleveland, OH), an
independent CLIA- and CAP-accredited laboratory with an FDA-approved MPO assay.
ELISA data from the CHL were requested as raw absorbance values and analyzed in the
same manner. No modifications were requested to their processing techniques or calibration
standards.
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4.2.8 MAPS assay protocol
Two concentrated buffer2 stocks were used to make the three3 solutions required for the
MAPS assay protocol: MAPS loading/wash buffer (PS-6.5 ), MPO dilution buffer (PS-6.5T),
and MAPS imaging solution (BLI-6 ). The components of these solutions can be found in
Table 4.1. To minimize variance, the assay was performed with as little deviation from the
protocol as possible.4
At the beginning of each assay, plasma samples and RBP were removed from −80 ℃
storage and thawed on 4 ℃ cold-blocks or on ice. All pipetted sample preparation solutions
were added to container walls with the reverse-volume method. For each sample to be
assayed, a 1.2 mL polypropylene cluster tube was filled with 500 µL PS-6.5 . A working MPO
solution was made by adding 2 µL stock 100,000 µg/L MPO to 18 µL PS-6.5T in a 200 µL
polypropylene tube and mixing on a vortex mixer (working concentration: 10,000 µg/L).
Eight additional 200 µL tubes each received PS-6.5T: 77.60 µL added to the first tube,
20 µL to each of the remaining seven. The first MPO standard was made by adding 2.40 µL
10,000 µg/L MPO to the 77.60 µL PS-6.5T tube and mixing by vortex, final concentration
300 µg/L. From this, serial dilutions of 60, 50, 40, 30, 20, 10, and 0 µL were made from the
preceding solutions into 20 µL PS-6.5T with vortex mixing at each step. This produced a
series of MPO standards with 300, 225, 161, 107, 64.3, 32.1, 10.7, and 0 µg/L MPO. 2 µL
from these standards was added to separate cluster tubes already containing 500 µL PS-6.5 .
Plasma samples were then added as 2 µL volumes to the other prepared cluster tubes, which
were sealed with polypropylene caps and mixed thoroughly5 on a vortex mixer. Finally, 2 µL
2Stock solution pHs are calculated and are not adjusted prior to use. pH adjustment introduces solutes not
tested in the assay and increases the frequency of solution contamination.
3PS-6.5 and PS-6.5T differ only by polysorbate 20 (Tween20) and shared a common concentrate.
4The protocol is described in greater detail than in standard methods sections in the anticipation that this
text will be used by others to replicate the assay in the future.
5 ensured by visually verifying that a sustained vortex formed in each tube
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RBP was added to each of the cluster tubes already containing pure MPO standard solutions,
which were then mixed in the same manner as the plasma samples. Solutions were then
loaded in triplicate 100 µL volumes to a tissue culture-treated polystyrene microtiter plate.6
Once loaded, the plate was covered and mixed for 30 min7 at 1,000 rpm on an orbital shaker.
The required volume of BLI-6 was prepared without L-012 or hydrogen peroxide (H2O2)
during the incubation step and pipettes were set with the proper volumes for rapid addition
of both reagents at the completion of the plate washes. On completion, the samples were
transferred into a bleached vacuum flask with an 8-channel aspirator with suction applied to
the rims of the well floors to remove as much liquid as possible without contacting the plastic
surface. Each well was washed twice by addition of 150 µL PS-6.5 and aspiration as before to
remove wash buffer. A third wash volume of 300 µL PS-6.5 was thoroughly aspirated from
each well. L-012 and H2O2 were added and rapidly mixed into BLI-6 before it was added
in 150 µL volumes to each well. The plate was shaken briefly up to 1,000 rpm and imaged
immediately in the ONYX/M. Data for quantification were obtained at the 5 min timepoint.
4.3 Results
4.3.1 Patient characteristics
The clinical characteristics of the patient population as they presented prior to catheterization
are shown in Table 4.2. Recruited patients had diverse demographic and clinical profiles.
As expected, average plasma MPO concentration was lower in these patients presenting
6An 8-channel repeater pipette was used to deliver the samples. Tips were pre-wet with the full 300 µL
volume and the exterior of the tips was touched to the cluster tube wall to remove any adherent liquid
before the tips contacted the well walls.
7The duration was chosen arbitrarily but used consistently and precisely. See Figure 3.6 on page 100 for the
effects of incubation duration.
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Table 4.1: MAPS assay solutions. Shorthand aliases (italics) are used throughout when discussing the
MAPS protocol. Concentrated stocks were made in newly opened plastic labware to prevent contamination.
*200 mM (NH4)2SO4 is estimated based on a saturated (NH4)2SO4 solution calculated to be 4.05 M based
on saturation data from the literature.40 †These additives are not present in concentrated stocks; they are
added immediately prior to use each assay.
Solution Additive Concentration
MPO dilution buffer Na2HPO4 6.28 mM
PS-6.5T NaH2PO4 18.7 mM
NaCl 130 mM
Tween20† 200 ppm v/v
MAPS loading/wash buffer Na2HPO4 6.28 mM
PS-6.5 NaH2PO4 18.7 mM
NaCl 130 mM
Tween20† 50 ppm v/v
MAPS imaging solution trisodium citrate 21.9 mM
BLI-6 citric acid 3.09 mM
NaBr 20 mM
(NH4)2SO4 200 mM*
L-012† 50 µM
H2O2† 100 µM
Tween20† 100 ppm v/v
for elective catheterization than literature reports on higher-risk patients, such as those
presenting with acute coronary syndrome (ACS). Indications of CVD progression were
nonetheless elevated, noticeable in the prevalence of coronary artery bypass graft (CABG)
(8), percutaneous coronary intervention (PCI) (21), and known coronary artery disease
(CAD) (36). Of note, 17 patients had received intravenous heparin prior to sampling. As
demonstrated in Chapter 3, heparin anticoagulation during phlebotomy eliminates MPO
signal in the MAPS assay (see Figure 3.7 on page 101). Despite this possibility, samples from
patients treated with heparin had detectable MAPS bioluminescence and were included in
this analysis. Another possible confounder, thiocyanate, actually inhibits bromination as
indicated by pure MPO bioluminescence. (Data not shown) Of the 72 patients, 39 reported
that they are current smokers; literature reports on plasma SCN– in active smokers indicate
an ~2-fold increase over that of non-smokers.41,42
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Table 4.2: Clinical data from plasma donors. Mean ± standard deviation are given when applicable.
Parentheses indicate absent patient data. Reported ancestry: Eur (European), Afr (African), Asn (Asian),
Hisp (Hispanic).
†: Due to limited sample volume, only 67 samples were analyzed by the CHL.
N 72†
Age / y 63 ± 14
Female:Male 35:37
Eur:Afr:Asn:Hisp 54:15:2:1
BMI / kg/m2 29 ± 7
Family CVD history 34 (6)
Current smoker 39 (1)
Hypertension 58
Diabetes mellitus 23
Known CAD 36
Prior PCI 21
Prior CABG 8
Total cholesterol / mg/dL 172 ± 48
LDL / mg/dL 98 ± 37
HDL / mg/dL 46 ± 22
Aspirin 49
β-blockers 41 (1)
Statins 39
P2Y12 inhibitors 21
Heparin 17
ELISA MPO / µg/L 20 ± 16
MAPS MPO / µg/L 14 ± 13
4.3.2 MAPS assay and ELISAs on clinical plasma samples
To determine if the MAPS assay is a suitable alternative to a clinical MPO ELISA kit,
plasma samples from the 72 patient cohort were first analyzed in triplicate with both methods.
The ELISA kit protocol was modified to be as similar to MAPS as possible, such that the
assays were considered “in parallel” in order to isolate disagreement due to the mechanistic
differences between MAPS and ELISA. The samples were also analyzed by another ELISA
performed at the CHL with no modifications to their proprietary technique. Only 67 of the
patient plasma samples had adequate volume for shipment and analysis by the CHL.
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Figure 4.2: Calibration curves for ELISA and MAPS assays. WLS calibration curves for (A) ELISA
450 nm absorbance and (B) MAPS bioluminescence used for the initial measurements of 72 clinical plasma
samples. (C) Calibration curve from the CHL ELISA used for 67 patient samples with adequate sample
volume. Each of the three curves is shown as a dashed line with triplicate 95% prediction intervals shown in
gray, darker where independent calibration curves overlap. ELISA calibration curves were consistently and
substantially concave while any deviation from linearity in MAPS curves is convex and comparably minor.
The concavity resulted in a statistically significant difference in the limits of detection between the two
parallel assays: 7.4 µg/L (95% confidence interval 6.7–8.1 µg/L) for ELISA and 6.0 µg/L (95% confidence
interval 5.3–6.6 µg/L) for MAPS (p = 0.002). Data from the CHL were provided as molar rather than mass
concentration, preventing direct comparison.
The first observable difference between the methods is in calibration curve parameters.
Both ELISA curves were moderately concave owing to the saturable nature of absorbance
measurements, perhaps additionally due to the concentrated plasma required for signal
saturating the available antibody binding sites on the plate surface. This downward concavity
was more pronounced near the upper limit of the calibration curve in the CHL data compared
to the parallel ELISA. (Figures 4.2A and 4.2C) In contrast, the MAPS assay calibration
curves were linear or marginally convex. (Figure 4.2B) This difference favors the MAPS assay,
as concavity increases the positive uncertainty of any given assay result. This advantage
manifests as a lower limit of detection for MAPS than with the parallel ELISA, 6.0 µg/L
(95% confidence interval 5.3–6.6 µg/L) and 7.4 µg/L (95% confidence interval 6.7–8.1 µg/L),
respectively (p = 0.002).
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Figure 4.3: Pearson correlations between MAPS and ELISAs performed on patient samples.
Unweighted correlations were computed from the assay estimates for each patient analyzed in triplicate.
Sample weights for weighted analysis were calculated by the inverse product of sample uncertainty from the
paired assay techniques. This uncertainty was computed by WLS regression. ELISA in this analysis refers to
the benchtop kit performed in parallel with MAPS. MAPS-ELISA correlation N = 72; both correlations with
CHL N = 67 (reduced due to limited volumes).
Although data from the CHL are not in the same unit dimensions as the MAPS and
parallel ELISA results, they can be compared with correlation. WLS regression with the two
assays resulted in highly correlated MPO estimates (Pearson r = 0.969). The CHL assay
correlated with the parallel ELISA more than with the MAPS assay (r = 0.893 and 0.860,
respectively) but it was still the outlier. Adjusting for the uncertainty in results from each
assay by weighting the each regressed value by the inverse product of the compared method’s
uncertainty did not change this trend; MAPS and the parallel ELISA correlated more with
each other than either did with the CHL ELISA. (Figure 4.3)
The assay techniques were also compared by testing for systematic differences in their
results. Across the 72-patient cohort, MAPS and the parallel ELISA were not significantly
different by paired comparison (p = 0.46). In order to determine if this lack of disagreement
was due to combined uncertainty, each patient sample was again weighted by the inverse
product of the confidence interval magnitude and tested again as paired outcomes; this
resulted in even less significance than the unweighted test (p = 0.61). (Figure 4.4A)
This comparison could not be repeated with MAPS and CHL results as the CHL data
were in molar concentration instead of mass concentration, but the data from the CHL
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Figure 4.4: Clinical plasma MPO measured by ELISAs and MAPS. (A) Regressed plasma MPO
from 72 clinical plasma samples, each measured in triplicate. Error bars represent 95% confidence intervals
constructed from combined calibration curve– and inter-replicate–uncertainty as determined by WLS regression.
The dashed line shows perfect 1:1 agreement between the two assays. Collectively, assay results were not
significantly different from this perfect agreement by either unweighted (p = 0.46) or uncertainty-weighted
(p = 0.61) regression and were strongly correlated by unweighted (r = 0.969) and weighted (r = 0.960)
analysis. (B) Similarly regressed MPO from 67 patient samples with adequate volume for analysis by the
CHL. Paired statistical comparison was limited due to the imprecision in reported MPO molecular weight
far exceeding the imprecision in regressed values. The two assays were still well correlated by unweighted
(r = 0.860) and weighted (r = 0.895) analysis.
and MAPS assays are nonetheless correlated with unweighted and weighted r = 0.860 and
0.895, respectively. (Figure 4.4B) The CHL data can be compared to the MAPS and parallel
ELISA data together, however, by estimating MPO to be 150,000 kDa for conversion to
mass-concentration. Although this approximation is too rough for direct comparison of either
parallel assay to the CHL data, the differences between CHL and both methods can be
compared directly; the correction term cancels and thus does not have a substantial effect
on the result. The disagreement between CHL and MAPS was not significantly different
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Figure 4.5: CHL disagreement with MAPS and parallel ELISA. Results from the CHL assay were
roughly converted to mass-concentration before each patient sample discrepancy was calculated for both
MAPS and the parallel ELISA. The two parallel assays agreed more with each other than either did with
CHL, as demonstrated by the dashed line representing perfect agreement. Generalized linear regression failed
to demonstrate significant difference between the disagreements of either parallel assay with the CHL results
(p = 0.20).
(p = 0.20) from the disagreement between CHL and the parallel ELISA by generalized linear
regression. (Figure 4.5)
Despite the agreement across all patient samples, not all individual plasma measurements
agreed within the 95% confidence limits of the two parallel assays. The mean difference
(ELISA – MAPS) with 95% coverage was 2.3 (−9.2 to +14) µg/L MPO. There was no
MPO-dependent statistical trend in the discrepancy. (Figure 4.6A) Uncertainty in the
MPO measurements, which incorporates variance from both the calibration curve and
individual plasma sample measurements, was also consistently distributed between the two
assays. The difference (ΔELISA – ΔMAPS) in assay uncertainty with 95% coverage was
−2.1 (−14 to +10) µg/L MPO. (Figure 4.6B)
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Figure 4.6: ELISA and MAPS assay discrepancy. (A) The difference in assay MPO measurements
(ELISA − MAPS) from the 72 clinical samples. Mean disagreement with 95% prediction limits was
2.3 (−9.2 to +14) µg/L MPO. (B) The difference in assay MPO uncertainty (95% confidence limits,
ΔELISA − ΔMAPS) from the 72 clinical samples. Mean disagreement with 95% prediction limits was −2.1
(−14 to +10) µg/L MPO. Together, these metrics show reasonable agreement between the assay methods.
4.3.3 MAPS assay reproducibility
A common and important metric of assay utility is the absolute and relative dispersion of
independent results. The MAPS assay was reproduced independently in triplicate for each of
the 72 plasma samples over three days and the absolute (x¨q) and relative (ω) variability was
quantified according to the method described in Appendix Section §7.3. Median variability
was 0.67 µg/L MPO and 95% of assays reproducible within 5.8 µg/L without considering the
MPO-dependence of replication dispersion. OLS linear regression of variability with respect
to uncertainty-weighted replicate mean resulted in a proportion 0.119 (95% confidence interval
0.106–0.131), predicting a coefficient of variability of ~10%. (Figure 4.7A) Computing the
coefficient of variability directly agreed with this prediction with a median ω = 8.6% with
95th percentile coverage by 27%. This one-tailed limit was high owing to assay results near
the limits of detection, but they were retained in the analysis so as not to subject the metrics
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Figure 4.7: MAPS assay reproducibility. (A) Replication variability s¨q from four independent MAPS
assay replicates each performed in triplicate. Median variability was 0.67 µg/L MPO with 95% of assays
reproducible within 5.8 µg/L. Deviation was proportional to measured MPO by a ratio of 0.119 (95%
confidence interval 0.106–0.131). Dashed lines are the mean linear relationship of assay MPO ± 95%
prediction interval. (B) Replication reproducibility s¨q normalized to variance-weighted mean MPO x¨q, giving
a more robust version of the coefficient of variation (ω). Median variation was 8.6% with 95% assays within
27% relative variation, represented by dashed lines. These values were strongly affected by samples near the
limits of assay detection, but these remained in the analysis dataset to prevent experimenter bias.
to researcher bias. (Figure 4.7B) These numbers cannot be compared to ELISA as this was
prohibited by cost. The irony of this did not go unnoticed.
4.4 Discussion
MPO is a potentially useful CVD risk stratification biomarker and a prognostic indicator
for patients presenting with major adverse cardiovascular events (MACEs). This study
shows that human plasma MPO can be assayed by a new method, the MAPS assay, as an
alternative to the costly and time-intensive ELISAs used in the clinical setting today. One
of the potential advantages of a point-of-care MPO assay is its predictive value over short
timespans, especially when utilizing serial measurements.23 The MAPS assay described herein
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improves greatly upon ELISA in terms of cost and required person-hours in addition to its
greatly reduced complexity and plasma sample volume requirement.
The means of measurement in the MAPS assay fundamentally differs from that of ELISA,
which relies on immunoconjugated horseradish peroxidase (HRP) to measure the mass
concentration of MPO bound to adsorbed immunoglobulins. The MAPS assay instead
measures MPO activity through its halogenation-dependent bioluminescence of L-012 (see
Section §2.3.3, page 53). Each mechanism has potential disadvantages. The MAPS assay
assumes enzyme activity equivalence between plasma MPO and the purified MPO added to
RBP for the standard solutions. Hypomorphic MPO due to a genetic polymorphism could
result in underestimated MPO concentration. ELISA is subject to a similar problem, but
with antigenic variation leading to underestimated assay results. Additionally, ELISA can
also be affected by sample MPO as a result of what could be considered a critical assay
design flaw: MPO and HRP can both catalyze the reaction responsible for the change in
450 nm absorbance. Thus ELISA ΔAbs450 is not a linear function of MPO concentration; it
is an integration of MPO activity, HRP activity, and the combined affinity of two different
antibodies for sample MPO. This study did not identify any patients with highly discrepant
MPO results from the two assays. Given the estimated 0.05–0.15% rate of hypomorphic
MPO, large-scale clinical trials with the MAPS assay should include either genetic screening
for MPO deficiency or a whole-blood bioluminescence assay (see Section §2.3.1, page 48).43–45
ELISA is a well-validated and accepted method of protein quantification in both basic
science research and clinical laboratories responsible for guiding patient care. From this, it
is reasonable to consider any disagreement between equally validated ELISAs to be within
acceptable limits. Although the technique is considered to be reproducible, many sources
of error still affect ELISA results beyond the expected random variation. Systematic error
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can emerge from extrinsic sources such as operator technique, handling samples, and bias
introduced by the measuring instruments. Error may also come from intrinsic sources; these
include epitope frequency, differing antibody affinity, and chemical interactions between the
analyte and different assay components. The parallel ELISA was designed to minimize the
procedural systematic error between it and MAPS in order to isolate disagreement resulting
from the fundamental, mechanistic differences between the two assays, namely measuring
adsorbed MPO activity versus immunologically bound MPO concentration. Surprisingly,
the parallel assays agreed far more than the two ELISAs did, even though both ELISAs are
FDA-approved and suitable as gold standards of MPO concentration. This strongly supports
the further development of MAPS as an alternative to MPO ELISA in the clinical setting.
Although similar to ELISA in terms of sensitivity and reproducibility, the MAPS assay
has many practical advantages that make it a desirable alternative. Most obvious is the
difference in cost: ELISA has numerous biological components that drive raw material costs
to > $20 per patient sample run in triplicate. Conversely, the most costly consumable in the
MAPS assay is the plastic used to isolate MPO; reagents consumed in a 24-patient assay run
in triplicate add no significant cost in comparison; a patient sample can be run in triplicate
against 24 standard concentration samples for ~30¢. The lack of biologic reagents is another
advantage belonging to the MAPS assay—ELISA kits require 4 ℃ storage and thus have a
very limited shelf-life, while MPO and RBP can be stored for years at −80 ℃, and no loss
in L-012 stock activity was observed over the >3 years of storage at −20 ℃ some aliquots
endured during the assay development. Additionally, ELISA requires numerous manipulations
spanning many hours; the MAPS assay required only one incubation for which 30 min was
chosen arbitrarily for consistency despite evidence that 15 min was more than sufficient (see
Figure 3.6 on page 100). MAPS also demonstrated increased linearity and sensitivity than
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ELISA, in part because luminescence is less saturable than absorbance. (Figure 4.2) Higher
sensitivity also allows MAPS to be measured from plasma diluted to 0.4% v/v compared to
4% v/v required by standard ELISA, further extending the dynamic range in addition to
requiring far less sample material.
Like any assay method, MAPS is not without its disadvantages, both intrinsic and
circumstantial. As of the time of this writing, the plasma proteins required for MPO
adsorption onto polystyrene are unknown (see Figure 3.11 on page 105). The effect of
intravenous heparin, which is common among the patient population with the most to gain
from this assay, is also not known. The pilot clinical study did not detect a statistical
difference in the ELISA−MAPS discrepancy when comparing the heparin-treated patients
to the untreated group, but his trial was neither powered nor designed to detect such a
difference. This pilot study demonstrates the fundamental feasibility of the MAPS assay in a
clinical setting, but further analysis of outcome predictive value for CVD in the same manner
as MPO ELISA is required.
Although the advanced ONYX/M imaging system was used throughout the development
of this assay, MAPS can be measured with common laboratory equipment. A feasibility
test using a low-sensitivity camera intended to image gel electrophoresis bands was able to
resolve the standard curve on a plate set up in parallel with one of the clinical sample blocks.
Two microtiter plate luminometers in addition to a single-channel, test tube luminometer
also had adequate sensitivity to discriminate MPO luminescence at all levels of the MAPS
standard curve. (Data not shown) This establishes the feasibility of further studies in a wide
range of clinical settings. The microtiter plate platform served as a convenient and reliable
source of hydrophilic polystyrene, but the MAPS assay is amenable to other platforms as
well. For example, treated polystyrene in the form of a dipstick could increase the portability
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of the MAPS assay to that of blood glucose meters. The work described here focuses on
the application to CVD diagnosis and prognosis, but there are other clinical scenarios (e.g.,
transplant rejection or sepsis) for which a rapid MPO measurement via the MAPS assay could
reduce the time between onset and treatment of potentially life-threatening complications.46,47
In conclusion, a facile MPO activity assay was developed for application with clinical
plasma samples as an alternative to ELISA. The MAPS assay has many practical advantages
including a > 10-fold reduction in cost, sample material consumption, and labor requirement.
Importantly, the MAPS assay was comparable to ELISA in results, uncertainty, and
reproducibility in a test with 72 cardiac catheterization patient samples.
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Chapter 5
Conclusions and Future Directions
5.1 New strategies in CVD management
Atherosclerosis, the disease process behind most cardiovascular disease (CVD), has a larger
burden of morbidity, mortality, and health-related economic costs than any other single
pathology. With the exception of the 1918 influenza pandemic, this has held true in the
United States for the entirety of the last century.1 As sanitation and infectious disease
prevention improve in developing nations, CVD predictably rises in public health statistics
to take the same position.2,3 Through the long history of CVD research, the disease and the
atherosclerosis driving it went from being considered a normal part of human physiology, then
to a disorder of lipid intake and metabolism, and finally to a systemic inflammatory condition
resulting from complex interactions between coagulation, metabolism, hemodynamics, and
the immune system.4–9 Although large atheromas in the coronary arteries can impede blood
flow and gradually lead to hypoxia on exertion, the true danger of CVD is the collection of
sequelae known as MACEs. MACEs are usually considered to comprise stroke, MI, and ACS;
these are results of degradation at the fibrous cap normally covering atheromatous plaques.
Without the anti-thrombotic surface maintained by endothelial cells, the coagulation cascade
is activated at the inflamed arterial wall. As the thrombus grows, it can completely occlude
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the artery or release thromboemboli that are trapped in the arterial tree as luminal diameter
decreases with each subsequent branching. As an unfortunate legacy of our evolutionary
heritage, both the human heart and brain are poorly supported by redundant vasculature and
anastomoses despite the importance and metabolic demand of each organ. CVD can progress
without symptoms for decades until if manifests as a MACE; this has led to increased efforts
to develop methods of identifying vulnerable plaques and patients statistically inclined to
develop disseminated vascular inflammation so that primary and secondary intervention can
slow or halt CVD progression rather than tertiary intervention dominating CVD treatment
costs as is true today.10,11 Biomarkers for many facets of CVD are being developed, including
myocardial strain, hypercoagulability, lipid dysregulation, and inflammation.12–15
5.2 Elevated plasma MPO: cause or consequence?
In the preceding chapters, MPO has been discussed as both a novel biomarker for CVD
progression and a possible contributor to the molecular processes behind atheromatous plaque
initiation, development, and rupture. Although most published studies show that MPO
measured by ELISA is a useful biomarker even after adjusting for established measures of
CVD risk, studies failing to demonstrate such utility are also in the literature, albeit in smaller
numbers.16–30 This contradiction appears to have origins beyond typical publication biases. As
pointed out by others, neutrophils are the primary source of plasma MPO and are exquisitely
sensitive to activating stimuli. Study methodologies rarely take this into consideration; there
is no standard protocol designed to control for the effects of anticoagulants, sample handling,
or external reference standardization.31–35 At the core of this issue is the scarcity of well-
powered, well-designed studies of MPO biomarker utility. This is somewhat understandable,
given the high cost of measuring MPO with current, ELISA-based techniques. The work
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described in these chapters was intended to be a step toward a solution to this problem. The
MAPS assay allows for independent studies on the predictive and prognostic value of MPO
activity to be performed by investigators without large, high-profile funding sources. If the
results of such studies are favorable, the same economic advantages of the MAPS assay over
ELISA in the research setting will apply equally well to the point-of-care, as the population
most afflicted by CVD is also the population least able to afford expensive diagnostic tests.
Although not the focus of the work described herein, the causative role MPO may play in
CVD pathophysiology can also be investigated by adapting these methods. Animal studies
attempting to deduce this role have thus far been conflicting.36,37 Human studies into the
role of MPO-dependent oxidation in atherosclerosis are even fewer than the biomarkers
studies. The MAPS assay and whole-blood L-012 bioluminescence offer powerful new tools in
investigating the potential oxidative MPO burden in human and animal models. Examples
of specific use include rapidly identifying MPO+/− and MPO−/− individuals for prospective
clinical studies, determining the neutrophil priming effects of stimuli such as smoking or
poorly regulated diabetes, and directly imaging atherosclerosis in experimental animal models
with L-012.
5.3 Further MAPS assay development
As discussed in Chapter 3, there are remaining questions involving the MAPS assay and the
molecular interactions that allow it to be performed. One of the foremost is the interaction or
combination of interactions required for MPO adsorption to tissue culture-treated polystyrene.
The range of pH that allows this interaction is narrow, indicating a degree of specificity behind
it. (see Figure 3.13 on page 109) Although few proteins were tested individually and with no
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success, (see Figure 3.11 on page 105) there might be a single protein or specific mixture that
allows adsorption with equal affinity to that seen from RBP or human plasma, but with fewer
unknown parameters to potentially confound the assay result. The mechanism of the robust
bioluminescence enhancing effect seen with concentrated (NH4)2SO4 added to adsorbed MPO
is also unknown and presents another area of future research. (see Figure 3.15 on page 114)
This could not only have implications in further development of the MAPS assay, but may
also provide new insight into the biochemistry of MPO and related oxidoreductase enzymes.
Although this work, specifically that in Chapter 4, describes a pilot clinical study
comparing the MAPS assay to ELISA measurements, there has yet to be an investigation
into the independent predictive value of plasma MPO bioluminescence for CVD outcomes.
Even if MAPS proves only as predictive as literature reports of plasma MPO concentration
measured by ELISA, the aforementioned economic advantages would be sufficient to give
MAPS utility beyond that of immunologic techniques. Additionally, there is potential for
MPO activity to be an improved prognostic indicator compared to MPO concentration,
especially considering the possible causative role the ROS produced by MPO may play in
atherogenesis. Investigations into new platforms, such as portable dipsticks or disposable
biosensors, further open the concept behind the MAPS assay to a diverse range of research
possibilities. To further encourage development of the MAPS assay and investigation into its
utility in other clinical applications, the work described here was published in an open access
journal.38
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List of chemical and reagent aliases
4-ABH 4-aminobenzoic hydrazide
AcDPBS pH = 6.0 DPBS with 5 mM acetic acid, pH adjusted with NaOH
B(OH)3 Boric acid
CAPS 3-(cyclohexylamino)-1-propanesulfonic acid
DMSO Dimethyl sulfoxide
DPBS Dulbecco’s phosphate buffered saline
EDTA Ethylenediaminetetraacetic acid
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
BLI-6 MAPS imaging solution, see Table 4.1
isoflurane 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
L-012 8-amino-5-chloro-7-phenyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione
luminol 5-amino-2,3-dihydrophthalazine-1,4-dione
MEBSS Modified Earle’s balanced salt solution
PMA Phorbol-12-myristate-13-acetate
PS-6.5 MAPS loading/wash buffer, see Table 4.1
PS-6.5T MPO dilution buffer, see Table 4.1
PVDF Polyvinylidene fluoride
O2–· Superoxide
Tris 2-amino-2-(hydroxymethyl)propane-1,3-diol
Tween20 Polysorbate 20, polyoxyethylene (20) sorbitan monolaurate
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Chapter 6
Pathway analysis of clinical genomic
sequencing data
6.1 Contribution to authorship
I participated in a multi-group collaboration to analyze full genomic, expression, and clinical
outcome data from a cohort of patients undergoing aromatase inhibition therapy as a treatment
for breast cancer. My specific contribution involved the annotation and analysis of gene
networks disproportionately affected by de novo mutations found in solid tumor biopsies
compared against a matched, normal skin genome. Over the course of the project, the primary
contributing authors met many times every month to discuss progress, complications, and
new developments in the ongoing data analyses, patient recruitment, and conclusions of the
project. I contributed to the manuscript by writing the main-text section on gene network
analysis, the corresponding methods and discussion found in the online supplement, compiling
and statistically analyzing a myriad annotated network maps overrepresented in the mutation
dataset, and producing two figures. (Figure 6.4B and Supplementary Figure 6.6)
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The full text of the manuscript is reproduced below, edited only for consistency in figure
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publication.2
6.2 Published manuscript
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A.,
Hoog, J., Goiffon, R. J., Goldstein, T. C., Ng, S., Lin, L., Crowder, R., Snider, J., Ballman, K.,
Weber, J., Chen, K., Koboldt, D. C., Kandoth, C., Schierding, W. S., McMichael, J. F.,
Miller, C. A., Lu, C., Harris, C. C., McLellan, M. D., Wendl, M. C., DeSchryver, K.,
Allred, D. C., Esserman, L., Unzeitig, G., Margenthaler, J., Babiera, G. V., Marcom, P. K.,
Guenther, J. M., Leitch, M., Hunt, K., Olson, J., Tao, Y., Maher, C. a., Fulton, L. L.,
Fulton, R. S., Harrison, M., Oberkfell, B., Du, F., Demeter, R., Vickery, T. L., Elhammali, A.,
Piwnica-Worms, H., McDonald, S., Watson, M., Dooling, D. J., Ota, D., Chang, L.-W.,
Bose, R., Ley, T. J., Piwnica-Worms, D., Stuart, J. M., Wilson, R. K. & Mardis, E. R.
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486,
353–60 (June 2012)
1This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported
License. A full citation of the original work is provided in this non-commercial reproduction, thus satisfying
the conditions of the license. For a summary of terms, see http://creativecommons.org/licenses/
by-nc-sa/3.0/. The complete legal definition of this license can be found at http://creativecommons.
org/licenses/by-nc-sa/3.0/legalcode.
2Supplemental material can be found at http://www.nature.com/nature/journal/v486/n7403/extref/
nature11143-s1.pdf
[169]
Published manuscript
6.2.1 Abstract
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in
two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing
and analysis. Eighteen significantly mutated genes (SMGs) were identified, including five
genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1 ) previously linked to haematopoietic
disorders. Mutant MAP3K1 was associated with luminal A status, low-grade histology and
low proliferation rates, whereas mutant TP53 was associated with the opposite pattern.
Moreover, mutant GATA3 correlated with suppression of proliferation upon aromatase
inhibitor treatment. Pathway analysis demonstrated that mutations in MAP2K4, a MAP3K1
substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in oestrogen-
receptor-positive breast cancer are associated with specific patterns of somatic mutations
that map into cellular pathways linked to tumour biology, but most recurrent mutations
are relatively infrequent. Prospective clinical trials based on these findings will require
comprehensive genome sequencing.
6.2.2 Introduction
Oestrogen-receptor-positive breast cancer exhibits highly variable prognosis, histological
growth patterns and treatment outcomes. Neoadjuvant aromatase inhibitor treatment trials
provide an opportunity to document oestrogen-receptor-positive breast cancer phenotypes
in a setting where sample acquisition is easy, prospective consent for genomic analysis
can be obtained and responsiveness to oestrogen deprivation therapy is documented.1 We
therefore conducted massively parallel sequencing (MPS) on 77 samples accrued from two
neoadjuvant aromatase inhibitor clinical trials.2,3 Forty-six cases underwent whole-genome
[170]
Published manuscript
sequencing (WGS) and 31 cases underwent exome sequencing, followed by extensive analysis
for somatic alterations and their association with aromatase inhibitor response. Case selection
for discovery was based on the levels of the tumour proliferation marker Ki67 in the surgical
specimen, because high cellular proliferation despite aromatase inhibitor treatment identifies
poor prognosis tumours exhibiting oestrogen-independent growth4 (Supplementary Figure 1)
Twenty-nine samples had Ki67 levels above 10% (‘aromatase-inhibitor-resistant tumours’,
median Ki67 21%, range 10.3–80%) and 48 were at or below 10% (‘aromatase-inhibitor-
sensitive tumours’, median Ki67 1.2%, range 0–8%). Cases were also classified as luminal
A or B by gene expression profiling.3 We subsequently examined interactions between Ki67
biomarker change, histological categories, intrinsic subtype and mutation status in selected
recurrently mutated genes in 310 cases overall. Pathway analysis was applied to contrast the
signalling perturbations in aromatase-inhibitor-sensitive versus aromatase-inhibitor-resistant
tumours.
6.2.3 Results
The mutation landscape of luminal-type breast cancer
Using paired-end MPS, 46 tumour and normal genomes were sequenced to at least 30-
fold and 25-fold haploid coverage, respectively, with diploid coverage of at least 95%
based on concordance with SNP array data (Supplementary Table 1). Candidate somatic
events were identified using multiple algorithms,5,6 and were then verified by hybridization
capture-based validation that targeted all putative somatic single nucleotide variants (SNVs)
and small insertions/deletions (indels) that overlap coding exons, splice sites and RNA
genes (tier 1), high-confidence SNVs and indels in non-coding conserved or regulatory
regions (tier 2), as well as non-repetitive regions of the human genome (tier 3). In
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addition, somatic structural variants and germline structural variants that potentially affect
coding sequences (Supplementary Information) were assessed. Digital sequencing data
from captured target DNAs from the 46 tumour and normal pairs (Supplementary Table 2
and Supplementary Information) confirmed 81,858 mutations (point mutations and indels)
and 773 somatic structural variants. The average numbers of somatic mutations and
structural variants were 1,780 (range 44–11,619) and 16.8 (range 0–178) per case, respectively
(Supplementary Table 3). Tier 1 point mutations and small indels predicted for all 46 cases
also were validated using both 454 and Illumina sequencing (Supplementary Information).
BRC25 was a clear outlier with only 44 validated tiers 1-3 mutations, all at low allele
frequencies (ranging from 5% to 26.8%). This sample probably had low tumour content
despite histopathology assessment, but the data are included to avoid bias.
The overall mutation rate was 1.18 validated mutations per megabase (Mb) (tier 1:
1.05; tier 2: 1.14; tier 3: 1.20). The mutation rate for tier 1 was higher than that
observed for acute myeloid leukaemia (0.18–0.23),6,7 but lower than that reported for
hepatocellular carcinoma (1.85),8 malignant melanoma (6.65)9 and lung cancers (3.05–
8.93).10,11 (Supplementary Table 4) The background mutation rate across the 21 aromatase-
inhibitor-resistant tumours was 1.62 per Mb, nearly twice that of the 25 aromatase-inhibitor-
sensitive tumours at 0.824 per Mb (P = 0.02, one-sided t-test). A trend for more somatic
structural variations in the aromatase-inhibitor-resistant group was also observed, as the
validated somatic structural variation frequency in the 21 aromatase-inhibitor-resistant
tumour genomes was 21.69 versus an average of 12.76 in 25 aromatase-inhibitor-sensitive
tumours (P = 0.16, one-sided t-test). (Figure 6.1) If ten TP53 mutated cases were excluded,
the background mutation rate still tended to be higher in the aromatase-inhibitor-resistant
group (P = 0.08). To demonstrate that a single-tumour core biopsy produced representative
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Figure 6.1: Genome-wide somatic mutations. Circos plots12 indicate validated somatic mutations
comprising tier 1 point mutations and indels, genome-wide copy number alterations, and structural
rearrangements in six representative genomes. Three on-treatment Ki67 less than or at 10% (top panel:
BRC15, BRC17 and BRC22) and three on-treatment Ki67 greater than 10% (bottom panel: BRC44, BRC47
and BRC50) cases are shown. Significantly mutated genes are highlighted in red. No purity-based copy
number corrections were used for plotting copy number.
genomic data, whole-genome sequencing of two pre-treatment biopsies was conducted for 5 of
the 46 cases. The frequency of mutations in the paired specimens showed high concordance
in all cases (correlation coefficiency ranged from 0.74 to 0.95) and a somatic mutation was
infrequently detected in only one of the two samples (4.65% overall). (Supplementary Figure 2)
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Significantly mutated genes in luminal breast cancer
The discovery effort was extended by studying 31 additional cases by exome sequencing,
producing an additional 1,371 tier 1 mutations. In total the 77 cases yielded 3,355 tier 1
somatic mutations, including 3,208 point mutations, 1 dinucleotide mutation and 146 indels,
ranging from 1 to 28 nucleotides. Of 2,145 missense mutations, 1,551 were predicted to be
deleterious by SIFT and/or PolyPhen.13,14 The MuSiC package was applied to determine the
significance of the difference between observed versus expected mutation events in each gene,
on the basis of the background mutation rate.15 This identified 18 SMGs with a convolution
false discovery rate (FDR) < 0.26. (Table 6.1 and Supplementary Table 6) The list contains
genes previously identified as mutated in breast cancer (PIK3CA, TP53, GATA3, CDH1, RB1,
MLL3, MAP3K1 and CDKN1B) as well as genes not previously observed in clinical breast
cancer samples, including TBX3, RUNX1, LDLRAP1, STNM2, MYH9, AGTR2, STMN2,
SF3B1, and CBFB.13,14,16–21
Thirteen mutations (3 nonsense, 6 frame-shift indels, 2 in-frame deletions and 2 missense)
were identified in MAP3K1, a serine/threonine kinase that activates the ERK and JNK
kinase pathways through phosphorylation of MAP2K1 and MAP2K4.22 (Table 6.1 and
Figure 6.2) Of interest, a missense (S184L) and a splice-region mutation (e2+3 probably
affecting splicing) in MAP2K4 were observed in two tumours with no MAP3K1 mutation.
(Figure 6.2) Single nonsynonymous mutations in MAP3K12, MAP3K4, MAP4K3, MAP4K4,
MAPK15, and MAPK3 were also detected. (Supplementary Table 5) TBX3 harboured three
small indels (one insertion and two deletions). TBX3 affects expansion of breast cancer
stem-like cells through regulation of FGFR.23 Two truncating mutations in the tumour
suppressor CDKN1B were identified.21 Four missense RUNX1 mutations were observed, with
three in the RUNT domain clustered within the 8 amino acid putative ATP-binding site
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(R166Q, G168E and R169K). RUNX1 is a transcription factor affected by mutation and
translocation in the M2 subtype of acute myeloid leukaemia and is implicated in tethering
the oestrogen receptor to promoters independently of oestrogen response elements.24,25 Two
mutations (N104S and N140*) were also identified in CBFB, the binding partner of RUNX1.
Additional mutations included 3 missense (2 K700E and 1 K666Q), in SF3B1, a splicing
factor implicated in myelodysplasia and chronic lymphocytic leukaemia.26,27 One missense
mutation, one nonsense mutation and two indels were found in the MYH9 gene, involved in
hereditary macrothrombocytopenia as well as being observed in an ALK translocation in
anaplastic large cell lymphoma.28,29
We also identified three SMGs (LDLRAP1, AGTR2, and STMN2 ) not previously
implicated in cancer. A missense and a nonsense mutation were observed in LDLRAP1,
a gene associated with familial hypercholesterolaemia.30 AGTR2, angiotensin II receptor
type 2, harboured two missense mutations (V184I and R251H). Angiotensin signalling and
oestrogen receptor intersect in models of tissue fibrosis.31 STMN2, a gene activated by JNK
family kinases and therefore regulated by MAP3K1 and MAP2K4, harboured one frameshift
deletion and one missense mutation.32,33 Three deletions and one point mutation were
identified in a large, infrequently spliced non-coding (lnc) RNA gene, MALAT1 (metastasis
associated lung adenocarcinoma transcript 1), that regulates alternative splicing by modulating
the phosphorylation of SR splicing factor.34 (Supplementary Figure 3) Translocations
and point mutations of MALAT1 have been reported in sarcoma and colorectal cancer
cell lines.35,36 Five additional MALAT1 mutations were found in the recurrent screening
set. (Supplementary Table 5d) The locations of these mutations clustered in a region
of species homology (F1 and 2 domains) that could mediate interactions with SRSF1.34
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Table 6.1: Significantly mutated genes identified in 46 whole genomes and 31 exomes sequenced
in luminal breast cancer patients.
Gene Total MS NS Indel SS P value FDR
MAP3K1 13 2 3 8 – 0 0
PIK3CA 45 44 – 1 – 0 0
TP53 18 13 1 1 1 0 0
GATA3 8 1 – 4 3 1.15 × 10−19 7.41 × 10−16
CDH1 8 1 1 5 1 3.07 × 10−15 1.59 × 10−11
TBX3 3 – – 3 – 2.58 × 10−6 0.011
ATR 6 6 – – – 3.73 × 10−6 0.014
RUNX1 4 4 – – – 6.59 × 10−6 0.021
ENSG00000212670* 2 2 – – – 2.31 × 10−5 0.066
RB1 4 2 1 – 1 2.76 × 10−5 0.071
LDLRAP1 2 1 1 – – 4.27 × 10−5 0.092
STMN2 2 1 – 1 – 4.15 × 10−5 0.092
MYH9 4 1 1 2 – 8.96 × 10−5 0.178
MLL3 5 1 1 3 – 1.04 × 10−4 0.191
CDKN1B 2 – 1 1 – 1.39 × 10−4 0.24
AGTR2 2 2 – – – 1.71 × 10−4 0.256
SF3B1 3 3 – – – 1.79 × 10−4 0.256
CBFB 2 1 1 – – 1.70 × 10−4 0.256
* ENSG00000212670 is not in RefSeq release 50.
MS, Missense; NS, nonsense; SS, splice site.
(Supplementary Figure 4) Non-coding mutation clusters were found in ATR, GPR126 and
NRG3. (Supplementary Information and Supplementary Table 7)
Correlating mutations with clinical data
To study clinical correlations, mutation recurrence screening was conducted on an additional
240 cases. (Supplementary Table 8 and Supplementary Figure 1) By combining WGS, exome
and recurrence screening data, we determined the mutation frequency in PIK3CA to be
41.3% (131 of 317 tumours). (Supplementary Table 5a–d and Supplementary Figure 3)
TP53 was mutated in 51 of 317 tumours (16.1%). (Supplementary Table 5a–d and
Supplementary Figure 3) Additionally, 52 nonsynonymous MAP3K1 mutations in 39 tumours
and 10 mutations in its substrate MAP2K4 were observed, representing a combined case
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Figure 6.2: MAP3K1 and MAP2K4 mutations observed in 317 samples. Somatic status of all
mutations was obtained by Sanger sequencing of PCR products or Illumina sequencing of targeted capture
products. The locations of conserved protein domains are highlighted. Each nonsynonymous substitution,
splice site mutation or indel is designated with a circle at the representative protein position with colour to
indicate translation effects of the mutation. Asterisk, nonsense mutations that cause truncation of the open
reading frame.
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frequency of 15.5%. (Supplementary Table 5a-d and Figure 6.3) Of note, 52 of the 62 non-silent
mutations in MAP3K1 and MAP2K4 were scattered indels or other protein-truncating events
strongly suggesting functional inactivation. In addition, 13 tumours harboured two non-silent
MAP3K1 mutations, indicative of bi-allelic loss and reinforcing the conclusion that this gene
is a tumour suppressor. Twenty nine tumours harboured a total of 30 mutations in GATA3,
consisting of 25 truncation events, one in-frame insertion, and 4 missense mutations including
3 recurrent mutations at M294K. (Supplementary Table 5a-d and Supplementary Figure 3)
BRC8 harboured a chromosome 10 deletion that includes GATA3. CDH1 mutation data
were available for 169 samples and, as expected, its mutation status was strongly associated
with lobular breast cancer.14 (Table 6.2A) We applied a permutation-based approach in
MuSiC to ascertain relationships between mutated genes.15 Negative correlations were found
between mutations in gene pairs such as GATA3 and PIK3CA (P = 0.0026), CDH1 and
GATA3 (P = 0.015), and CDH1 and TP53 (P = 0.022). MAP3K1 and MAP2K4 mutations
were mutually exclusive, albeit without reaching statistical significance (P = 0.3). In
contrast, a positive correlation between MAP3K1/MAP2K4 and PIK3CA mutations was
highly significant (P = 0.0002). (Supplementary Table 9)
Two independent mutation data sets, designated ‘Set 1’ (discovery cohort) and ‘Set 2’
(validation cohort), from these clinical trial samples were analysed separately and then in
combination, with a FDR-corrected P value to gauge the overall strength and consistency of
genotype-phenotype relationships. (Table 6.2A, Table 6.2B, and Supplementary Figure 1)
TP53 mutations in both data sets correlated with significantly higher Ki67 levels, both at
baseline (P = 0.0003) and at surgery (P = 0.001). Furthermore, TP53 mutations were
significantly enriched in luminal B tumours (P = 0.04) and in higher histological grade
tumours (P = 0.02). In contrast, MAP3K1 mutations were more frequent in luminal A
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Figure 6.3: Structural variants in significantly mutated or frequently deleted genes. One
MAP3K1 deletion in BRC49 and one MAP2K4 deletion in BRC47, and one ELP3 -NRG1 fusion in BRC49
identified using Illumina paired-end reads from whole-genome sequence data. Arcs represent multiple
breakpoint-spanning read pairs with sequence coverage depth plotted in black across the region. Chr,
chromosome.
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Table 6.2A: Correlations between mutations and clinical features—Luminal subtype and
histology grade.
*Mutation percentage (mutant cases/total cases in a category), counts are based on all cases (Set 1 and Set 2
combined).
†Unadjusted P value from Fisher’s exact test or Chi-square test as appropriate.
‡Benjamini-Hochberg FDR-adjusted P value using all cases (Set 1 and Set 2 combined).
§Only 77 cases in Set 1 had CDH1 sequencing results.
Gene Expression/histopathology Mutation frequency* Set 1 P* Set 2 P† Whole set FDR P‡
TP53 Luminal subtype A 9.3% (13/140) 0.001 0.46 0.041
Luminal subtype B 21.5% (38/177)
TP53 Histological grade I 4.5% (3/66) 0.05 0.067 0.02
Histological grade II/III 19.2% (48/250)
MAP3K1 Luminal subtype A 20.0% (28/140) 0.018 0.028 0.005
Luminal subtype B 6.2% (11/177)
MAP3K1 Histological grade I 25.8% (17/66) 0.061 0.011 0.005
Histological grade II/III 8.8% (22/250)
CDH1 Histological type ductal 5.9% (10/169) 0.411§ 2.8 × 10−11 3.9 × 10−10
Histological type lobular 50.0% (20/40)
Table 6.2B: Correlations between mutations and clinical features—Mutation and Ki67 index.
*Geometric means are based on all cases (Set 1 and Set 2 combined).
†Unadjusted P value from Wilcoxon rank sum test.
‡Benjamini-Hochberg FDR-adjusted P value using all cases (Set 1 and Set 2 combined).
Gene Ki67 variable Wild type mean* Mutant mean* Set 1 P† Set 2 P† Whole set FDR P‡
TP53 Baseline 13.1 25.1 3.7 × 10−5 0.012 0.0003
Surgery 1.4 4 0.0002 0.014 0.001
% change −89.2 −84.3 0.09 0.28 0.24
MAP3K1 Baseline 15.8 8.1 0.049 0.001 0.002
Surgery 1.86 0.75 0.11 0.1 0.05
% change −88.3 −90.5 0.49 0.65 0.55
GATA3 Baseline 14.8 11.5 0.13 0.95 0.56
Surgery 1.95 0.38 0.001 0.23 0.012
% change −86.8 −96.9 0.003 0.08 0.012
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tumours (P = 0.02), in grade 1 tumours (P = 0.005) and in tumours with lower Ki67 at
baseline (P = 0.001) with consistent findings across both data sets. GATA3 mutation did not
influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage Ki67
decline (P = 0.01). This finding requires further verification because it was significant in
Set 1 (uncorrected P value 0.003) but was a marginal finding in Set 2 (P = 0.08). However,
it suggests GATA3 mutation may be a positive predictive marker for aromatase inhibitor
response.
Structural variation and DNA repair mechanisms
Analysis of copy number alterations (CNAs) revealed arm-level gains for 1q, 5p, 8q, 16p,
17q, 20p and 20q and arm-level losses for 1p, 8p, 16q, and 17p in the 46 WGS tumour
genomes. (Supplementary Figure 5) A total of 773 structural variants (579 deletions, 189
translocations and 5 inversions) identified by WGS were validated as somatic in 46 breast
cancer genomes by capture validation. No recurrent translocations were detected but six
in-frame fusion genes were validated by reverse transcription followed by PCR (Supplementary
Information and Supplementary Tables 10–13). Seven tumours had multiple complex
translocations with breakpoints suggestive of a catastrophic mitotic event (‘chromothripsis’).
(Supplementary Table 11) Analysis of the structural variant genomic breakpoints shows the
spectra of putative chromothripsis-related events are the same as seen for other somatic events,
with the majority of structural variants arising from non-homologous end-joining. We classified
somatic (mitotic) and germline (meiotic) structural variants into four groups: variable number
tandem repeat, non-allelic homologous recombination, microhomology-mediated end joining,
and non-homologous end joining (NHEJ), according to criteria described in Supplementary
Information. The fraction of each classification is shown for germline and somatic (mitotic)
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events. (Supplementary Table 14) There were significantly more somatic NHEJ events in
tumour genomes than the other three types (P < 2.2 × 10−16).
Pathways relevant to aromatase inhibitor response
Pathscan analysis (Supplementary Table 15 and Supplementary Information) indicated that
somatic mutations detected in the 77 discovery cases affect a number of pathways, including
caspase cascade/apoptosis, ErbB signalling, Akt/PI3K/mTOR signalling, TP53/RB signalling
and MAPK/JNK pathways.37 (Figure 6.4A) To discern the pathways relevant to aromatase
inhibitor sensitivity, we conducted separate pathway analyses for aromatase-inhibitor-sensitive
versus aromatase-inhibitor-resistant tumours. Whereas the majority of top altered pathways
(FDR ≤ 0.15) in each group are shared, several pathways were enriched in the aromatase-
inhibitor-resistant group, including the TP53 signalling pathway, DNA replication, and
mismatch repair. Specifically, 38% of the aromatase-inhibitor-resistant group (11 of 29
tumours) have mutations in the TP53 pathway with three having double or triple hits
involving TP53, ATR, APAF1, or THBS1. In contrast, only 16.6% (8 of 48 tumours) of the
Ki67 low group had mutations in the TP53 signalling pathway, each with only a single hit in
genes TP53, ATR, CCNE2, or IGF1. (Supplementary Table 16)
GeneGo pathway analysis of MetaCore interacting network objects was used to identify
genes in the 77 luminal breast cancers with low-frequency mutations that cluster into pathway
maps. Eight networks assembled from significant maps encompassed mutations from 71
(92%) of the tumours. (Figure 6.4B) Many of the network objects shared pathways with
SMGs such as TP53, MAP3K1, PIK3CA, and CDH1. GeneGo analysis also revealed that
several genes with low-frequency mutations were actually subunits of complexes, resulting in
higher mutation rates for that object, for example, the condensin complex (4 mutations in 4
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genes) and the MRN complex (4 mutations in 3 genes). Several pathways without multiple
SMGs, such as the apoptotic cascade, calcium/phospholipase signalling and G-protein-coupled
receptors, were significantly affected by low-frequency mutations. Grouping tumours by
SMGs and pathway mutation status showed that whereas 55 (71%) of the tumours contained
SMGs in significant pathways, an additional 16 (21%) contained only non-SMGs in these
pathways. Thus, tumours without a given SMG often had other mutations in the same
relevant pathway. (Figure 6.4B, Supplementary Figure 6, Supplementary Table 17 and
Supplementary Information)
We also applied PARADIGM to infer pathway-informed gene activities using
gene expression and copy-number data to identify several ‘hubs’ of activity.38
(Supplementary Figure 7, Supplementary Figure 8 and Supplementary Information) As
expected, ESR1 and FOXA1 were among the hubs activated cohort-wide while other hubs
exhibited high but differential changes in aromatase-inhibitor-resistant tumours including
MYC, FOXM1, and MYB. (Supplementary Figure 8) The concordance among the 104
MetaCore maps from GeneGo analysis described above is significant, with 75 (72%) matching
one of the PARADIGM subnetworks at the 0.05 significance level after multiple test correction
(P < 4.4 × 10−6; Bonferroni-adjusted hypergeometric test). (Supplementary Figure 9)
We identified significant subnetworks associated with Ki67 biomarker status involving
transcription factors controlling large regulons. (Supplementary Figure 10 and Supplementary
Information)
The PARADIGM-inferred pathway signatures were further used to derive a map of the
genetic mechanisms that may underlie treatment response. A subnetwork was constructed in
which interactions were retained only if they connected two features with higher than
average absolute association with Ki67 biomarker status. (Supplementary Figure 10,
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Figure 6.4: Key cancer pathway components altered in luminal breast tumours. (A) Only
genetic alterations identified in 46 WGS cases are shown. Alterations were discovered in key genes in
the TP53/RB, MAPK, PI3K/AKT/mTOR pathways. Genes coloured blue and red are predicted to be
functionally inactivated and activated, respectively, through focused mutations including point mutations
and small indels (M), copy number deletions (C), or other structural changes (S) that affect the gene. The
inter-connectedness of this network (several pathways) shows that there are many different ways to perturb a
pathway.
continued on next page
[184]
Published manuscript
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(B) Eight interaction networks from canonical maps are significantly over-represented by mutations in 77
luminal breast tumours (46 WGS and 31 exome cases). In the concentric circle diagram, tumours are arranged
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[185]
Published manuscript
Supplementary Figure 11, and Supplementary Information) Consistent with the PathScan
results, among the largest of the hubs in the identified network were a central DNA damage
hub with the second highest connectivity (55 regulatory interactions; 1% of the network) and
TP53 with the 14th highest connectivity (26 connections; 0.5% of the network). Additional
highly connected hubs identified in order of connectivity were MYC with 79 connections
(1.4%), FYN with 45 (0.8%), MAPK3 with 43, JUN with 40, HDAC1 with 40, SHC1 with
39, and HIF1A/ARNT complex with 39. (Supplementary Figure 11)
To identify higher-level connections between mutations and clinical features, we compared
the samples on the basis of pathway-derived signatures. For each clinical attribute and each
SMG, we dichotomized the discovery samples into a positive and a negative group to derive
pathway signatures that discriminated between the groups. (see details in Supplementary
Information) We then computed all pair-wise Pearson correlations between pathway signatures
and clustered the resulting correlations. (Figure 6.5) The entire process was repeated using
validated mutations and signatures derived from the validation set. (Supplementary Figure 12)
In line with expectation, PIK3CA, MAP3K1, MAP2K4, and low risk preoperative endocrine
prognostic index (PEPI) scores (PEPI is an index of recurrence risk post neoadjuvant
aromatase inhibitor therapy) cluster with the luminal A subtypes and with each other, and
are supported by the validation set analysis.4 The luminal B-like signatures included TP53,
RB1, RUNX1 and MALAT1, which also associated with other poor outcome features such
as high baseline and surgical Ki67 levels, high grade histology and high PEPI scores. The
TP53 and MALAT1 associations in the discovery set also were supported by the validation
set analysis.
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Figure 6.5: Pathway signatures reveal connections between mutations and clinical outcomes.
PARADIGM-based pathway signatures were derived for tumour feature dichotomies including mutation
driven gene signatures (mutant versus non-mutant), histopathology type (lobular versus ductal), PEPI score
(PEPI = 0 favourable versus PEPI > 0 unfavourable), PAM50 (50-gene intrinsic breast cancer subtype
classifier) luminal A subtype (luminal A versus luminal B) and the reverse (luminal B versus luminal A),
histopathology grade (grades II and III versus I), baseline Ki67 levels (≥14% versus <14%), and end-of-
treatment Ki67 levels (≥10% versus <10%) and overall PEPI score (higher than mean unfavourable versus
lower than mean favourable). Pearson correlations were computed between all pair-wise signatures; positive
correlations, red; negative correlations, blue; column features ordered identically as rows. Correlation analysis
on the 77 samples in the discovery set is shown. Asterisk: Ki67 < 2.7%, oestrogen-receptor-positive, node
negative, and tumour size ≤ 5 cm.
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Druggable gene analysis
We defined mutations in druggable tyrosine kinase domains including in ERBB2 (a V777L
and a 755–759LRENT in-frame deletion homologous to gefitinib-sensitizing EGFR mutations
in lung cancer), as well as in DDR1 (A829V, R611C), DDR2 (E583D), CSF1R (D735H,
M875L), and PDGFRA (E924K).39 In addition, pleckstrin homology domain mutations were
observed in AKT1 (C77F) and AKT2 (S11F) and a kinase domain mutation was identified
in RPS6KB1 (S375F). (Supplementary Table 18)
6.2.4 Discussion
The low frequency of many SMGs presents an enormous challenge for correlative analysis, but
several statistically significant patterns were identified, including the relationship between
MAP3K1 mutation, luminal A subtype, low tumour grade and low Ki67 proliferation index.
On this basis, for patients with MAP3K1 mutant luminal tumours, neoadjuvant aromatase
inhibitor could provide a favourable option. In contrast, tumours with TP53 mutations,
which are mostly aromatase inhibitor resistant, would be more appropriately treated with
other modalities. MAP3K1 activates the ERK family, thus, loss of ERK signalling could
explain the indolent nature of MAP3K1-deficient tumours.22 However, MAP3K1 also activates
JNK through MAP2K4, which also can be mutated.40 Loss of JNK signalling produces a
defect in apoptosis in response to stress, which would hypothetically explain why these
mutations accumulate.41,42 PIK3CA harboured the most mutations (41.3%) but was neither
associated with clinical nor Ki67 response, confirming our earlier report.43 However, the
positive association between MAP3K1/MAP2K4 mutations and PIK3CA mutation at both
the mutation and pathway levels suggests cooperativity. (Figure 6.4A)
[188]
Published manuscript
The finding of multiple SMGs linked previously to benign and malignant haematopoietic
disorders suggests that breast cancer, like leukaemia, can be viewed as a stem-cell disorder
that produces indolent or aggressive tumours that display varying phenotypes depending
on differentiation blocks generated by different mutation repertoires.44 Whereas only
MLL3 showed statistical significance in the analysis of 46 WGS cases, multiple mutations
in genes related to histone modification and chromatin remodelling are worth noting.
(Supplementary Table 19) An array of coding mutations and structural variations was
discovered in methyltransferases (MLL2, MLL3, MLL4 and MLL5 ), demethyltransferases
(KDM6A, KDM4A, KDM5B and KDM5C ), and acetyltransferases (MYST1, MYST3 and
MYST4 ). Furthermore, our analysis identified several adenine-thymine (AT)-rich interactive
domain-containing protein genes (ARID1A, ARID2, ARID3B and ARID4B) that harboured
mutations and large deletions, reinforcing the role of members from the SNF/SWI family in
breast cancer.
Pathway analysis enables the evaluation of mutations with low recurrence frequency where
statistical comparisons are conventionally underpowered. For example, the eight samples
with MAP2K4 mutations were sufficient to derive a reliable pathway-based gene signature in
PARADIGM that aligns with MAP3K1. This approach also pointed to a putative connection
between MALAT1 and the TP53 pathway. Finally, we provide evidence that transcriptional
associations to Ki67 response reside in a connected network under the control of several
key ‘hub’ genes including MYC, FYN and MAP kinases, among others. Targeting these
hubs in resistant tumours could produce therapeutic advances. In conclusion, the genomic
information derived from unbiased sequencing is a logical new starting point for clinical
investigation, where the mutation status of an individual patient is determined in advance
and treatment decisions are driven by therapeutic hypotheses that stem from knowledge of
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the genomic sequence and its possible consequences. However, the accrual of large numbers
of patients and the use of comprehensive sequencing and gene expression approaches will be
required because of the extreme genomic heterogeneity documented by this investigation.
6.2.5 Methods Summary
Clinical trial samples were accessed from the preoperative letrozole phase 2 study
(NCT00084396) that investigated the effect of letrozole for 16 to 24 weeks on surgical
outcomes and from the American College of Surgeons Oncology Group (ACOSOG) Z1031
study (NCT00265759) that compared anastrozole with exemestane or letrozole for 16 to 18
weeks before surgery.2,3 (REMARK flow charts, Supplementary Figure 1) Baseline snap-frozen
biopsy samples with greater than 70% tumour content (by nuclei) underwent DNA extraction
and were paired with a peripheral blood DNA sample. Two formalin-fixed biopsies were
obtained at baseline and at surgery, and were used to conduct oestrogen receptor and Ki67
immunohistochemistry as previously published.4 Paired end Illumina reads from tumours
and normal samples were aligned to NCBI build36 using BWA. Somatic point mutations
were identified using SomaticSniper, and indels were identified by combining results from a
modified version of the Samtools indel caller (http://samtools.sourceforge.net/), GATK
and Pindel.45 Structural variations were identified using BreakDancer and SquareDancer
(unpublished).5 All putative somatic events found in 46 cases were validated by targeted
custom capture arrays (Nimblegen)/Illumina sequencing and all tier 1 mutations for 46 WGS
cases also were validated using PCR/454 sequencing. All statistical analyses, including
SMG, mutation relation and clinical correlation were done using the MuSiC package
and/or by standard statistical tests.15 (Supplementary Information) Pathway analysis was
performed with PathScan, GeneGo Metacore (http://www.genego.com/metacore.php) and
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PARADIGM. A complete description of the materials and methods used to generate this
data set and results is provided in the Supplementary Methods section.
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Supplementary Figure 6.6: Key cancer pathway components altered in luminal breast tumours.
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Supplementary Figure 6.6 (continued from previous page)
Eight interaction networks from canonical maps are significantly over-represented by mutations in 77 luminal
breast tumours (46 WGS and 31 exome cases). Maps were grouped by function and arranged to reflect
overall hierarchy of signaling through protein-protein interactions. Mutated genes are represented in black
and sized to reflect the number of tumors containing each mutation. SMGs are shown as red nodes with
reference numbers indicated in the key. White nodes are non-mutated network objects. In the concentric
circle diagram, tumors are arranged as radial spokes and categorized by their mutation status in each network
(concentric ring color) and SMG mutation status (black dots). Tumor classification by pathway analysis
shows many tumors unaffected by a given SMG often harbor other mutations in the same network. For full
annotation, see Supplementary Information for Gene Interaction Network Analysis.
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6.2.6 Supplementary methods
Gene Interaction Network Analysis The interaction networks were compiled from
Metacore maps (GeneGo, Inc.) significantly intersecting with the mutation list (corrected
FDR < 0.05). Mutated genes in multiple network objects were only considered in one object
to prevent redundant mutation counts. Network objects were classified into eight functional
networks and arranged hierarchically in Cytoscape.46,47 SMGs AGTR2, STMN2, MLL3, and
SF3B1 were not included in any maps by Metacore, so curated interactions were added with
members of the most applicable network. Some interactions between non-mutated nodes
were removed for clarity. The number of tumors harboring a node mutation is indicated by
node size. SMGs from each network are differentiated in red and by a reference number;
other mutated objects are colored black. All 77 tumors were classified by network and SMG
mutation status in a concentric display. Each patient is represented by a spoke in the wheel,
affected networks for each patient are indicated by the appropriate color, and SMG mutations
are shown as black dots in the parent network. The MLL2/3 complex is represented as a
single network node with multiple mutated constituent genes. Of these, only MLL3 was
considered an SMG in patient classification. (Supplementary Data Files)
6.3 References
1. Chia, Y. H., Ellis, M. J. & Ma, C. X. Neoadjuvant endocrine therapy in primary breast
cancer: indications and use as a research tool. Br. J. Cancer 103, 759–64 (Sept. 2010).
2. Olson, J. A., Budd, G. T., Carey, L. A., Harris, L. A., Esserman, L. J., Fleming, G. F.,
Marcom, P. K., Leight, G. S., Giuntoli, T., Commean, P., Bae, K., Luo, J. & Ellis, M. J.
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase
inhibitor therapy: results from a multicenter phase II trial. J. Am. Coll. Surg. 208,
906–14, 906–14 (May 2009).
[194]
References
3. Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J.,
DeSchryver, K., Allred, D. C., Esserman, L. J., Unzeitig, G. W., Margenthaler, J.,
Babiera, G. V., Marcom, P. K., Guenther, J. M., Watson, M. A., Leitch, M., Hunt, K.
& Olson, J. A. Randomized phase II neoadjuvant comparison between letrozole,
anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich
stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the
baseline PAM50-based int. J. Clin. Oncol. 29, 2342–9 (June 2011).
4. Ellis, M. J., Tao, Y., Luo, J., A’Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross,
H. A., von Kameke, A., Miller, W. R., Smith, I., Eiermann, W. & Dowsett, M. Outcome
prediction for estrogen receptor-positive breast cancer based on postneoadjuvant
endocrine therapy tumor characteristics. J. Natl. Cancer Inst. 100, 1380–8 (Oct. 2008).
5. Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S.,
McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., Shi, X., Fulton, R. S., Ley, T. J.,
Wilson, R. K., Ding, L. & Mardis, E. R. BreakDancer: an algorithm for high-resolution
mapping of genomic structural variation. Nat. Methods 6, 677–81 (Sept. 2009).
6. Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K.,
Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A.,
Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S.,
Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J.,
Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E.,
McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X.,
Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J.,
Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A.,
Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J.,
Graubert, T. A., DiPersio, J. F., Wilson, R. K. & Ley, T. J. Recurring mutations found
by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–66
(Sept. 2009).
7. Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling,
D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., Cook, L., Abbott, R.,
Larson, D. E., Koboldt, D. C., Pohl, C., Smith, S., Hawkins, A., Abbott, S., Locke, D.,
Hillier, L. W., Miner, T., Fulton, L., Magrini, V., Wylie, T., Glasscock, J., Conyers, J.,
Sander, N., Shi, X., Osborne, J. R., Minx, P., Gordon, D., Chinwalla, A., Zhao, Y.,
Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M., Baty, J.,
Ivanovich, J., Heath, S., Shannon, W. D., Nagarajan, R., Walter, M. J., Link, D. C.,
Graubert, T. A., DiPersio, J. F. & Wilson, R. K. DNA sequencing of a cytogenetically
normal acute myeloid leukaemia genome. Nature 456, 66–72 (Nov. 2008).
[195]
References
8. Totoki, Y., Tatsuno, K., Yamamoto, S., Arai, Y., Hosoda, F., Ishikawa, S., Tsutsumi, S.,
Sonoda, K., Totsuka, H., Shirakihara, T., Sakamoto, H., Wang, L., Ojima, H., Shimada,
K., Kosuge, T., Okusaka, T., Kato, K., Kusuda, J., Yoshida, T., Aburatani, H. &
Shibata, T. High-resolution characterization of a hepatocellular carcinoma genome.
Nat. Genet. 43, 464–9 (May 2011).
9. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J.,
Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., Ye, K.,
Alipaz, J., Bauer, M. J., Beare, D., Butler, A., Carter, R. J., Chen, L., Cox, A. J.,
Edkins, S., Kokko-Gonzales, P. I., Gormley, N. A., Grocock, R. J., Haudenschild, C. D.,
Hims, M. M., James, T., Jia, M., Kingsbury, Z., Leroy, C., Marshall, J., Menzies, A.,
Mudie, L. J., Ning, Z., Royce, T., Schulz-Trieglaff, O. B., Spiridou, A., Stebbings, L. A.,
Szajkowski, L., Teague, J., Williamson, D., Chin, L., Ross, M. T., Campbell, P. J.,
Bentley, D. R., Futreal, P. A. & Stratton, M. R. A comprehensive catalogue of somatic
mutations from a human cancer genome. Nature 463, 191–6 (Jan. 2010).
10. Pleasance, E. D., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A., Jones, D.,
Lin, M.-L., Beare, D., Lau, K. W., Greenman, C., Varela, I., Nik-Zainal, S., Davies, H. R.,
Ordoñez, G. R., Mudie, L. J., Latimer, C., Edkins, S., Stebbings, L., Chen, L., Jia, M.,
Leroy, C., Marshall, J., Menzies, A., Butler, A., Teague, J. W., Mangion, J., Sun, Y. A.,
McLaughlin, S. F., Peckham, H. E., Tsung, E. F., Costa, G. L., Lee, C. C., Minna, J. D.,
Gazdar, A., Birney, E., Rhodes, M. D., McKernan, K. J., Stratton, M. R., Futreal, P. A.
& Campbell, P. J. A small-cell lung cancer genome with complex signatures of tobacco
exposure. Nature 463, 184–90 (Jan. 2010).
11. Lee, W., Jiang, Z., Liu, J., Haverty, P. M., Guan, Y., Stinson, J., Yue, P., Zhang, Y.,
Pant, K. P., Bhatt, D., Ha, C., Johnson, S., Kennemer, M. I., Mohan, S., Nazarenko, I.,
Watanabe, C., Sparks, A. B., Shames, D. S., Gentleman, R., de Sauvage, F. J., Stern, H.,
Pandita, A., Ballinger, D. G., Drmanac, R., Modrusan, Z., Seshagiri, S. & Zhang, Z.
The mutation spectrum revealed by paired genome sequences from a lung cancer
patient. Nature 465, 473–7 (May 2010).
12. Krzywinski, M., Schein, J., Birol, I., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J.
& Marra, M. A. Circos: an information aesthetic for comparative genomics. Genome
Res. 19, 1639–45 (Sept. 2009).
13. Usary, J., Llaca, V., Karaca, G., Presswala, S., Karaca, M., He, X., Langerød, A.,
Kåresen, R., Oh, D. S., Dressler, L. G., Lønning, P. E., Strausberg, R. L., Chanock, S.,
Børresen-Dale, A.-L. & Perou, C. M. Mutation of GATA3 in human breast tumors.
Oncogene 23, 7669–78 (Oct. 2004).
14. Berx, G., Cleton-Jansen, A. M., Nollet, F., de Leeuw, W. J., van de Vijver, M.,
Cornelisse, C. & van Roy, F. E-cadherin is a tumour/invasion suppressor gene mutated
in human lobular breast cancers. EMBO J. 14, 6107–15 (Dec. 1995).
[196]
References
15. Dees, N. D., Zhang, Q., Kandoth, C., Wendl, M. C., Schierding, W., Koboldt, D. C.,
Mooney, T. B., Callaway, M. B., Dooling, D., Mardis, E. R., Wilson, R. K. & Ding, L.
MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589–98
(Aug. 2012).
16. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A.,
Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W.,
Vogelstein, B. & Velculescu, V. E. High frequency of mutations of the PIK3CA gene in
human cancers. Science (80-. ). 304, 554 (Apr. 2004).
17. Prosser, J., Thompson, A. M., Cranston, G. & Evans, H. J. Evidence that p53 behaves
as a tumour suppressor gene in sporadic breast tumours. Oncogene 5, 1573–9 (Oct.
1990).
18. T’Ang, A., Varley, J. M., Chakraborty, S., Murphree, A. L. & Fung, Y. K. Structural
rearrangement of the retinoblastoma gene in human breast carcinoma. Science (80-. ).
242, 263–6 (Oct. 1988).
19. Wang, X.-X., Fu, L., Li, X., Wu, X., Zhu, Z., Fu, L. & Dong, J.-T. Somatic mutations
of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol. Oncol.
Res. 17, 429–33 (June 2011).
20. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P.,
Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., Tomsho, L. P.,
Peters, B. A., Pujara, K., Cordes, S., Davis, D. P., Carlton, V. E. H., Yuan, W., Li, L.,
Wang, W., Eigenbrot, C., Kaminker, J. S., Eberhard, D. A., Waring, P., Schuster, S. C.,
Modrusan, Z., Zhang, Z., Stokoe, D., de Sauvage, F. J., Faham, M. & Seshagiri, S.
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature
466, 869–73 (Aug. 2010).
21. Spirin, K. S., Simpson, J. F., Takeuchi, S., Kawamata, N., Miller, C. W. & Koeffler, H. P.
p27/Kip1 mutation found in breast cancer. Cancer Res. 56, 2400–4 (May 1996).
22. Fanger, G. R., Johnson, N. L. & Johnson, G. L. MEK kinases are regulated by EGF
and selectively interact with Rac/Cdc42. EMBO J. 16, 4961–72 (Aug. 1997).
23. Fillmore, C. M., Gupta, P. B., Rudnick, J. A., Caballero, S., Keller, P. J., Lander, E. S.
& Kuperwasser, C. Estrogen expands breast cancer stem-like cells through paracrine
FGF/Tbx3 signaling. Proc. Natl. Acad. Sci. U. S. A. 107, 21737–42 (Dec. 2010).
24. Mao, S., Frank, R. C., Zhang, J., Miyazaki, Y. & Nimer, S. D. Functional and physical
interactions between AML1 proteins and an ETS protein, MEF: implications for the
pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 19, 3635–44 (May 1999).
[197]
References
25. Stender, J. D., Kim, K., Charn, T. H., Komm, B., Chang, K. C. N., Kraus, W. L.,
Benner, C., Glass, C. K. & Katzenellenbogen, B. S. Genome-wide analysis of estrogen
receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel
tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 30,
3943–55 (Aug. 2010).
26. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D.,
Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C.,
Godfrey, A. L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L. J.,
Stephens, P. J., McLaren, S., Massie, C. E., Tarpey, P. S., Varela, I., Nik-Zainal, S.,
Davies, H. R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A. P., Teague, J. W.,
Baxter, E. J., Score, J., Galli, A., Della Porta, M. G., Travaglino, E., Groves, M.,
Tauro, S., Munshi, N. C., Anderson, K. C., El-Naggar, A., Fischer, A., Mustonen, V.,
Warren, A. J., Cross, N. C. P., Green, A. R., Futreal, P. A., Stratton, M. R. &
Campbell, P. J. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N.
Engl. J. Med. 365, 1384–95 (Oct. 2011).
27. Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner,
L., Sivachenko, A., DeLuca, D. S., Zhang, L., Zhang, W., Vartanov, A. R., Fernandes,
S. M., Goldstein, N. R., Folco, E. G., Cibulskis, K., Tesar, B., Sievers, Q. L., Shefler, E.,
Gabriel, S., Hacohen, N., Reed, R., Meyerson, M., Golub, T. R., Lander, E. S.,
Neuberg, D., Brown, J. R., Getz, G. & Wu, C. J. SF3B1 and other novel cancer genes
in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–506 (Dec. 2011).
28. Chen, Z., Naveiras, O., Balduini, A., Mammoto, A., Conti, M. A., Adelstein, R. S.,
Ingber, D., Daley, G. Q. & Shivdasani, R. A. The May-Hegglin anomaly gene MYH9
is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway.
Blood 110, 171–9 (July 2007).
29. Lamant, L., Gascoyne, R. D., Duplantier, M. M., Armstrong, F., Raghab, A.,
Chhanabhai, M., Rajcan-Separovic, E., Raghab, J., Delsol, G. & Espinos, E. Non-
muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large
cell lymphoma. Genes. Chromosomes Cancer 37, 427–32 (Aug. 2003).
30. Wilund, K. R., Yi, M., Campagna, F., Arca, M., Zuliani, G., Fellin, R., Ho, Y.-K.,
Garcia, J. V., Hobbs, H. H. & Cohen, J. C. Molecular mechanisms of autosomal
recessive hypercholesterolemia. Hum. Mol. Genet. 11, 3019–30 (Nov. 2002).
31. Dellê, H., Rocha, J. R. C., Cavaglieri, R. C., Vieira, J. M., Malheiros, D. M. A. C. &
Noronha, I. L. Antifibrotic effect of tamoxifen in a model of progressive renal disease.
J. Am. Soc. Nephrol. 23, 37–48 (Jan. 2012).
[198]
References
32. Tararuk, T., Ostman, N., Li, W., Björkblom, B., Padzik, A., Zdrojewska, J., Hongisto,
V., Herdegen, T., Konopka, W., Courtney, M. J. & Coffey, E. T. JNK1 phosphorylation
of SCG10 determines microtubule dynamics and axodendritic length. J. Cell Biol. 173,
265–77 (Apr. 2006).
33. Westerlund, N., Zdrojewska, J., Padzik, A., Komulainen, E., Björkblom, B., Rannikko,
E., Tararuk, T., Garcia-Frigola, C., Sandholm, J., Nguyen, L., Kallunki, T., Courtney,
M. J. & Coffey, E. T. Phosphorylation of SCG10/stathmin-2 determines multipolar
stage exit and neuronal migration rate. Nat. Neurosci. 14, 305–13 (Mar. 2011).
34. Tripathi, V., Ellis, J. D., Shen, Z., Song, D. Y., Pan, Q., Watt, A. T., Freier, S. M.,
Bennett, C. F., Sharma, A., Bubulya, P. A., Blencowe, B. J., Prasanth, S. G. &
Prasanth, K. V. The nuclear-retained noncoding RNA MALAT1 regulates alternative
splicing by modulating SR splicing factor phosphorylation. Mol. Cell 39, 925–38 (Sept.
2010).
35. Rajaram, V., Knezevich, S., Bove, K. E., Perry, A. & Pfeifer, J. D. DNA sequence
of the translocation breakpoints in undifferentiated embryonal sarcoma arising in
mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation.
Genes. Chromosomes Cancer 46, 508–13 (May 2007).
36. Xu, C., Yang, M., Tian, J., Wang, X. & Li, Z. MALAT-1: a long non-coding RNA and
its important 3’ end functional motif in colorectal cancer metastasis. Int. J. Oncol. 39,
169–75 (July 2011).
37. Wendl, M. C., Wallis, J. W., Lin, L., Kandoth, C., Mardis, E. R., Wilson, R. K. &
Ding, L. PathScan: a tool for discerning mutational significance in groups of putative
cancer genes. Bioinformatics 27, 1595–602 (June 2011).
38. Vaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D. &
Stuart, J. M. Inference of patient-specific pathway activities from multi-dimensional
cancer genomics data using PARADIGM. Bioinformatics 26, i237–45 (June 2010).
39. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan,
B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N.,
Christiani, D. C., Settleman, J. & Haber, D. A. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N. Engl. J. Med. 350, 2129–39 (May 2004).
40. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by
ERK, JNK, and p38 protein kinases. Science 298, 1911–2 (Dec. 2002).
41. Widmann, C., Johnson, N. L., Gardner, A. M., Smith, R. J. & Johnson, G. L.
Potentiation of apoptosis by low dose stress stimuli in cells expressing activated
MEK kinase 1. Oncogene 15, 2439–47 (Nov. 1997).
[199]
References
42. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways
in cancer development. Nat. Rev. Cancer 9, 537–49 (Aug. 2009).
43. Ellis, M. J., Lin, L., Crowder, R., Tao, Y., Hoog, J., Snider, J., Davies, S., DeSchryver, K.,
Evans, D. B., Steinseifer, J., Bandaru, R., Liu, W., Gardner, H., Semiglazov, V.,
Watson, M., Hunt, K., Olson, J. & Baselga, J. Phosphatidyl-inositol-3-kinase alpha
catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen
receptor positive breast cancer. Breast Cancer Res. Treat. 119, 379–90 (Jan. 2010).
44. Prat, A. & Perou, C. M. Mammary development meets cancer genomics. Nat. Med.
15, 842–4 (Aug. 2009).
45. Larson, D. E., Harris, C. C., Chen, K., Koboldt, D. C., Abbott, T. E., Dooling, D. J.,
Ley, T. J., Mardis, E. R., Wilson, R. K. & Ding, L. SomaticSniper: identification of
somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311–7
(Feb. 2012).
46. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L. & Ideker, T. Cytoscape 2.8: new
features for data integration and network visualization. Bioinformatics 27, 431–2 (Feb.
2011).
47. Saito, R., Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-l., Lotia, S., Pico, A. R.,
Bader, G. D. & Ideker, T. A travel guide to Cytoscape plugins. Nat. Methods 9, 1069–76
(Nov. 2012).
[200]
Manuscript abbreviations
FDR False discovery rate
indel Insertion/deletion
Mb Megabase
NHEJ Non-homologous end joining
PEPI Preoperative endocrine prognostic index
SMG Significantly mutated gene
SNV Single nucleotide variant
WGS Whole-genome sequencing
[201]
Chapter 7
Statistical and Computational Analysis
Methods
7.1 Introduction
Various computational tools were developed throughout the work presented herein. Some
tools are limited to macros or simple programs to assist in the imaging data analysis pipeline,
while others are new statistical methods adapted from peer-reviewed techniques developed
with accompanying programming to automate complex analyses. This chapter contains both
source code and step-by-step explanation of new statistical techniques that generalizable
to broad applications; specific notes on uses particular to the aforementioned experiments
appear as footnotes where appropriate.
7.2 WLS calibration algorithm
Statistical basis
Throughout this project, data were analyzed with a weighted least squares (WLS) regression
algorithm adapted from multiple literature reports on calibration methods.1–4 The method
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constructs a standard curve by weighting each calibration standard according to the inter-
replicate variance and comparing first- and second-order models on the basis of degrees of
freedom and regression residuals. In the detailed description of the method that follows,
Table 7.1 may be used as a reference for the parameters found throughout.
This method uses the standard General Linear Model assumption that the error in
independent variable x is negligible compared to that of the dependent measurements y.
Standard concentrations xj (j = 1, 2, . . . , k) in the calibration curve are each prepared as
technical replicates i with ij = 1, 2, . . . ,mj and giving the total number of points used in
calibration n =
k∑
j=1
mj.1 The standard deviation sj of measurements yij is used in the
regression equation (7.1) to determine the parameter θ, which is then used to calculate an
estimated standard deviation under the assumption that σ ∝ y.2
s = θˆy¯ → θy¯j = s_j (7.1)
These estimated3 standard deviations are used to weight4 each calibration point j:
wj =
1
s_j2
= 1
(θy¯j)2
(7.2)
Using the weights assigned to each calibration standard, the WLS algorithm next computes
first- and second-order models for the data. The quadratic WLS regression curve is estimated
in the form
y_[Q] = y¯w + b1 (x− x¯w) + b2
(
x2 − x2w
)
(7.3)
1 In all experiments presented in Chapter 4, mj = 3 for all 1 ≤ j ≤ 8; thus n = 24.
2This method has a key advantage over estimating s_j using xj : it prevents s_j = 0 so long as y (0,∞] and
thus prevents undefined weights wx=0 as well as preventing outliers at high xj from artificially shifting the
weighted mean x¯w.
3The WLS algorithm can optionally be set to use measured sj to determine weights, but s_j is still required
for inverse regression so this behavior is disabled by default.
4Should any values of s_j be sufficiently small to cause wj = 0 due to float point precision errors, the algorithm
scales all values of s_j by the mean of all s_ to maintain relative weighting and recomputes all wj .
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where y_[Q] is the mean regression estimate as a function of x,
y¯w =
k∑
j=1
mj∑
i=1
wjyij
k∑
j=1
mjwj
(7.4)
is the weighted mean of all calibration measurements,
x¯w =
k∑
j=1
mj∑
i=1
wjxij
k∑
j=1
mjwj
(7.5)
is the weighted mean of all calibration standard values, and
x2w =
k∑
j=1
mj∑
i=1
wjx
2
ij
k∑
j=1
mjwj
(7.6)
is the weighted mean of all squared calibration standard values. To calculated the remaining
parameters b1 and b2, the minimum sum of the squared residuals is computed by partially
differentiating SSE in terms of each unknown parameter, setting each ∂SSE
∂b
= 0, and
solving the resulting system of equations for the unknown parameters.
SSE =
k∑
j=1
mj∑
i=1
(
yij − y_j[Q]
)2
(7.7)
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To make the equations for b1 and b2 more compact, some intermediate variables are defined:
Σx2 =
k∑
j=1
mj∑
i=1
wjx
2
ij −
 k∑
j=1
mjwj
 (x¯w)2 (7.8)
Σxy =
k∑
j=1
mj∑
i=1
wjxijyij −
 k∑
j=1
mjwj
 x¯wy¯w (7.9)
Σxs =
k∑
j=1
mj∑
i=1
wjx
3
ij −
 k∑
j=1
mjwj
 x¯wx2w (7.10)
Σsy =
k∑
j=1
mj∑
i=1
wjx
2
ijyij −
 k∑
j=1
mjwj
x2w y¯w (7.11)
Σs2 =
k∑
j=1
mj∑
i=1
wjx
4
ij −
 k∑
j=1
mjwj
(x2w)2 (7.12)
ΣD[Q] = Σx2Σs2 − (Σxs)2 (7.13)
From these, values for b1 and b2 are computed by
b1 =
ΣxyΣs2 − ΣxsΣsy
ΣD[Q]
(7.14)
b2 =
Σx2Σsy − ΣxsΣxy
ΣD[Q]
(7.15)
These are then used in equation (7.3) to find y_j[Q] so that the weighted residual standard
deviation can be computed by
sRw[Q] =
√√√√√√
k∑
j=1
mj∑
i=1
wj
(
yij − y_j[Q]
)2
n− 3 (7.16)
The linear WLS model is then similarly computed for comparison with the quadratic.
The model takes a familiar form of equation (7.3) with b2 = 0 the differentiation strategy
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described for quadratic regression is simplified:
y_[L] = y¯w + b1 (x− x¯w) (7.17)
ΣD[L] =
k∑
j=1
mj∑
i=1
wj (xij − x¯w)2 (7.18)
b1 =
k∑
j=1
mj∑
i=1
wj (xij − x¯w) yij
ΣD[L]
∣∣∣∣∣∣∣∣∣ b2 = 0 (7.19)
sRw[L] =
√√√√√√
k∑
j=1
mj∑
i=1
wj
(
yij − y_j[L]
)2
n− 2 (7.20)
The two models are compared using the F -ratio test with the critical value Fα/21,n−3
determined by the desired false positive rate α:
Ftest =
(
k∑
j=1
mj∑
i=1
wj
(
yij − y_j[L]
)2 − k∑
j=1
mj∑
i=1
wj
(
yij − y_j[Q]
)2)
(n− 3)
k∑
j=1
mj∑
i=1
wj
(
yij − y_j[Q]
)2 (7.21)
The quadratic WLS model is used only if Ftest > Fα/21,n−3.
Once the appropriate model is selected, the results of the regression are plotted with
equation (7.3) or (7.17) and solved algebraically to find estimated values xu for each unknown
sample u. For linear,
xu[L] = x¯w − y¯u − y¯w
b1
(7.22)
and for quadratic,
xu[Q] =
−b1−
√
4b2 (y¯u − y¯w) + 4b22x2w + b21 + 4b1b2x¯w
2b2
∣∣∣∣∣∣
b1<0
xu[Q] =
−b1 +
√
4b2 (y¯u − y¯w) + 4b22x2w + b21 + 4b1b2x¯w
2b2
∣∣∣∣∣∣
b1>0
(7.23)
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Two band intervals can be predicted about the regression model. To simplify notation, the
term K is defined for both linear and quadratic models:
K[L] =
1
k∑
j=1
mjwj
+ (x− x¯w)
2
ΣD[L]
(7.24)
K[Q] =
1
k∑
j=1
mjwj
+ (x− x¯w)
2 Σs2
ΣD[Q]
+
(
x2 − x2w
)2
Σx2
ΣD[Q]
− 2(x− x¯w)
(
x2 − x2w
)
Σxs
ΣD[Q]
(7.25)
The confidence bands can be thought of as the confidence intervals for the calibration curve
itself:
y˘conf[L] = y_[L] ± sRw[L] t1−α/2,n−2
√
K[L] (7.26)
y˘conf[Q] = y_[Q] ± sRw[Q] t1−α/2,n−3
√
K[Q] (7.27)
where t1−α/2,n−3 and t1−α/2,n−2 are the critical values of the t-distribution with a false positive
error rate α and degrees of freedom accounting for quadratic and linear regression parameters,
respectively. Prediction bands give the confidence intervals for the mean of m replicate
measurements on the measurement uncertainty implied by the regression variance.5
y˘pred[L] = y_[L] ± sRw[L] t1−α/2,n−2
√
(y¯w + b1 (x− x¯w))2 θ2
m
+K[L] (7.28)
y˘pred[Q] = y_[Q] ± sRw[Q] t1−α/2,n−3
√√√√(y¯w + b1 (x− x¯w) + b2 (x2 − x2w))2 θ2
m
+K[Q] (7.29)
These prediction bands can be used to find the minimum a priori detectable concentration
of the analyte, x_λ, based on the false positive error rate α, the false negative error rate β,
and the number of technical replicates m. First, the critical signal yκ associated with the
one-sided t-distribution expected for y_x=0 is computed with certainty α:
yκ[L] = y¯w − b1x¯w + sRw[L] t1−α,n−2
√√√√√√(y¯w − b1x¯w)
2 θ2
m
+ 1
k∑
j=1
mjwj
+ x¯
2
w
ΣD[L]
(7.30)
5 the confidence bands are a special case of the prediction bands with m→∞
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yκ[Q] = y¯w − b1x¯w − b2x2w
+sRw[Q] t1−α,n−3
√√√√√√√
(
y¯w − b1x¯w − b2x2w
)2
θ2
m
+ 1
k∑
j=1
mjwj
+
x¯2wΣs2 +
(
x2w
)2
Σx2 − 2x¯wx2wΣxs
ΣD[Q]
(7.31)
The minimum expected analyte x_λ detectable with power 1− β is found by solving for its
expected t-distribution with the critical value β intersecting with yκ:
yκ[L] = y¯w + b1
(
x_λ[L] − x¯w
)
+ sRw[L] tβ,n−2
√√√√√√√
(
y¯w + b1
(
x_λ[L] − x¯w
))2
θ2
m
+ 1
k∑
j=1
mjwj
+
(
x_λ[L] − x¯w
)2
ΣD[L]
(7.32)
yκ[Q] = y¯w + b1
(
x_λ[Q] − x¯w
)
+ b2
(
x_2λ[Q] − x2w
)
+ sRw[Q] tβ,n−3

(
y¯w + b1
(
x_λ[Q] − x¯w
)
+ b2
(
x_2λ[Q] − x2w
))2
θ2
m
+ 1
k∑
j=1
mjwj
+
(
x_λ[Q] − x¯w
)2
Σs2
ΣD[Q]
+
(
x_2λ[Q] − x2w
)2
Σx2
ΣD[Q]
− 2
(
x_λ[Q] − x¯w
) (
x_2λ[Q] − x2w
)
Σxs
ΣD[Q]

1
2
(7.33)
Equations (7.32) and (7.33) are not analytically solvable and are thus solved iteratively for
x_λ without limits of precision.
Although the prediction bands are sufficient for single comparisons and graphical
representation of calibration curves, they do not correct for true error rate resulting from
repeated use of the same standards. To correct for this, a third interval for inverse regression
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is computed by using the F -distribution.5
y˘cal[L] = y_[L] ± sRw[L]
√
2Fα/22,n−2 K[L] (7.34)
y˘cal[Q] = y_[Q] ± sRw[Q]
√
3Fα/23,n−3 K[Q] (7.35)
These equations demonstrate the trade-off required to use the more-accurate quadratic model:
as 2Fα/22,n−2 < 3F
α/2
3,n−3 is always true, the quadratic model is more precise than the linear only
when this inequality is compensated for by the relationship between sRw[Q] and sRw[L].
The intersection of this band with the t-distribution of mu unknown sample replicates with
mean y¯u and standard deviation su determines the confidence intervals about the calibration
result. The upper and lower bounds for replicates of an unknown sample calibrated with a
linear curve are found by solving the following equations for x_u,min[L] and x_u,max[L]:
y¯u − su√
mu
t1−α/2,mu−1 = y¯w + b1
(
x_u,min[L] − x¯w
)
+ sRw[L]
√
2Fα/22,n−2
√√√√√√√ 1k∑
j=1
mjwj
+
(
x_u,min[L] − x¯w
)2
ΣD[L]
(7.36)
y¯u +
su√
mu
t1−α/2,mu−1 = y¯w + b1
(
x_u,max[L] − x¯w
)
− sRw[L]
√
2Fα/22,n−2
√√√√√√√ 1k∑
j=1
mjwj
+
(
x_u,max[L] − x¯w
)2
ΣD[L]
(7.37)
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The quadratic model equations are analogously solved for x_u,min[Q] and x_u,max[Q]:
y¯u − su√
mu
t1−α/2,mu−1 = y¯w + b1
(
x_u,min[Q] − x¯w
)
+ b2
(
x_2u,min[Q] − x2w
)
+ sRw[Q]
√
3Fα/23,n−3
 1k∑
j=1
mjwj
+
(
x_u,min[Q] − x¯w
)2
Σs2
ΣD[Q]
+
(
x_2u,min[Q] − x2w
)2
Σx2
ΣD[Q]
− 2
(
x_u,min[Q] − x¯w
) (
x_2u,min[Q] − x2w
)
Σxs
ΣD[Q]

1
2
(7.38)
y¯u +
su√
mu
t1−α/2,mu−1 = y¯w + b1
(
x_u,max[Q] − x¯w
)
+ b2
(
x_2u,max[Q] − x2w
)
− sRw[Q]
√
3Fα/23,n−3
 1k∑
j=1
mjwj
+
(
x_u,max[Q] − x¯w
)2
Σs2
ΣD[Q]
+
(
x_2u,max[Q] − x2w
)2
Σx2
ΣD[Q]
− 2
(
x_u,max[Q] − x¯w
) (
x_2u,max[Q] − x2w
)
Σxs
ΣD[Q]

1
2
(7.39)
The full expansions of equations (7.38) and (7.39) demonstrate why xu,min and xu,max must
be solved iteratively for numeric solutions rather than analytically.
Implementation
The code for WLS calibration was written in SPSS version 19, but has been updated most
recently using SPSS 21. No new functions were introduced during the rewrites, but other
SPSS versions have not been tested. The program requires a minimum of 4 SPSS variables
indicating the following quantities:
1. measurement: numeric variable (absorbance, luminescence, etc.)
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Table 7.1: Parameters used in WLS regression.
parameter(s) description equation
xj value of the regression independent variable (concentration) –
yij measurement of the dependent variable at x = xj –
j, k calibration concentrations with j = 1, 2, . . . , k –
ij ,mj replications of each standard calibration point xj with ij = 1, 2, . . . ,mj –
n total calibration measurements,
k∑
j=1
mj –
sj , σj the standard deviation of yj and the theoretical lim
mj→∞
sj –
θ regression term used to find s_j (7.1)
s_j estimated standard deviation for yj (7.1)
y¯j the unweighted mean of yj –
wj weight of calibration point j (7.2)
y_[Q] measurement at x predicted by quadratic WLS regression (7.3)
y_[L] measurement at x predicted by linear WLS regression (7.17)
y¯w weighted mean of all calibration measurements, also the 0th order regression term (7.4)
b1 first-order regression term (7.14), (7.19)
b2 second-order regression term (7.15)
x¯w weighted mean of all calibration standard values (7.5)
x2w weighted mean of all squared calibration standard values (7.6)
Σx2
Intermediate computation terms as if you are reading this
(7.8)
Σxy (7.9)
Σxs (7.10)
Σsy (7.11)
Σs2 (7.12)
ΣD[Q] (7.13)
ΣD[L] (7.18)
K[L] (7.24)
K[Q] (7.25)
α the false positive error rate, also known as the critical p value –
β the false negative error rate, 1− power –
tα/τ,δ τ -sided t-distribution critical value with probability α and δ degrees of freedom –
F
α/τ
δ, τ -sided F -distribution critical value with probability α and δ,  degrees of freedom –
Ftest F -distribution value used to compare linear and quadratic WLS regression (7.21)
sRw[Q] standard deviation of quadratic regression residuals (7.16)
sRw[L] standard deviation of linear regression residuals (7.20)
y˘conf[L]
confidence and prediction intervals for linear and quadratic WLS regression
(7.26)
y˘conf[Q] (7.27)
y˘pred[L] (7.28)
y˘pred[Q] (7.29)
yκ[L] critical y_ indicating non-zero analyte with confidence 1− α (7.30)
yκ[Q] (7.31)
x_λ[L] minimal detectable analyte with false positive rate α and false negative rate β (7.32)x_λ[Q] (7.33)
y˘cal[L] multiple-comparison calibration intervals to determine unknown analyte from
repeated measures
(7.34)
y˘cal[Q] (7.35)
x_u[L]
Inverse regression results with upper and lower bounds for unknown sample u
(7.22)
x_u[Q] (7.23)
x_umin[L] (7.36)
x_umax[L] (7.37)
x_umin[Q] (7.38)
x_umax[Q] (7.39)
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Table 7.2: Example of minimal dataset fitting the requirements of the WLS regression program
for SPSS. Unknown samples are not strictly required; calibration curves can be constructed without being
used to determine unknown analyte concentrations. Note that the data file must contain at least 4 rows to
satisfy the required conditions, 6 rows if there are any unknowns being regressed.
analyte measurement group known
0 100 1 1
0 121 1 1
3713 2 0
4175 2 0
1000 8198 3 1
1000 10611 3 1
2. analyte concentrations: numeric variable, the known standard curve values (does
not need to be blank for “unknown” concentrations) must have at least 2 duplicates
per value
3. standard indicator: binary variable, 1 for all values of the standard curve, 0 for all
other measurements to be estimated by the standards
4. group: no format requirement, must be unique for every set of measurements6
In addition to the standard SPSS variable naming rules, no variables may be named “x” or
“y” for programming reasons. An example of data meeting the minimum requirements can
be found in Table 7.2. Running the WLS regression requires two steps: first, the program
must be called, either by running the code directly or by calling the program with the
‘insert file=’ command as shown below in code block 7.2.
Source Code 7.1: WLS regression
1 DEFINE !WLSreg1 (
2 stdVals =! tokens (1)
3 /grpVar =! tokens (1)
6For example, an experiment with 3 standard concentrations and 2 unknown samples requires 5 unique values
of this grouping variable
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4 /stdGrp =! tokens (1)
5 /alpha =! tokens (1)
6 /Mxs=! tokens (1)
7 /beta=! tokens (1)
8 /trueSD =! tokens (1)
9 /curveSegs =! tokens (1)
10 /bandsM =! tokens (1)
11 )
12
13 * set output to prevent clutter in analysis window
14 SET PRINTBACK=NONE RESULTS=NONE.
15 OUTPUT NAME mainOutput.
16 OUTPUT NEW.
17 OUTPUT NAME dummyOutput.
18 OUTPUT ACTIVATE dummyoutput.
19
20 * prepare standard variable names for convenient coding.
21 DATASET NAME calibration.
22 AUTORECODE !grpVar /INTO Split.
23 VALUE LABELS split.
24 IF !stdGrp x = !stdVals.
25 IF !stdGrp y = !Mxs.
26 EXECUTE.
27
28 * find calibration replicate coefficients of variation.
29 AGGREGATE
30 /OUTFILE =* MODE=ADDVARIABLES
31 /BREAK=x
32 /sdY=SD(Y)
33 /meanY=MEAN(Y).
34 DATASET DECLARE linreg.
35 REGRESSION
36 /MISSING LISTWISE
37 /STATISTICS COEFF OUTS R ANOVA
38 /CRITERIA=PIN (.05) POUT (.10)
39 /NOORIGIN
40 /DEPENDENT sdY
41 /METHOD=ENTER meanY
42 /OUTFILE=COVB(linreg).
43 * make a plot in main output window for later inspection
44 OUTPUT ACTIVATE mainOutput.
45 SET RESULTS=LISTING.
46 TSET NEWVAR=NONE.
47 CURVEFIT
48 /VARIABLES=sdY WITH meanY
49 /NOCONSTANT
50 /MODEL=LINEAR
51 /PLOT FIT.
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52 OUTPUT ACTIVATE dummyOutput.
53 SET RESULTS = NONE.
54 DATASET ACTIVATE linreg.
55 FLIP VARIABLES=CONST_ meanY
56 /NEWNAMES=ROWTYPE_.
57 DATASET NAME linreg2 WINDOW=FRONT.
58 FORMATS SIG(F8.6) EST(F16.8).
59 SELECT IF (CASE_LBL =" meanY").
60 EXECUTE.
61 WRITE OUTFILE ="C:\TEMP\regessingWeights.sps"
62 /" COMPUTE sdC1 = " EST ".".
63 EXECUTE.
64
65 * prepare estimated weights for regression.
66 DATASET ACTIVATE calibration.
67 DATASET CLOSE linreg.
68 DATASET CLOSE linreg2.
69 INSERT FILE="C:\TEMP\regessingWeights.sps".
70 EXECUTE.
71
72 AGGREGATE
73 /OUTFILE =* MODE=ADDVARIABLES
74 /BREAK=
75 /calMin=MIN(! stdVals)
76 /calMax=MAX(! stdVals).
77 EXECUTE.
78 * conditionally assign weights , true or estimated SD depending on
user choice.
79 !IF (! trueSD =1) !THEN
80 COMPUTE w=1/( sdY)**2.
81 EXECUTE.
82 AGGREGATE
83 /OUTFILE =* MODE=ADDVARIABLES
84 /BREAK=
85 /w_min=MIN(w)
86 /sdY_mean=MEAN(sdY).
87 IF (w_min =0) w=1/( sdY/sdY_mean)**2.
88 EXECUTE.
89 DELETE VARIABLES sdY_mean w_min.
90 !IFEND
91
92 !IF (! trueSD =0) !THEN
93 COMPUTE w=1/( sdC1*meanY)**2.
94 EXECUTE.
95 AGGREGATE
96 /OUTFILE =* MODE=ADDVARIABLES
97 /BREAK=
98 /w_min=MIN(w)
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99 /sdY_mean=MEAN(sdY).
100 IF (w_min =0) w=1/(( sdC1*meanY)/sdY_mean)**2.
101 EXECUTE.
102 DELETE VARIABLES sdY_mean w_min.
103 !IFEND
104
105 **************** quadratic model ****************.
106 * section for all of the weights and x multipliers for quadratic.
107 COMPUTE wx = w*x.
108 COMPUTE wx2 = w*x*x.
109 COMPUTE wx3 = w*x*x*x.
110 COMPUTE wx4 = w*x*x*x*x.
111 COMPUTE wxy = w*x*y.
112 COMPUTE wx2y = w*x*x*y.
113 COMPUTE wy = w*y.
114 COMPUTE x2 = x*x.
115 COMPUTE dummy =1.
116 EXECUTE.
117 AGGREGATE
118 /OUTFILE =* MODE=ADDVARIABLES /BREAK =dummy
119 /Sw = SUM(w)
120 /Swx = SUM(wx)
121 /Swx2 = SUM(wx2)
122 /Swx3 = SUM(wx3)
123 /Swx4 = SUM(wx4)
124 /Swxy = SUM(wxy)
125 /Swx2y = SUM(wx2y)
126 /Swy = SUM(wy)
127 /Sx2 = SUM(wx2)
128 /Nc = NU(! stdVals).
129 COMPUTE xBar = Swx/Sw.
130 COMPUTE x2Bar = Swx2/Sw.
131 COMPUTE yBar = Swy/Sw.
132 COMPUTE sxx = Swx2 -Sw*Xbar **2.
133 COMPUTE sfx = Swx3 - Sw*xBar*x2Bar.
134 COMPUTE sff = Swx4 -Sw*x2Bar **2.
135 COMPUTE sxy = Swxy -Sw*xBar*yBar.
136 COMPUTE sfy = Swx2y - Sw*x2Bar*yBar.
137 EXECUTE.
138
139 * weighted residuals of the intercept -only model , and their sums.
140 COMPUTE yRsq = w*(y-yBar)**2.
141 EXECUTE.
142 AGGREGATE
143 /OUTFILE =* MODE=ADDVARIABLES
144 /BREAK =dummy
145 /SyRsq = SUM(yRsq).
146
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147 * common denominator for Quad WLS.
148 COMPUTE Del = sxx*sff -sfx **2.
149 EXECUTE.
150
151 * quad WLS parameters and estimate curve points.
152 COMPUTE b1 = (sff*sxy -sfx*sfy)/Del.
153 COMPUTE b2 = (sxx*sfy -sfx*sxy)/Del.
154 EXECUTE.
155 COMPUTE yHatQ = yBar + b1*(x-xBar) + b2*(x**2- x2Bar).
156 EXECUTE.
157
158 * weighted quad model residuals and their sums.
159 COMPUTE RsqQ = w*(y-yHatQ)**2.
160 EXECUTE.
161 AGGREGATE
162 /OUTFILE =* MODE=ADDVARIABLES
163 /BREAK =dummy
164 /SRsqQ = SUM(RsqQ).
165
166 * residual variance of the model.
167 COMPUTE sRQ = sqrt(SRsqQ / (Nc -3)).
168 EXECUTE.
169
170 * the Scheffe coefficient and the common radical term for the bands.
171 COMPUTE Fq=sqrt (3*IDF.F(1-! alpha/2,3,Nc -3)).
172 COMPUTE U = 1/Sw + (x-xBar)**2* sff/Del + (x**2- x2Bar)**2* sxx/Del
-2*(x-xBar)*(x**2- x2Bar).
173 EXECUTE.
174
175 **************** linear model ****************.
176 * analogous multipliers (simpler than quad).
177 COMPUTE wDxy = w*(x-xBar)*y.
178 COMPUTE wDx2 = w*(x-xBar)**2.
179 EXECUTE.
180 AGGREGATE
181 /OUTFILE =* MODE=ADDVARIABLES /BREAK =dummy
182 /Swdxy = SUM(wDxy)
183 /SwDx2 = SUM(wDx2).
184
185 * lin WLS parameter and estimate curve points.
186 COMPUTE b0=Swdxy/SwDx2.
187 EXECUTE.
188 COMPUTE yHatL = yBar + b0*(x-xBar).
189 EXECUTE.
190
191 * weighted linear model residuals and their sums.
192 COMPUTE RsqL = w*(y-yHatL)**2.
193 EXECUTE.
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194 AGGREGATE
195 /OUTFILE =* MODE=ADDVARIABLES
196 /BREAK =dummy
197 /SRsqL = SUM(RsqL).
198 * residual variance of the model.
199 COMPUTE sRL = sqrt(SRsqL / (Nc -2)).
200 EXECUTE.
201
202 * compare linear and quadratic and convert quadratric to linear
should it be needed.
203 * if linear is better: .
204 DO IF ((SRsqL -SRsqQ)/sRQ**2<IDF.F(1-!alpha ,1,Nc -3)).
205 COMPUTE b1 = b0.
206 COMPUTE Del = SwDx2.
207 COMPUTE b2=0.
208 COMPUTE sxx =0.
209 COMPUTE sfx =0.
210 COMPUTE sff =1.
211 COMPUTE Rsq = 1-SRsqL/SyRsq.
212 COMPUTE Fs = sqrt (2*IDF.F(1-! alpha/2,2,Nc -2)).
213 COMPUTE sR = sRL.
214 * else if quadratic is worth the loss of DoF: .
215 ELSE.
216 COMPUTE Rsq = 1-SRsqQ/SyRsq.
217 COMPUTE Fs = sqrt (3*IDF.F(1-! alpha/2,3,Nc -3)).
218 COMPUTE sR = sRQ.
219 END IF.
220 EXECUTE.
221
222 * getting the true replicate , mean , and SD for ALL groups.
223 * needed for t distribution used in calibration.
224 AGGREGATE
225 /OUTFILE =* MODE=ADDVARIABLES
226 /BREAK=Split
227 /M=nu(!Mxs)
228 /yAve = mean(!Mxs)
229 /ySD = SD(!Mxs).
230 COMPUTE ySE = ySD / sqrt(m).
231 COMPUTE tInv = Idf.t(1-! alpha/2,m-1).
232 EXECUTE.
233
234 * inverse regression results , depending on what kind of model was
used.
235 IF (b1 <0 AND b2 <>0) xInv = -(b1+(4*b2*yAve -4*b2*yBar +4*b2**2* x2Bar+
b1 **2+4* b1*b2*xBar)**(1/2))/(2*b2).
236 IF (b1 >0 AND b2 <>0) xInv = -(b1 -(4*b2*yAve -4*b2*yBar +4*b2**2* x2Bar+
b1 **2+4* b1*b2*xBar)**(1/2))/(2*b2).
237 IF (b2=0) xInv = (yAve - yBar + b1*xBar)/b1.
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238 EXECUTE.
239
240 * NLR to iteratively solve for CI max.
241 SORT CASES BY split.
242 SPLIT FILE BY split.
243 SET RESULTS = NONE.
244 DATASET DECLARE temp.
245 OMS
246 /SELECT TABLES
247 /IF COMMANDS=[’Nonlinear Regression Analysis ’] SUBTYPES=[’
Parameter Estimates ’]
248 /DESTINATION FORMAT=SAV NUMBERED=TableNumber_
249 OUTFILE=’temp ’.
250 * NonLinear Regression.
251 MODEL PROGRAM max=1.
252 COMPUTE PRED_=yBar+b1*max -b2*x2Bar -b1*xBar -tInv*ySE+b2*max**2-
253 Fs*sR*(1/Sw+(sff*(max -xBar)**2)/Del+(sxx*(x2Bar -max **2) **2)/Del
+(2* sfx*(x2Bar -max **2)*(max -xBar))/Del)**(1/2).
254 NLR yAve
255 /OUTFILE=’C:\Users\Reece\AppData\Local\Temp\SPSSFNLR.TMP ’
256 /PRED PRED_
257 /CRITERIA SSCONVERGENCE 1E-8 PCON 1E-8.
258 OMSEND.
259 DATASET ACTIVATE temp.
260 WRITE OUTFILE=’C:\temp\maxval.sps ’
261 /’IF ( split=’ Var1 ’) ’ Var2 ’=’ Estimate ’.’ /’
EXECUTE.’ .
262 EXECUTE.
263 DATASET ACTIVATE calibration.
264 INSERT FILE =’C:\temp\maxval.sps ’ .
265 RENAME VARIABLES (max=xMaxInv).
266 DATASET CLOSE temp.
267
268 * do it again for the min.
269 DATASET DECLARE temp.
270 OMS
271 /SELECT TABLES
272 /IF COMMANDS=[’Nonlinear Regression Analysis ’] SUBTYPES=[’
Parameter Estimates ’]
273 /DESTINATION FORMAT=SAV NUMBERED=TableNumber_
274 OUTFILE=’temp ’.
275 * NonLinear Regression.
276 MODEL PROGRAM min=1.
277 COMPUTE PRED_=yBar+b1*min -b2*x2Bar -b1*xBar+tInv*ySE+b2*min **2+
278 Fs*sR*(1/Sw+(sff*(min -xBar)**2)/Del+(sxx*(x2Bar -min **2) **2)/Del
+(2* sfx*(x2Bar -min **2)*(min -xBar))/Del)**(1/2).
279 NLR yAve
280 /OUTFILE=’C:\Users\Reece\AppData\Local\Temp\SPSSFNLR.TMP ’
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281 /PRED PRED_
282 /CRITERIA SSCONVERGENCE 1E-14 PCON 0.
283 OMSEND.
284 DATASET ACTIVATE temp.
285 WRITE OUTFILE=’C:\temp\minval.sps ’
286 /’IF ( split=’ Var1 ’) ’ Var2 ’=’ Estimate ’.’ /’
EXECUTE.’ .
287 EXECUTE.
288 DATASET ACTIVATE calibration.
289 INSERT FILE =’C:\temp\minval.sps ’ .
290 RENAME VARIABLES (min=xMinInv).
291 DATASET CLOSE temp.
292
293 split file off.
294 * critical value of dependent var based on alpha.
295 COMPUTE lC = yBar -b1*xBar -b2*x2Bar+Idf.t(1-!alpha ,Nc -(2+(b2 <>0)))*
sR*sqrt((sdC1*(yBar -b1*xBar -b2*x2Bar))**2/! bandsM +1/Sw + (xBar)
**2* sff/Del + (x2Bar)**2* sxx/Del -2*(- xBar)*(-x2Bar)*sfx/Del).
296 EXECUTE.
297
298 * regress the limit of detection based on beta.
299 COMPUTE TB = IDF.t(!beta ,Nc -(2+(b2 <>0))).
300 EXECUTE.
301 SET RESULTS = NONE.
302 DATASET DECLARE temp.
303 OMS
304 /SELECT TABLES
305 /IF COMMANDS=[’Nonlinear Regression Analysis ’] SUBTYPES=[’
Parameter Estimates ’]
306 /DESTINATION FORMAT=SAV NUMBERED=TableNumber_
307 OUTFILE=’temp ’.
308 * NonLinear Regression.
309 MODEL PROGRAM xD=1.
310 COMPUTE PRED_=yBar -b1*(xBar -xD)-b2*(x2Bar -xD**2)+
311 sR*tB*(1/Sw+(sdC1*(yBar -b1*(xBar -x)-b2*(x2Bar -x**2)))**2/! bandsM
+(sff*(xBar -xD)**2)/Del+(sxx*(x2Bar -xD**2) **2)/Del -(2* sfx*(
x2Bar -xD**2)*(xBar -xD))/Del)**(1/2).
312 NLR lC
313 /OUTFILE=’C:\Users\Reece\AppData\Local\Temp\SPSSFNLR.TMP ’
314 /PRED PRED_
315 /CRITERIA SSCONVERGENCE 1E-8 PCON 1E-8.
316 OMSend.
317 DATASET ACTIVATE temp.
318 WRITE OUTFILE=’C:\temp\xD.sps ’
319 /’COMPUTE xD = ’ Estimate ’.’ /’EXECUTE.’ .
320 EXECUTE.
321 DATASET ACTIVATE calibration.
322 INSERT FILE =’C:\temp\xD.sps ’.
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323 DATASET CLOSE temp.
324
325 * compute confidence and prediction bands.
326 COMPUTE tC = IDF.t(1-! alpha/2,Nc -(2+(b2 <>0))).
327 EXECUTE.
328
329 * summary of parameters.
330 data list list (",")
331 /dummy (F8.0) xXLS (F8.0) YXLS (A750) yMax (A750) yMin (A750)
yBandMax (A750) yBandMin (A750).
332 BEGIN DATA.
333 1, 0, " ", " ", " ", " ", " " .
334 END DATA.
335 DATASET NAME excelOutput WINDOW=FRONT.
336 DATASET ACTIVATE calibration.
337 COMPUTE dummy = $CASENUM.
338 EXECUTE.
339 SORT CASES BY dummy.
340 DATASET ACTIVATE excelOutput.
341 MATCH FILES
342 /FILE=*
343 /TABLE=calibration
344 /BY dummy.
345 EXECUTE.
346 COMPUTE tC = IDF.t(1-! alpha/2,Nc -(2+(b2 <>0))).
347 EXECUTE.
348 OUTPUT ACTIVATE mainOutput.
349 FORMATS Rsq(F16 .12) yBar(E15.5) b1(E15.5) xBar(E15.5) b2(E15.5)
x2Bar(E15.5) tC(E15.5) sR(E15.5) sW(E15 .5) sff(E15 .5) Del(E15
.5) sxx(E15.5) sfx (E15.5).
350 SUMMARIZE
351 /TABLES= Rsq yBar b1 xBar b2 x2Bar tC sR sW sff Del sxx sfx
352 /CELLS = NONE
353 /FORMAT= NOCASENUM list nototal nocasenum
354 /MISSING=VARIABLE.
355 SUMMARIZE
356 /TABLES= Rsq
357 /CELLS = NONE
358 /FORMAT= NOCASENUM list nototal nocasenum
359 /MISSING=VARIABLE.
360 SET RESULTS = NONE.
361 OUTPUT ACTIVATE dummyOutput.
362 DATASET ACTIVATE calibration.
363 DATASET CLOSE excelOutput.
364
365 * dataset with regression values summarized.
366 dataset copy summary.
367 DATASET ACTIVATE summary.
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368 SORT CASES BY !grpVar.
369 MATCH FILES file=*
370 /BY !grpVar
371 /first=first.
372 EXECUTE.
373 SELECT IF (first).
374 EXECUTE.
375 DELETE VARIABLES first.
376
377 * construct curve dataset so cal curve can be graphed.
378 NEW FILE.
379 INPUT PROGRAM.
380 LOOP x=0 TO !curveSegs.
381 COMPUTE dummy =1.
382 END CASE.
383 END LOOP.
384 END FILE.
385 END INPUT PROGRAM.
386 EXECUTE.
387 DATASET NAME curves.
388 DATASET ACTIVATE curves.
389 MATCH FILES /FILE=*
390 /TABLE=summary
391 /BY=dummy
392 /KEEP lC, tC, xD, xBar x2Bar yBar , b1, b2, sdC1 , calMin , calMax ,
Del , sfx , sxx , sff , sW , sR.
393 EXECUTE.
394 COMPUTE x=calMin +($casenum -1)/! curveSegs *(calMax -calMin).
395 EXECUTE.
396 COMPUTE yPred = yBar -b1*(xBar -x)-b2*(x2Bar -x**2).
397 EXECUTE.
398 COMPUTE yMax = yBar -b1*(xBar -x)-b2*(x2Bar -x**2)+sR*tC*(1/Sw+(sdC1*
yPred)**2/! bandsM +(sff*(xBar -x)**2)/Del+(sxx*(x2Bar -x**2) **2)/
Del -(2* sfx*(x2Bar -x**2)*(xBar -x))/Del)**(1/2).
399 COMPUTE yMin = yBar -b1*(xBar -x)-b2*(x2Bar -x**2)-sR*tC*(1/Sw+(sdC1*
yPred)**2/! bandsM +(sff*(xBar -x)**2)/Del+(sxx*(x2Bar -x**2) **2)/
Del -(2* sfx*(x2Bar -x**2)*(xBar -x))/Del)**(1/2).
400 COMPUTE yBandMax = yBar -b1*(xBar -x)-b2*(x2Bar -x**2)+sR*tC*(1/Sw+(
sff*(xBar -x)**2)/Del+(sxx*(x2Bar -x**2) **2)/Del -(2* sfx*(x2Bar -x
**2)*(xBar -x))/Del)**(1/2).
401 COMPUTE yBandMin = yBar -b1*(xBar -x)-b2*(x2Bar -x**2)-sR*tC*(1/Sw+(
sff*(xBar -x)**2)/Del+(sxx*(x2Bar -x**2) **2)/Del -(2* sfx*(x2Bar -x
**2)*(xBar -x))/Del)**(1/2).
402 EXECUTE.
403 FORMATS x(F8.5) yPred(F8.5) yMax(F8.5) yMin(F8.5) yBandMax(F8.5)
yBandMin(F8.5).
404 EXECUTE.
405
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406 * clean up.
407 DELETE VARIABLES tC xBar x2Bar yBar b1 b2 calMin calMax Del sfx
sxx sff Sw Sw sR.
408 DATASET ACTIVATE summary.
409 DELETE VARIABLES Split x y sdY meanY sdC1 calMin calMax wx wx2 wx3
wx4 wxy wx2y wy x2 dummy Sw Swx Swx2 Swx3
410 Swx4 Swxy Swx2y Swy Sx2 Nc xBar x2Bar yBar yRsq SyRsq sxx sfx sff
sxy sfy Del b1 b2 yHatQ RsqQ
411 SRsqQ sRQ Fq U wDxy wDx2 Swdxy SwDx2 b0 yHatL RsqL SRsqL sRL Fs
sR M yAve ySD ySE tInv
412 TB tC.
413 FORMATS xInv(F8.5) xMaxInv(F8.5) xMinInv(F8.5) xD(F8.5) Rsq(F8.6) .
414 DATASET ACTIVATE calibration.
415 DELETE VARIABLES Split x y sdY meanY sdC1 calMin calMax wx wx2 wx3
wx4 wxy wx2y wy x2 dummy Sw Swx Swx2 Swx3
416 Swx4 Swxy Swx2y Swy Sx2 Nc xBar x2Bar yBar yRsq SyRsq sxx sfx sff
sxy sfy Del b1 b2 yHatQ RsqQ
417 SRsqQ sRQ Fq U wDxy wDx2 Swdxy SwDx2 b0 yHatL RsqL SRsqL sRL Fs
sR M yAve ySD ySE tInv
418 TB tC.
419 FORMATS xInv(F8.5) xMaxInv(F8.5) xMinInv(F8.5) xD(F8.5) Rsq(F8.6) .
420
421 OUTPUT ACTIVATE mainOutput.
422 DATASET ACTIVATE curves.
423 ADD FILES /FILE=*
424 /FILE=’calibration ’
425 /KEEP=x yPred yMin yMax yBandMin yBandMax !stdVals !Mxs.
426 EXECUTE.
427 SELECT IF (~ missing (! stdVals) OR ~missing(x)).
428 EXECUTE.
429 IF MISSING(x) x=! stdVals.
430 EXECUTE.
431 DELETE VARIABLES !stdVals.
432 !ENDDEFINE.
Because most of the code can be called remotely, use of the WLS algorithm requires little
additional code. Lines 1 and 14 of code block 7.2 are intended to keep the SPSS window
from becoming too cluttered with intermediate calculations. Line 2 is optional so long as the
entirety of code block 7.1 is run once in the SPSS session before code block 7.2 is run. For
a description of the key values, see Table 7.3. Code block 7.2 is completed to analyze the
example dataset in Table 7.2.
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Table 7.3: Key values for running WLS regression. See code block 7.2 for context of use.
value description
stdVals known concentrations
grpVar replicate group identifier
stdGrp binary indicating standards
alpha false positive rate
Mxs measurement variable
beta false negative rate
trueSD 0 for estimated weight (recommended), 1 for s2j weight
curveSegs resolution of regression bands (recommended 100–200)
bandsM replicates m in determining prediction bands
Source Code 7.2: Calling WLS regression
1 SET PRINTBACK=none RESULTS=NONE.
2 INSERT FILE="C:\SPSS code\WLS regression macro.sps".
3 EXECUTE.
4 !WLSreg1
5 stdVals = analyte
6 grpVar = group
7 stdGrp = known
8 alpha = 0.05
9 Mxs = measurement
10 beta = 0.10
11 trueSD = 1
12 curveSegs = 200
13 bandsM = 2.
14 SET PRINTBACK=LISTING RESULTS=LISTING.
7.3 Assay reproducibility metrics
The reproducibility of the MPO activity on a polymer surface (MAPS) assay was determined
taking into consideration the uncertainty in each individual assay, resulting in more robust
parameters than the traditional standard deviation and coefficient of variation. These
parameters were calculated by adapting methods designed to combine variances from
independent experiments for meta-analyses.6,7 Similar to Section §7.2, Table 7.4 provides a
list of parameter definitions used for these calculations. The method is presented symbolically
[223]
Assay reproducibility metrics
to describe the general case; parameter values used in evaluating the MAPS assay are noted
where applicable.
Each patient sample q was analyzed a with a total of T independent replications; each
replicated assay was performed with internal technical replicates m.7 For each of the
independent replicates r, the variance s2qr was back-calculated from the 1− α8 confidence
interval about the predicted mean.9 The variance was then used to weight each assay result:
w˙qr =
1
s2qr
=
(√
mqr (x_qr,max − x_qr,min)
2 t1−α/2,m−1
)−2
(7.40)
Next, the weighted mean is calculated for each sample:
x˙q =
T∑
r=1
w˙qrx_qr
T∑
r=1
w˙qr
(7.41)
An estimate of the heterogeneity of variance ∆ˆ2 is calculated, which adds additional variance
to the final reproducibility statistic based on how widely dispersed the estimates and variances
are for each sample.
∆ˆ2q = max
0,
T∑
r=1
w˙qr (x_qr − x˙q)2 − (T − 1)
T∑
r=1
w˙qr −
(
T∑
r=1
w˙2qr
)(
T∑
r=1
w˙qr
)−1
 (7.42)
New weights for each replicate are then computed accounting for ∆ˆ2q:
w¨qr =
1
w˙qr + ∆ˆ2q
(7.43)
This had the effect of increasing the relative weight given to uncertain measurements if the
spread among replications was wide. From these corrected weights, a new weighted mean
7With regards to Chapter 4, the MAPS assay was replicated four times with technical triplicates, [T,m] = [4, 3]
8α = 0.05 from the 95% confidence intervals
9Although the confidence intervals were not technically symmetric about the mean, the deviation from
symmetry was not great enough to create a noticeable impact on the final reproducibility metrics.
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Table 7.4: Parameters used in MAPS reproducibility metrics.
parameter(s) description equation
x_qr, x_qr,max, x_qr,max measured value with upper and lower confidence limits –
r, T independent replicate of x_q with r = 1, 2, . . . , T –
mqr number of technical replicates composing x_qr –
α false positive error rate –
tα,δ t-distribution critical value with probability α and δ degrees of freedom –
s2qr back-calculated variance of independent measurement x_qr (7.40)
w˙qr weight assigned to measurement x_qr based on s2qr (7.40)
x˙q weighted mean of all xq (7.41)
∆ˆ2q heterogeneity of variance term for weight adjustment (7.42)
w¨qr heterogeneity-adjusted weight (7.43)
x¨q heterogeneity-adjusted weighted mean (7.44)
s¨q standard deviation of the heterogeneity-adjusted weighted means (7.45)
ω coefficient of variability from independent, uncertain measurements (7.46)
were calculated as previously along with a weighted standard deviation from the standard
error of the weighted mean:
x¨q =
T∑
r=1
w¨qrx_qr
T∑
r=1
w¨qr
(7.44)
s¨q =
√√√√√√ TT∑
r=1
w¨qr
(7.45)
Lastly, the coefficient of variability is computed in the same manner as a more traditional
coefficient of variation:
ω = s¨q
x¨q
(7.46)
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7.4 ImageJ macros
7.4.1 Quadrangular ROI array
This ImageJ macro was written to define an array of identical elliptical regions of interest
(ROIs) to ensure that quantification of luminescence from microtiter plate wells would not be
confounded by varying ROI position or size. It was based on a previous text-editing script
written to aid other lab members with grid ROIs made in IVIS image analysis software Living
Image. The macro version was written shortly after the arrival of the ONYX/M imaging
system, the data from which are best analyzed in the open-source ImageJ. The macro can be
installed to ImageJ or any of its builds, e.g., Fiji, containing the ROI manager tool. It can
also be run from the text dialog. Instructions can be found in the macro comment header.
Source Code 7.3: Quadrangular ROI array
1 // This plugin makes quadranglular arrays of ROIs defined by 4
corners;
2 // The ROIs are labeled with grid , row , and column numbers and stored
in the ROI manager;
3 // This is intended for analyzing microtiter plate images , originally
developed for bioluminescence;
4 // written by Reece Goiffon , rjgoiffon@wustl.edu;
5 // Washington University School of Medicine , 2010 -2013;
6 // last tested and updated with the Fiji distribution of ImageJ 1.47q
;
7
8 // Instructions for a grid of I rows and J columns :;
9 // 1. draw and place an elliptical selection at Row1 ,Column1;
10 // 2. add this ROI to the ROI manager (default shortcut: t);
11 // 3. drag the selection to Row1 ,ColumnJ and add to the ROI manager;
12 // 4. drag the selection to RowI ,Column1 and add to the ROI manager;
13 // 5. drag the selection to RowI ,ColumnJ and add to the ROI manager
14 // 6. (optional) define more grids by continuing to drag the
selection and adding to the ROI manager;
15 // total number of ROIs must be N*4 where N is the number of
arrays desired;
16 // 7. run the macro and enter the desired number of rows/columns per
array. all arrays have the same I and J;
17
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18 macro "Quadrangular ROI array" {
19 Nrows =8;
20 Ncols =12;
21 Ngrids = 1;
22
23 Dialog.create ("Grid ROI creator ");
24 Dialog.addMessage ("You must have placed 4 corner ROIs into the ROI
manager for each grid \n Make sure that 1 is diagonal from 4
\n Note that rotation doesn ’t matter .")
25 Dialog.addNumber ("Rows:", Nrows);
26 Dialog.addNumber (" Columns:", Ncols);
27 Dialog.show();
28 Nrows = Dialog.getNumber ();
29 Ncols = Dialog.getNumber ();
30
31 R = roiManager ("count ");
32 getDimensions(W, H, c, s, f);
33 if (floor(R/4)!=R/4) {
34 exit("You need four corner ROIs per grid .");
35 }
36 setBatchMode(true);
37 Ngrids = R / 4;
38 ROIs=Nrows*Ncols*Ngrids;
39
40 cornerX = newArray(R);
41 cornerY = newArray(R);
42 for (i=0; i<4* Ngrids; i++) {
43 roiManager (" select", i);
44 getSelectionBounds(x, y, w, h);
45 cornerX[i] = x;
46 cornerY[i] = y;
47 }
48
49 Xs = newArray(Ngrids*Nrows*Ncols);
50 Ys = newArray(Ngrids*Nrows*Ncols);
51 for (g=0; g<Ngrids; g++) {
52 for (i=0; i<Nrows; i++) {
53 for (j=0; j<Ncols; j++) {
54 jj=j/(Ncols -1);
55 ii=i/(Nrows -1);
56
57 Xs[g*Nrows*Ncols+i*Ncols+j] = cornerX[g*4]*(1 -jj)*(1-ii)
58 +cornerX[g*4+1]*( jj)*(1-ii)
59 + cornerX[g*4+2]*(1 -jj)*(ii)
60 + cornerX[g*4+3]*( ii)*(jj);
61
62 Ys[g*Nrows*Ncols+i*Ncols+j] = cornerY[g*4]*(1 -jj)*(1-ii)
63 +cornerY[g*4+1]*( jj)*(1-ii)
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64 + cornerY[g*4+2]*(1 -jj)*(ii)
65 + cornerY[g*4+3]*( ii)*(jj);
66
67 }
68 }
69 }
70
71 roiManager ("Reset ");
72 newImage ("temp", "32-bit Black", W, H, 1);
73 names=newArray(ROIs);
74 for (g=0; g<Ngrids; g++) {
75 for (i=0; i<Nrows; i++) {
76 for (j=0; j<Ncols; j++) {
77 k = g*Ncols*Nrows + i*Ncols + j;
78 selectWindow ("temp");
79 run(" Specify ...", "width ="+w+" height ="+h+" x="+Xs[k]+" y="+Ys[
k]+" oval");
80 roiManager ("Add");
81 if(j<9) {
82 colName = "00"+(j+1);
83 } else if (j<99) {
84 colName = "0"+(j+1);
85 } else {
86 colName = j+1;
87 }
88 if(i<9) {
89 rowName = "00"+(i+1);
90 } else if (i<99) {
91 rowName = "0"+(i+1);
92 } else {
93 rowName = i+1;
94 }
95 if(g<9) {
96 gridName = "00"+(g+1);
97 } else if (g<99) {
98 gridName = "0"+(g+1);
99 } else {
100 gridName = g+1;
101 }
102 roiManager (" Select", k);
103 roiManager (" Rename","G"+ gridName +"R"+ rowName +"C"+ colName);
104
105 }
106 }
107 }
108
109 selectWindow ("temp");
110 close ();
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111 setBatchMode(false);
112 roiManager (" Deselect ");
113 setOption ("Show All", true);
114 run(" Select None");
115 }
7.4.2 ONYX vignette correction
Vignetting is the non-uniform intensity of an imaging system due to the optical properties of
camera apertures. Proprietary image analysis software for use with out-of-the-box imaging
platforms such as the IVIS100 correct for vignetting10 , but the imaging conditions in the
ONYX/M are too customizable to offer universal correction settings. By using techniques
from the optical engineering literature, the ONYX/M could be calibrated for any stage
height, iris aperture, and focal length using a single test image, non-linear regression, and
the following ImageJ macro.8,9
The camera was first focused on a grid test pattern, which was replaced with a clean,
unbent sheet of 20 lb. copy paper. A 1 min mean intensity exposure was taken with the
ONYX/M illumination set to result in the intensity distribution near the middle of pixel
saturation. (Figure 7.1B) Dead pixels were removed to prevent bias and the image was fit to
the equation:
S = C cos4 θ = C cos4
(
tan−1
(
r
A
))
(7.47)
where r was calculated as the radial distance / pixels from the image center, S is signal
intensity, and C = S| r = 0. (Figure 7.1A) From these regression parameters, a noiseless image
was calculated and normalized such that peak intensity C = 1 resulting in the calibration
matrix C. (Figure 7.1C) When run on an image stack, the ImageJ macro computes the
10often called “flat-field correction”
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Figure 7.1: ONYX imaging vignette correction. (A) The principle of the vignette correction. An
image of a white, matte surface with even illumination at the desired focal plane is fit to equation (7.47),
the standard reflectance map equation.8,9 (B) Example calibration image. Noise is the sum of camera noise
(both random and systematic due to sensor defects) and an interference pattern from the array of lights
illuminating the stage. (C) Calibration matrix computed from regression parameters obtained from the
image in (B) and equation (7.47). (D) Back-corrected version of the image shown in (B) processed with
equation (7.48) and correction matrix shown in (C).
Hadamard quotient of each stack image matrix I and the calibration image matrix:
Icorrected = IC (7.48)
Some deviation from model equation (7.48) due to the non-uniform illumination from the
ONYX stage lights results in some non-uniformity when the transformation is applied to
the original calibration image. (Figure 7.1D) Despite this slight imperfection, systematic
variance in experimental imaging sequences were greatly reduced with this technique.
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Source Code 7.4: ONYX imaging vignette correction
1 // This macro is required to fix the images obtained on the Onyx ,
which have systematic bias due to vignetting;
2 // A calibration image must be taken with even , moderate illumination
with the focus and stage settings identical to the images to be
corrected;
3 // this calibration image must then be fit to C*(cos(arctan(r/A)))^4;
4 // where r is the radius (pixels) from image center and C, A require
fitting;
5 // from the regression parameters , calculate a calibration image from
r and the obtained value of A (set C=1);
6 // this image path needs to be added to lines 10 and 11, the filename
to line 14;
7
8 macro "ONYX vignette correction "{
9 process = getTitle ();
10 open("<insert path of calibration image >");
11 imageCalculator (" Divide create 32-bit stack",process ,"<insert path
of calibration image >");
12 selectWindow (" Result of "+ process);
13 rename (" CORRECTED "+ process);
14 selectWindow ("<insert name of calibration image >");
15 close ()
16 selectWindow (" CORRECTED "+ process);
17 }
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